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Preface 
 
This thesis is a result of three years of graduate work performed at the Hevesy 
laboratory, Risø National Laboratory, The Technical University of Denmark, under 
the supervision of Dr. Lars Martiny, Head of the Radiation Research Division. 
 
The main parts of the work presented here is Part I; which have involved the 
installation of a Tritium Chemistry Facility for the synthesis of radiolabelled 
compounds with tritium, and Part II; the development of new tritium labelling 
methods for peptides.  
 
The intention of Part I is to supply background information of radioactivity in 
general, tritium uses in research and development and in the result section of Part I 
the installed Hevesy Tritium Facility (HTF) is introduced. 
 
One of the overall objectives for this work was investigation of new tritium labelling 
techniques for peptides. The background and results from this research is presented 
in Part II and the Appendix I. 
 
Finally, a substantial part (over a period of 8 months) of the research presented in 
this thesis was performed in the Bergman group, University of California, Berkeley. 
As a visiting scholar, I was involved in investigation of Host-Guest (supramolecular) 
chemistry in joint project collaboration between Prof. Robert G. Bergman and Prof. 
Kenneth Raymond. Part III of this thesis is the research report from my external 
research visit and it can be read as an independent Part. 
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Objectives and Aims 
 
 
 
The objectives of Part I of this thesis in to provide an introduction to radioactivity in 
general, and to tritium as it is indeed a workhorse in (pharmaceutical) research and 
development.  
 
The radiohydrogen isotope, tritium, has generally found many useful applications. In 
life sciences and in the pharmaceutical industry tritium functions as the workhorse as 
a tracer for new chemical entities and this isotope is essential as a tool for early 
ADME studies.  
 
A significant part of the graduate studies presented here, has involved the acquisition 
of laboratory instrumentation for performing of gaseous tritium chemistry. The 
process of setting up the Hevesy Laboratory’s tritium labelling facility as well as 
necessary analytical instruments will be described in detail. This also mean, that this 
part will function as a materials and methods section for the second part of this 
thesis; “Development of New Tritium Labelling Methods for Peptides”. 
 
The aim of this part is also to function as an introduction to the tritium isotope; here 
the general/current tritium (T2) chemistry methodologies, for labelling of small 
chemical compounds, are briefly overviewed. One example of isotopic scrambling in 
tritiation of an unsaturated compounds and the general mechanism of this 
phenomena will be proposed as a part of the results section. 
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Background 
 
Radioactivity  
 
The term “Radio-activity” was introduced by, the pioneers of radioactive elements, 
Henri Becquerel, Marie Curie and Pierre Curie. In 1903 these three individuals were 
recognised for their work by sharing the Nobel Prize in physics1, 2. 
 
In general, non-stable atomic isotopes will disintegrate into more stable elements. 
This nuclidic disintegration can occur in different pathways depending on the 
isotope/nuclidic composition and energy levels. A result of the nuclidic 
disintegration is, in all cases, emission of either particles (neutrons, protons or 
electrons) or electromagnetic radiation. This phenomenon is in general known as 
Radioactivity.  
 
The terminology of related to the different radioactive decays is listed in table 1. 
 
Terminology Abbreviation Process  
Beta Decay - and + 
Emission of a beta particle (negatron or 
positron) from the nucleus.   
Electron Capture  / EC Nuclidic capture of an inner shell electron. 
Gamma Ray  Electromagnetic emission from the nucleus. 
X-ray or Röntgen  
Electromagnetic emission from the electron 
shell surrounding the nucleus. 
Internal Conversion IC 
Electron emission from interaction of the 
nucleus and an inner shell electron. 
Auger Electron  
Conversion electron emitted from the 
electron shells. 
Alfa Particle  Emission of an alpha particle ( 
 ) from the 
nucleus of the parent isotope.  
Isomeric Transition IT 
Nuclidic evaporation of energy () from a 
meta-stable isotope, to leave the nucleus in a 
lower energy state. 
Spontaneous Fission SF 
Spontaneous spallatation of a nuclide for 
formation of two or more daughter nuclides  
 
Table 1. General terminology of decay pathway in radioactive disintegrations. 
 
All elements of the periodic table have radioactive isotopes. An isotope of the same 
element in the periodic table, have the same number of protons (p+) and different 
number of neutrons (n) hence the word isotope. Actually the word isotope originates 
from the greek words iso topos which means “same place”. In general, neutron 
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deficient nuclides tend to disintegrate either by EC (p+ + e-  n) or positron 
emission (p  n + +) and neutron rich nuclides by negatron emission (n  p+ + -).   
 
Isotopes of the same element are generally considered to have the same chemical 
properties and behave similar chemically. (This is though not completely true due to 
isotope effects and different vibrational energy states of the chemical bonds). This is 
why radioactive isotopes can be used as tracers for the stable counterparts. 
 
Radioactivity is measured in disintegrations (the number of decaying nuclides) in a 
given timeframe. The SI unit for radioactive amounts is Becquerel (Bq) which means 
the amount of disintegrations per second. Another widely used (especially with 
tritium) unit for radioactive amounts is Curie (Ci). One Curie is standardized from 
the total disintegrations from 1 gram of radium-226 and equals 37*109 Bq.   
 
 
The Beta Decay 
The energy profile for an emitted beta particle (- or +) is characteristic for each 
radionuclide and this energy profile can be illustrated by liquid scintillation counting 
(LSC). The kinetic energy of the emitted beta particle has a continuous spectrum, for 
tritium the mean energy is 5.7 keV and a maximum energy of 18.6 keV. Compared 
to other radioisotopes this is a very low energy (in the range of Auger electron 
energies) and this make tritium difficult to detect by other methods than scintillation. 
The emitted particle from tritium has a maximum range of 6 mm in air.  Detection of 
tritium is therefore normally performed by liquid scintillation counting. In figure 1 a 
few  spectra are illustrated made by LSC.  
 
 
 
 
 
Figure 1. Illustration of beta-decay energy profiles of five important radioisotopes used in research and 
development. These spectrums are acquired on a Wallac Rack-beta 1412 liquid scintillation counter. 
The energy profiles are plottet counts (intensity) by channel (with a 1024 multi channel analyser). All 
the isotopes here emit negatron particles, Cu-64 i the only nuclide emitting both negatrons and 
positrons.   
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The Radiotracer Principle and Application of Tracers 
    
“The radiotracer method is clearly one of the most powerful tools in scientific 
research”, Wang and Willis, 1963. 
 
The above citation of Wang and Willis3 could arguably be somewhat of an 
exaggeration, but the use of radioactive tracers is without doubt a very powerful and 
indispensable tool in science. Radioactive Indicators or Radiotracers used for the 
investigation of biological processes was first described by George de Hevesy in 
1923. He described the application of radioactive lead isotopes and the distribution 
in various parts of plants simply by dipping them into a solution containing a 
radioactive isotope4. Later on (in 1943), he was the recipient of the Nobel Prize in 
chemistry for his work on the use of isotopes as tracers in the study of chemical 
processes5.   
 
Since radiolabelled compounds have (almost) the same physiochemical properties as 
the non-radioactive compounds of with the same elements, the radiolabelled 
compound can be used as tracers for the molecules in biological systems. Thereby, 
radiolabelled tracers provide an outstanding tool for the investigation of biological 
systems.  
  
The radiotracer principle is widely used in administration, distribution, metabolism 
and excretion (ADME) studies for characterisation of new chemical entities6, 7. A 
part of the regulatory process and development of a new pharmaceutical is the 
requirement of studies of the distribution of the drug in experimental animals. 
Depending of the radioisotope used for these studies different detection instruments 
can be used. When tritiated compounds are used in in-vivo distribution studies - 
autoradiography is the method used. Whole Body Autoradiography (WBA) is a 
method for tracing a molecule in different parts and organs of an animal body. The 
WBA method involves the detection of radioactivity from thin biological slices from 
a frozen animal on a photographic sensitive plate.8 
 
Another applicable method for the use of radiolabelled molecules is in receptor 
affinity studies. In large drug development programs, radiolabelled receptor ligands 
can be used for screening of large chemical libraries in High Throughput Screening 
(HTS). Displacement of known radiolabelled ligands toward a receptor target is one 
of the methods for evaluation of new potential ligands (antagonists or agonists).  
 
During the last 3 years of studies I was also involved in the radiolabelling of a few 
neuroreceptor ligands with the iodine-125 isotope. One of many very useful 
radiolabelling methods is called the radioiododestannyllation reaction; this will later 
in this thesis be briefly reviewed and one example of this method has been presented 
(Appendix II). These radioligands synthesised as a part of this graduate work, are 
currently under investigation in receptor affinity and WBA/autoradiography studies9, 
10.  
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The Hydrogen Isotopes 
 
Hydrogen-1 is the far most abundant element in our solar system and it is also the 
simplest atom having only one proton in its nucleus. The three most important 
isotopes of hydrogen are protium (P or 1H), deuterium (D or 2H) and tritium (T or 
3H). Tritium is a non-stable isotope with one proton and two neutrons in its nucleus 
and disintegrates by emission of a beta particle (3H  3He + -). In table 2, the 
mentioned isotopes are listed. 
 
The Hydrogen (H) Isotopes 
Isotope Natural Abundance Halflife and Decay Properties 
1H / P 99.9885 % Stable 
2H / D 0.0115 % Stable 
3H / T Trace 12.33 years, pure - emission  (emax = 18.7 keV and emean = 5.7 keV) 
Table 2. Overview of the hydrogen isotopes. 
 
Whilst protium and deuterium are found on the earth, tritium is only found in trace 
amounts. The natural occurring tritium arises from nuclear processes in the earth 
crust and by nuclear reactions happening when charged particles impact the earth’s 
atmosphere. The main part of tritium on the earth originates from the nuclear 
detonations happening in the atom-bomb-race-age, where several atmospheric 
nuclear detonations caused the injection of tritium into the earth’s environment. The 
minimum estimated world inventory of tritium has been calculated as 15•109 GBq 
(405 MCi ~ 4700 kg T) while the natural equilibrium is ~ 70 MCi. The vapour, 
HTO, is formed readily and is the most commonly encountered form of tritium in the 
environment.11  
 
Formation of a tritium nucleus can occur in many nuclear spallatation processes, in 
SF or particle collisions. Also the production of high amount of tritium is yielded by 
neutron bombardment of lithium-6 (6Li + n  4He + 3H). This production method 
may be used as fuel breeding in thermonuclear experimental fusion reactors (TER)12. 
An example of ternary fission is illustrated in figure 2.  
 
 
 
Figure 2. Illustration of a ternary fission process when a nuclide is bombarded with thermal neutrons. 
In this illustration two heavy daughter and tritron nuclides are produced.  
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Regulatory and Health Issues Regarding Tritium 
 
Working with high amounts of gaseous tritium places a demand for special 
laboratory equipment as well as special licenses from the regulatory authorities13, 14. 
In the installation of a tritium facility, surveillance of contamination levels on 
surfaces and radioactivity in the air is a minimum requirement. A significant part of 
these graduate studies has involved the installation of tritium monitoring instruments 
for safe handling of tritium and also acquiring the permissions for the stockholding 
of up to 10 TBq tritium stored on uranium (see the results section).  
 
The general objective of tritium (and radioactivity in general) safe handling is to 
prevent acute injurious radioactivity exposures, to ensure that regulatory limits are 
not exceeded and to keep exposures as low as reasonable achievable (ALARA). 
Tritium can be present in the workplace in airbourne forms as gas (T2), vapour (HTO 
or T-solvents), dust or particles. The uptake of tritium in the human body can occur 
by inhalation, skin uptake or ingestion. For safety reasons it is therefore important 
that the tritium manifold is placed in a well ventilated fumehood.15         
 
After uptake of a tritium containing compound the in-vivo distribution depends on 
the nature of the molecular bound tritium. Dosimetry-wise there is a clear separation 
between organically bound (OBT), gaseous (T2) and aqueous tritium (HTO). The 
limit of the accumulated radioactivity dose is, in Denmark, 20 mSv per year for 
workers. This dose has been calculated and estimated to be equivalent to 
ingestion/inhalation of 1100 MBq (~30 mCi) of HTO or 490 MBq (~13 mCi) of 
OBT. The fate of a OBT in-vivo is of course dependent of the molecule labelled and 
the radioactive dose originating from these have to be evaluated from molecule to 
molecule. In figure 3, a model of the kinetic distribution for hydrogen in an average 
human body is illustrated. As it appear from the figure hydrogen can be modelled to 
be distributed into three hydrogen compartments, a central (H2O) compartment and 
two organic bound hydrogen compartments. 11  
 
 
 
 
 
Figure 3. Illustration of a hydrogen (noted as H in the figure) distribution model of an average human 
body. Hydrogen is distributed into 3 compartments and has different pool sizes and kinetic exchange 
constants. Compartment A is the central water pool, compartment B and C the organic bound hydrogen.  
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If the presented three compartment model is applied in tritium kinetic calculations of 
HTO introduced into the human body – the amount of tritium can be calculated 
using Matlab software. For illustratory purposes the kinetic profile of ingested HTO 
is plotted against time (figure 4). As it appear the elimination of HTO is fast in the 
first phase having a biological half life of approximately 12 days. After tritium 
distribution into the peripheral compartments and bound to organic molecules 
(oligosaccharides, lipids, proteins and DNA/RNA) the elimination happens much 
slower. 
 
When applying this model for HTO excretion, the first four biological half lifes of 
tritium can be calculated to 11.5 days, 31.3 days, 72 days and 127.2 days, where an 
amount of 1.3% (of the total ingestion) remains in the body after exposure. 
 
 
 
 
 
 
Figure 4. Plot of simulated of tritium distribution of consumed tritium water (HTO) in an average 
human generated in Matlab. The total tritium amount is plotted as the black line, central compartment 
(HTO) as the red line, and the two peripheral compartments as the blue and green lines. 
 
 
 
  
1.3 % Tritium left  
in-vivo after 365 days 
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General T2 Tritium Chemistry 
 
Tritium is a radioactive isotope of hydrogen and hence can provide valuable 
information if used in labelling of molecular tracers.  Nearly all organic molecules 
and pharmaceuticals contain hydrogen. Tritium is therefore an ideal isotope for 
tracing organic molecules.  
 
Practically all tritium labelled compounds are synthesised by the formation of a C-T 
bond because this is a relatively stable bond and C-T bonds are easy to create from 
gaseous tritium (T2). It is necessary to form stable tritium bonds to ensure non labile 
tritium in the formed molecule. At the end of every tritiation reaction the labile 
tritium (e.g. formed N-T and O-T bond) is removed by repeated lyophillations of the 
product with protic solvents (e.g. a mixture of H2O and MeOH)    
 
General hydrog chemistry is well developed and tritium labelled compounds are 
normally synthesised by either tritide reductions (T- + electrophile) or tritonations 
(T+ + nucleophile). Many reaction types have been developed for tritium and have 
also been the topic for historical perspectives16, 17, textbook18 and review 
publications19, 20. Due to the many descriptions for incorporation of T into organic 
molecules only a brief overview of methodologies will be given here.     
 
The first step in a (low pressure) gaseous tritiation reaction makes use of ditritium 
activation chemistry. This is normally performed by the application of platinum 
group metals (iridium, rhodium or palladium) which are excellent transition metals 
for dihydrogen activation chemistry. The general tritiation methodologies (and 
reaction types) is briefly illustrated in the following examples. 
 
Aliphatic sp2-sp2 and sp-sp Bond Tritiation 
General hydrogenation chemistry of unsaturated multiple bonds is a frequently used 
for tritium labelling of small molecules. The overall reaction is illustrated in scheme 
14. Varying tritium incorporations are often observed and this method can be used 
for synthesis of high specific activity compounds. An example of isotopic 
scrambling and the proposed mechanism for multiple tritium incorporations into an 
unsaturated compound is shown later in the result section. In a normal tritiation of a 
single double bond, the incorporation of one tritium is sometimes observed, leaving 
a specific activity of the labelled compound ~ 30 Ci/mmol (half of the expected).   
 
 
 
Scheme 1. Illustration of a general tritiation (hydrogenation) with use of heterogeneous and 
homogeneous catalysts.  
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Tritiodehalogenation 
The tritiodehalogenation reaction (tritiolysis of a halogen-carbon bond) is another 
commonly used method for  tritium labelling of aromatic compounds. In scheme 2, 
this general reaction is illustrated.   
 
Scheme 2. Illustration of a general tritiodehalogenation (tritiolysis) reaction using heterogeneous 
palladium and tritium gas. 
 
 
 
H/T exchange (Ir) Crabtree 
 
The discovery of C-H bond activation chemistry with organometallic complexes of 
iridium21, 22 and utilizing these similar complexes with tritium and deuterium gas has 
revolutionised the area of isotopically exchange (H/T) reactions16, 23. In scheme 3, 
the general reaction of substituted aromatic compounds is illustrated. The 
incorporation of tritium is generally dependent on the aromatic substitution of the 
substrate. C-H activation is normally performed close/ortho to directing groups on 
aryls e.g. O or N directing groups16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Illustration of the general H/T exchange reaction using organometallic iridium(I) complexes. 
Two commonly used iridium catalyst are shown in the figure.   
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nBuLi / TMEDA (Tritides) 
 
With the use of a very strong base, such as n-butyllithium (nBuLi) in combination 
with N,N,N’,N’-tetramethylethylenediamine (TMEDA), it is also possible to perform 
acid-base chemistry on T2. In this reaction tritiated butane and lithium tritide (LiT) 
are formed and the latter can be utilized in synthesis of complex tritides. In scheme 
4, a selection of important tritium reactions are listed for the synthesis of exotic 
tritides for reductive tritiation.19     
 
 
 
 
Scheme 4. Illustration of the synthesis of lithium tritide followed by reaction with a suitable 
electrophile for the synthesis of reducing reagents. 
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Results 
In this section the results from the installation of a tritium manifold system and the 
setup of the Hevesy Laboratory’s Tritium Facility is described in detail. A 
subsequent overview of tritium labelling of unsaturated phospholipids and the 
mechanism for isotopic scrambling is also given here. 
 
Description of the Tritium Manifold System 
 
The minimum demand for safe manipulation of high amounts of gaseous tritium is a 
manifold system. Design and acquiring of such a system was the first objective that 
had to be overcome for the work of this thesis. The results from installation of the 
Hevesy Laboratory Tritium Manifold are here illustrated, and this section can be 
read as a part of the materials and methods of the hydrogenation chemistry 
performed.   
 
The deuterium and tritium reactions were all performed on a custom designed tritium 
manifold system manufactured by RC Tritec, Teufen, Switzerland. The tritium 
manifold is constructed of several parts for ensuring a safe handling of carrier-free 
gaseous tritium (T2) in multi curie (Ci) amounts of radioactivity. It is primarily 
constructed with stainless steel tubing and Swagelok® high quality valves (figure 5). 
A picture of the Hevesy Laboratory’s24 tritium manifold is illustrated on figure 4, a 
picture of the backside on figure 6 and the schematic design with indication of 
calibrated tube volumes in figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The picture shows the tritium manifold system with annotations of the different components 
without the mounted tritium source/inlet uranium bed. 
 
 
 
 
The manifold is equipped with four pressure sensors; two Baumer® (0-4000 mbar) 
and two high vacuum Pirani (10-4 – 1000 mbar) sensors. The first Baumer® pressure 
sensors is for measurement of gaseous pressure in the central tube compartment and 
the second is for monitoring the pressure in the reaction vessel. A Pfeiffer (TMH 
Pressure sensors 
Reaction vessel 
Destillation branch 
Deuterium (D2) inlet 
Argon (Ar) inlet 
Nipro valves 
High vacuum 
Tritium waste bed 
Tritium (T2) inlet 
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071) turbo molecular drag pump with a membrane forepump is placed on the back of 
the manifold for creation of high vacuum. The first Pirani pressure sensor is located 
in front of the turbo pump and the second on the manifold system. On two LCD 
displays on the top of the aluminium panel the pressure from the two Baumer® 
pressure sensors is displayed and on a separate Pfeiffer® total pressure controller, 
(outside of the fumehood) the high vacuum is displayed.  
 
Tritium is stored on a uranium bed and is heated up to 500oC for release of T2 gas. 
An additional uranium waste bed is used for absorption of radioactive hydrogen gas 
after reaction.  
 
 
 
 
 
 
 
Figure 5. (right) Schematic drawing of a Swagelok® Nupro-SS-4-HTW bellow valve.  
 
 
 
Figure 6. The back of the manifold is shown to illustrate wires, vacuum pumps and pressure sensors.  
Membrane forepump 
Pfeiffer® DualGauge 
pressure controller 
Turbo pump 
Baumer® reactionvessel 
pressure sensor 
Pirani pressure sensor
LCD display for Baumer® 
pressure sensors 
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Figure 7. Schematic drawing of the Hevesy Laboratory’s24 tritium manifold system with information 
about the calibrated tube volumes. 
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The Hevesy Laboratory Tritium Facility 
 
In installations of a tritium manifold in a laboratory several considerations regarding 
safety and practical issues must be undertaken. The placement in a well ventilated 
fumehood or in a glovebox is a requirement for minimising the possibility of 
contamination incidents. Furthermore, for the analysis of products formed in 
tritiation reactions analytical instruments have to be set up. Ideally HPLC, mass 
spectrometry and LSC instruments are placed in dedicated analysis laboratories. In 
figure 8, a picture of the installed manifold system in the fumehood is illustrated, 
indicating the individual parts relevant to the manifold.  
 
 
Figure 8. The laboratory setup of the tritium manifold system and deuterium gas cylinder for deuterium 
chemistry experiments is shown in the picture. 
 
 
At the Hevesy laboratory, we chose to install a HPLC instrument inside the 
fumehood. This instrument is necessary for purification (preparative HPLC) and 
analysis of tritiated products. Here a Waters Breeze HPLC system was set up, with 
computer, binary pump and eluents outside of the fumehood. The injection port, UV 
detector and columns were all set up inside the fumehood. This installation (before 
applying tritium on the manifold) is illustrated on figure 9 on the next page.  
 
For radioactivity issues this setup was appropriate, of practical reasons the parts 
placed inside the fumehood can be considered tritium contaminated. All utensils 
must thus be wipe tested for a contamination check, before leaving this area. Also 
this setup minimises the risk of contamination of other areas of the laboratory when 
performing the reaction, purification and analysis in the same fumehood in a small 
confined area. 
Deuterium (D2) gas 
cylinder 
D2/T2 manifold 
Membrane pump 
Turbo pump 
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Figure 9. The picture shows the analytical and preparative HPLC system used for the deuterium and 
tritium experiments. 
 
Installation of radioanalytical tools 
When the fumehood and installation of the manifold were prepared for radioactivity, 
several changes of the fumehood were made, as well as, acquiring necessary 
radiodetectors for safety and analysis. In figure 10, the final setup of the tritium 
facility is illustrated. For safety and detection of gaseous tritium, a Canberra tritium 
in-air monitor was placed outside the fumehood equipped with a sampling tube. A 
Bioscan Triathler radioflow detector was placed inside the fumehood used with the 
HPLC system. For quantitative tritium measurements and wipe tests a Rackbeta LSC 
was used.  
 
 
Figure 10. A picture of the laboratory installation, of the tritium manifold system with the required 
instruments for tritium detection. Arm holes were cut in the fumehood’s front panel with slides for safe 
performance of gaseous tritium chemistry. 
  
HPLC waste 
HPLC inj. valve 
HPLC 
pump/computer 
Column oven 
HPLC flowdetector 
Tritium in-air 
monitor 
HPLC radiodetector 
Arm holes 
High activity tritium 
waste 
N2 trap for 
lyophilation 
Low activity 
waste Air sampling 
tube 
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Tritium waste management and laboratory contamination surveillance 
 
High amounts of radioactive tritium waste must be deposited according to the 
defined current law. Also, for radiation -safety and -protection reasons, described 
standard procedures for control of the tritium level of laboratory surfaces must be 
followed. In defined intervals and after each tritiation reaction, laboratory ‘hot-spots’ 
must be wipe tested and counted with liquid scintillation counting – the current 
Danish law has set a maximum limit of tritium to be 5000 Bq pr. cm2 laboratory 
surface and 500 Bq pr. cm2 skin surface.    
 
In the Hevesy laboratory, tritium waste handling has been described in standard 
operating procedures, and the produced waste is divided into the following classes 
and handled accordingly; 
 
Low amounts of tritium waste are gloves and 
utensils used in synthesis. This waste is double 
bagged and placed in white buckets for short time 
storage and deposited with the normal non-
radioactive waste (less than 500 MBq per bag). 
 
High amounts of tritium waste (more than 500 MBq 
per container), are further divided into two sub-
classes; 1) liquid HPLC waste and 2) solid waste 
from tritium reactions. This waste is sealed in 
Kautex bottles as shown in figure 10 on the last 
page, and afterwards placed in yellow buckets, 
before it is sent to the Danish Decommissioning25 for 
long term storage.  
 
 
  
 
 
 
 
 
 
 
High amounts of volatile organic bound tritium waste, e.g. tritiated butane as a by-
product from tritide reactions, are lyophilized into special glass vessels and stored in 
metal tubes containing absorbing materials (charcoal and vermiculite). See figure 11. 
Figure 11. (above) Buckets for 
tritium waste. (left) Vessel and 
tubes for storage of radioactive by-
products. 
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Schematised Principle of Tritiation Procedure  
The Tritec RC manifold system is based on a tritium absorbed on uranium storage 
technology. When metallic uranium is exposed to dihydrogen, the gas is efficiently 
absorbed onto the surface as hydride (for tritium it is absorbed as uranium tritide 
(UT3)). It is a very useful way for storage of tritium because the ditritium gas absorbs 
to a very low pressure at room temperature. The tritium gas is released from the 
storage bed by heating with a flame or heat gun to around 500oC (equals ca. 1 atm). 
A normal bed for storage of tritium contains 200 – 250 Ci of radioactivity. 
 
A normal tritiation procedure with this uranium tritide technology is illustrated on 
figure 12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Illustration of a standard tritiation procedure (red = tritium). A) Tritium gas is released from 
the storage bed to the manifold tube system and into the reaction vessel. B) The valves are closed to the 
reaction and excess of tritium reabsorbed onto the storage bed. C) After end reaction the excess of 
tritium gas is absorbed onto a uranium waste bed.  
A 
B 
C 
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Isotopic Scrambling Observed in Tritiation of Unsaturated Compounds  
 
Heterogeneous Olefinic Tritiation of Unsaturated Phospholipids 
 
Homogeneous olefinic tritiation of unsaturated phospholipids were performed, in 
collaboration with research partners at the University of Copenhagen26, and as a part 
of the bachelor project of Anna Pie Jakobsen Huda27. From a tritium chemist point of 
view, these experiments turned out to be excellent examples of the isotopic 
scrambling phenomena, regularly observed in olefinic tritiation reactions. The 
intension of this result section is to present a brief overview of the results from two 
reactions performed, as well as to give a short description of the mechanism behind 
isotopic scrambling. 
 
Heterogeneous olefinic hydrogenation is a widely used and standard method for 
tritiation of unsaturated compounds. This is also mentioned in the section of standard 
tritiation methods described earlier. Tritium labelling of lipids by this method have 
been described in the literature28-32. The effect of reaction conditions on the 
incorporation of tritium into unsaturated compounds has also been investigated, and 
the mechanisms for isotopic scrambling have been proposed in one example from 
the literature33. The results, published, indicate the amount of tritium incorporated 
into unsaturated lipids, and is mainly based on the measured specific radioactivity. 
From theoretical calculations the number of tritium atoms inserted into the products 
was calculated. In the results presented here, the amount of tritium incorporation into 
unsaturated phospholipids was analysed by mass spectrometry.     
 
 
 
Scheme 5. Schematic illustration of the tritium labelling of an unsaturated phospholipid (the first 
substrate; PLPC) using carrier-free tritium gas and a heterogeneous palladium catalyst (Pd/BaSO4). The 
incorporation of tritium is distributed along the unsaturated carbon chain due to isotopic scrambling and 
double-bond migration throughout the carbon chain. Placement of the tritium atoms was not assigned in 
the tritiated product instead the possible positions are illustrated in parentheses.   
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Results, from the two tritium labelling reactions performed, are here presented as an 
illustrative example of isotopic scrambling. In scheme 5 (last page) and scheme 6, 
the overall standard hydrogenation reactions is illustrated, indicating the possible 
positions of the incorporated tritium. 
 
 
 
Scheme 6. Illustration of the results from the tritium labelling of the second substrate; 9-cis-PC. In 
this case the unsaturated bonds are placed on the two different acyl chains. 
 
Materials. All chemicals were used as received from commercial vendors. The 
unsaturated phospholipids 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine 
(16:0 – 18:2) (PLPC) and 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (14:1 – 
14:1) (9-cis-PC) were acquired from Avanti® Polar Lipids, Inc. 5% palladium on 
barium sulfate was supplied by Sigma-Aldrich. 
 
General tritium labelling procedure. A round bottomed reaction vessel (1 ml) was 
loaded with Pd/BaSO4 (5.4 mg), the substrate [PLPC (16:0 – 18:2) (80 l, 25 mg/ml 
in CHCl3, 2 mg) or 9-cis-PC (14:1) (80 l, 25 mg/ml in CHCl3, 2 mg)] and DCM 
(920 l). The vessel was then equipped with a magnetic stirbar and mounted onto the 
tritium manifold system. Subsequently the reaction mixture was cooled to -192oC 
with liquid nitrogen and evacuated to below 5*10-3 mbar. At this point a leak test 
was performed for ensuring a tight connection between flask and manifold. The flask 
was flushed with argon three times and left under an argon (ca. 1000 mbar). The 
reaction mixture was then allowed to warm to room temperature while stirring in 5 
minutes for deoxygenising of solvent. The mixture was then recooled with liquid 
nitrogen and evacuated to below 5*10-3 mbar, before carrier-free tritium gas (T2) was 
released into the reaction vessel to a pressure of 500 mbar (the radioactivity amounts 
used was calculated to be approximately 4 Ci). The reaction was allowed to warm to 
room temperature then left with stirring for 2 hours at room temperature.  
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After reaction, the vessel was unmounted from the manifold and the catalyst was 
filtered off through a 1.2 m Whatman GF/C filter. The filtrate was lyophilized 
twice with addition of MeOH (2ml) for the removal of labile tritium and 
subsequently the product was subjected to HPLC for purification. 
 
Preparative HPLC was performed on a Waters Breeze system. Pump: Waters 1525, 
Binary Pump. UV Detector: Waters 2787, Dual  Absorbance Detector. Column: 
Phenomenex Jupiter C-4 column at ambient temperature (20oC). Mobile phase: A 
(5% MeCN, 0.1% TFA) and B (99.9% MeCN, 0.1% TFA). Gradient: 0-2 min 
(20%B), 2-10 min. (20%B to 100%B), 10-30 min. (100%B), 30-32 min. (100%B to 
20%B), 32-35 min. (20%B). Flow: 1 ml/min.  
 
[T]n-1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0 – 18:0) (PSPC): 
The radioactive products were collected from 14-19 minutes, analysed by LSC to 
yield total radioactivity of 9.0 GBq (243 mCi) and with mass spectrometry for 
investigation of tritium incorporation. Mass spectrum of products showed a 
distribution of several tritiated products. The range of tritium atoms incorporated 
into the phospholipid is illustrated by mass spectrometry in figure 13 (from 1 to 22 
T). 
 
 
 
 
Figure 13. Mass spectrum of tritiated phospholipid (16:0 – 18:0) showing the distribution of products 
obtained by heterogeneous tritiation of PLPC (16:0 – 18:2). The amount of T-atom incorporations into 
the carbon-chain is estimated to be between 1 and 20, giving a calculated specific activity from 28.8 – 
576 Ci/mmol.  
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[T]n-1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0 – 14:0) (DMPC): The 
radioactive products were collected from 14-22 minutes. Products were analysed by 
MS for the analysis of tritium distribution, as illustrated on figure 14 (from 4 to 22-
24 T). 
 
 
Figure 14. Mass spectrum of the tritiated phospholipid (14:0 – 14:0) showing the distribution of 
products obtained by heterogeneous tritiation of 9-cis-PC (14:1). The amount of T-atom 
incorporations into the carbon-chain is estimated to be between 4 and 22-24, giving an approximately 
specific activity from 115.2 – 691.2 Ci/mmol. 
 
 
  
 Part I. Introduction to Radioactivity and Tritium as a workhorse in Pharmaceutical R&D 
Conclusion. The heterogeneous olefinic tritiation reactions of unsaturated 
phospholipids performed here are illustrative examples of the isotopic scrambling 
phenomena. This will occur if elimination of a new C=C bond is favoured in contrast 
to formation of a new C-T bond. A proposed mechanism for this T-H scrambling is 
illustrated in scheme 7 (on next page). This mechanism presented here is simplified 
since many possible mechanisms can be imagined by the use of heterogeneous 
palladium. The proposed mechanism presented here is illustrated with 3 free bonding 
sites on palladium. These 3 vacant bond sites are imagined to be placed on the 
particular palladium surface and the occupied sites to bind with the either the support 
or heterogeneous palladium.    
 
Numerous possible products can be imagined from this hydrogenation reaction. If 
the elimination step in the mechanism is favoured, the newly formed olefin can re-
enter into the catalytic cycle. The tritium atoms will in this tritiation wander 
downwards the unsaturated lipid carbon chain. For this particular substrate the 
formation of a conjugated sp2 bond could be favored and consequently result in 
many tritium atoms being incorporated.   
 
 
 
 
 
 
 
Scheme 7. Simplified mechanism of isotopically tritium scrambling. The low partial pressure of tritium 
gas in this reaction is imagined to favour elimation of a new olefin over saturation of the carbon-carbon 
bond. 
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for development of new homogeneous hydrogenation chemistry. The first is a conjugated 
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is an iodinated angiotensin for investigation of dehydrohalogenation reaction.  
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Short Perspective, Objectives and Aims 
  
 
There is an enormous and increasing market in the field of therapeutic peptides and 
proteins and the medicinal industry have turned their priorities towards development 
of these biopharmaceutical drugs. In an era1 of ‘new’ synthetic polymeric 
formulations and bio-conjugated drugs the demand for clinical studies from the 
authorities is naturally increasing for development of safe therapeutics.    
 
The main objective of these graduate studies was the development of new tritium 
labelling methods for peptides and/or proteins. The current first choice and preferred 
tritium labelling methods for peptides and proteins involve either 
tritiodehalogenation of pre-halogenated peptides or tritio-acyl conjugation onto 
nucleophilic amino- or thiol- functional groups.  
 
Other methods have been presented in the literature but often these are more 
‘specialised’ and some are not generally applicable for labelling of newly developed 
drug candidates. 
 
For small peptides (up to approximately 30 AA) heterogeneous palladium 
tritiodehalogenation is feasible but problems have shown to occur when larger 
substrates are subjected to heterogenous catalysts and supports2. Whether it is due to 
clotting or sticking of the substrates to the solid catalyst or inaccessibility at the 
active site on the peptide or protein for the catalyst is undetermined.  
 
Within the last 5-10 years, a few research groups have presented methods for 
derivatising synthetic polypeptides and proteins with homogenous palladium 
coupling techniques (e.g. Sonogashira, Suzuki) and with some degree of success3.  
Considering the chemical properties of these substrates; high molecular weights, 
diversity of functional groups and fragile tertiary structures play important roles and 
also dictates the limitations, for allowable reactions conditions.  
 
Therefore, organometallic reactions on peptide and protein substrates must be 
carried out under mild conditions; preferable in a (buffered) aqueous medium, at 
temperatures to avoid denaturation and neutral to slightly acidic pH. For proteins, 
often salts and surfactants are necessary to maintain proteins in their native state4.   
 
There is a need for new and efficient labelling methods for peptides and proteins - 
this is why we initiated an investigation for the use of homogenous catalysis for the 
tritiodeiodination of peptide substrates.
 Part II. Development of New Tritium Labelling Methods for Peptides. 
Background  
 
 
Perspective on Therapeutic Peptides and Proteins  
 
Peptides and proteins are responsible for carrying out many important biological 
processes in living organisms. These biological macromolecules built of poly-amino 
acids – possess an enormous potential as pharmaceutical drugs. The market for 
proteins and peptides as biopharmaceutical drugs have been increasing for the last 
decade, which have also resulted in an expansion of the field of marketed synthetic 
therapeutic peptides5.    
 
Insulin was the first protein to be isolated and administered therapeutically and it 
remains today as a block buster biopharmaceutical drug for treatment of diabetes6. 
The discovery of insulin by Banting and Best7 in 1921 is perhaps one of the greatest 
discoveries in the history of medicine. This landmark discovery was thus also 
awarded the Nobel prize in physiology or medicine in 19238, and this hormone is 
perhaps the only single molecule known to be subject to three Nobel prizes in 
different scientific disciplines. Frederick Sanger in Chemistry (1958) for his work 
structure determination of proteins especially insulin 9, 10 and later in Dorothy C. 
Hodgkins (in 1964) for her work on three dimensional x-ray structures on 
macromolecules and insulin 11, 12.  
 
More than 60 therapeutic peptides with less than 50 amino acids have found their 
way onto the pharmaceutical market for applications towards a variety of diseases 
e.g. cancer, diabetes, cardiovascular/CNS diseases, infections, inflammation and 
obesity5. Within the total pharmaceutical market, peptides and proteins reached $28 
billion in 2000. Regarding the market for synthetic peptides alone, in the time-span 
from 2003 to 2005 the market increased from €5.3 billion to €8 billion and it is 
estimated to reach €11.5 billion in 20135, 13. 
 
Compared to small molecules - peptides and proteins have several advantages which 
include high affinity and specificity against their molecular targets. They bear 
unique three dimensional characteristics with chemical functionalities and properties 
‘designed’ for a biological function. In-vivo therapeutic peptides and proteins can be 
designed to have a relatively low immunogenicity as they are build of the natural 
building blocks; amino acids13.  
 
In contrast, the main drawback of peptides and proteins as pharmaceutical drugs 
remains the low bioavailability in orally dosed forms, low metabolic stability in-vivo 
and often high manufacturing costs compared to the small molecule therapeutica13.  
 
Bioavailability and biodistribution of peptides are mainly determined by their 
physiochemical properties; therefore peptides composed of natural amino acids are 
generally considered poor drug candidates (as orally dosed drugs). According to the 
‘Rules of Five’ describing the ‘drug-like-ness’ of a new molecular entities (NME) 
formulated by Christopher Lipinski14, 15, and the further appliance of these rules on 
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peptides support the poor bioavailability when dosed orally16. Out of several reasons, 
these biopharmaceuticals are simply too large molecules and have too many 
hydrogen bond donating and accepting groups to be absorbed from the intestinal 
mucosal membranes. For these reasons, until a few years ago, peptides and proteins 
were administered only by injection, either by subcutaneous, intramuscular or 
intravenous injection routes. After injection and the entrance into the body-fluids 
these then meets another challenge. Numerous of proteolytic enzymes with high 
selectivity against peptide bond cleavage are found in-vivo17. These enzymes are 
responsible for the often shorter half-lifes and the low metabolic stabilites of peptide 
drugs based on natural amino acids.  
 
To improve the physiochemical properties and the in-vivo stability of poly-peptides, 
drug discovery programs often include the use of unnatural amino acid residues 
and/or synthetic post-production modification of the polymer chain 18, 19. The scope 
of biopharmaceuticals (polymeric drugs) based on these modifications is without 
boundaries. The modification of a natural occurring peptide or protein raised a 
demand from the regulatory authorities for thoroughly performed clinical trials. An 
in-depth investigation of the pharmacokinetic and dynamic (PK/PD), as well as of 
the distribution, metabolism and excretion properties (DME) must be undertaken for 
these new molecular entities (NME)20. A (by now) standard and FDA approved 
modification of peptides and proteins is PEGylation and several of these modified 
drugs are currently used in clinics1. The synthesis of “new” well designed types of 
pharmaceuticals, together with the more stringent demands from the regulatory 
authorities (e.g. FDA and EMEA), also gives rise to a demand for the development 
of new and efficient radioactive labelling techniques of NMEs. 
 
When the traditional and non-modified peptide or protein drugs (e.g. Insulin) were 
approved as therapeutically used drugs – those could be argued to behave as the 
biomolecules already a part of the human-body. This argumentation resulted in more 
relaxed restrictions for the performed clinical trials from authorities. 
 
 
Chemical Synthesis of Peptides 
 
The structural diversity of the natural amino acids and with introduction of unnatural 
synthetic building blocks gives almost unlimited possible poly-peptide sequences. 
Peptides can be prepared (synthetically) by, recombinant methods, modification of 
isolated natural products, or lastly chemical synthesis in either solution or on solid 
support. It is possible to synthesise peptide therapeutics in multi kilogram scales and 
it is done in production environments. In the search for peptide drug candidates, 
synthesis is often performed on solid support and many techniques for synthesis of 
large combinatorial peptide libraries have been developed21. Total synthesis of 
peptides is a very well-described and still developing science 22. 
 
In this thesis, Solid Phase Peptide Synthesis (SPPS) have been applied for the 
synthesis of two peptide substrates. These substrates were used as model compounds 
for developing new deuterium and tritium labelling techniques. A brief introduction 
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to the history and development of the chemical synthesis of peptides is therefore 
presented here.  
 
The first description of the peptide-bond synthesis of dates back to around year 1900 
by Hermann Emil Fischer23. Fischer was limited to the chemistry of simple 
unprotected amino acids in solutions which had its limitations. Since then an 
evolution has happened on the development, analysis and use of peptides. Later on, 
the introduction of functional group protection on amino acids, made it possible for 
in-solution synthesis of several natural peptides24-26. 
 
The major breakthrough for peptide synthesis was the invention of chemical 
synthesis of peptides on functionalised solid matrixes by Bruce Merrifield in 196327. 
With his article, he demonstrates the synthesis of a tetrapeptide on insoluble polymer 
beads of styrene and divinylbenzene. This invention has indeed revolutionised the 
area of peptide synthesis and Merrifield was thus recognised with the Nobel prize in 
1984 for his work28.  
 
The basic strategy of SPPS is repeated amino (NH2-) and side chain- protected 
amino acid couplings onto a functionalised insoluble solid support. The main 
advantage of chemistry on a solid support is easy removal of excess used coupling 
reagents by filtration and washing.   
 
Today, numerous solid matrixes, coupling strategies and amino acid protections 
schemes have been developed29.  For a basic overview of SPPS with use of the Fmoc 
methodology (as applied for synthesis of the radiolabelling substrates) please refer to 
scheme 1 (next page). 
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Scheme 1. General overview of solid phase peptide synthesis using the Fmoc methodology, repeated 
HATU/DIPEA couplings and a hydroxyl-group functionalized solid support linker. 
 
 
Stepwise; (a standard sequence for peptide synthesis) begins with anchoring the first 
amino acid at the carboxyl group onto the solid support with a cleavable linker 
(loading). After the loading sequential (selective) N-deprotections and amino acid 
couplings are performed for construction of the peptide. After iterative FmocNH-
deprotections and couplings, the peptide is cleaved from the support by conditions 
determined by the linker.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Linkers of the Wang, Rink and Marrifield resins. 
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Three resins with functionalised linkers are illustrated in figure 1 (last page). In this 
thesis two types of resins have been used for the synthesis of the peptide substrates. 
For synthesis of Angiotensin-I the Wang resin was applied (please refer to the 
experimental section in appendix for details of this peptide synthesis). This resin is 
functionalised with a 4-benzyloxybenzyl alcohol linker and when the poly-peptide 
are cleaved from this resin the C-terminal becomes a carboxylic acid30. The modified 
enkephaline substrate, which was also synthesised, has a C-terminal amide function. 
For this the Rink amide resin31, functionalised with a trialkoxy-diphenyl-methyl 
Fmoc-amine, was applied (details about this peptide synthesis are described in the 
result section of this part). For comparison, the Merrifield resin, functionalised with 
a chloromethyl linker, originally applied and developed by for the first poly-peptide 
synthesis27, is also depicted on the figure. (The synthesis of the peptide substrates are 
described in greater detail in the result section). 
 
In the end of a synthesis - when the peptide is cleaved form the resin - the amino 
acid side group protections can also be cleaved. It depends on the later application of 
the peptide, if the side-chain protective groups are wanted cleaved or kept if these 
are needed in subsequent solution based reactions. Protection schemes and a more 
labile linker can be applied for this.  
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Protecting Group and Coupling Strategies in Peptide Synthesis 
 
There are two different N-protecting group methodologies in SPPS, fluoren-9-
ylmethoxycarbonyl (Fmoc) and tert.-butoxycarbonyl (Boc). The Boc strategy 
introduced by Merrifield takes advantages of the difference in lability of the N-
protective group and the side chain protective groups, which are cleaved by 
trifluoroacetic acid (TFA) and hydrogen fluoride (HF) respectively32.  
 
The use of hydrogen fluoride (HF) as the cleavage reagent, is not without any risks 
and can cause severe chemical burns, and HF chemistry also require special 
equipment. This is why peptide chemists have now phased out Boc chemistry and in 
replacement use Fmoc as the amino protective group. This revolutionary amino 
protection group was first described by Louis Carpino in 197033 as a new base labile 
amino protection group for use in organic syntheses34, 35. The mechanism for Fmoc 
deprotection is illustrated in scheme 2.  
 
In the work of this thesis, Fmoc chemistry have been applied29. In general the base 
(piperidine) facilitates the cleavage by elimination of dibenzofulvene followed by an 
irreversible decarboxylation, leaving the deblocked/unprotected free amine.  
 
 
 
 
 
 
 
Scheme 2. Mechanism for the Fmoc deprotection of amino acids in SPPS. 
 
 
In the general peptide synthesis, the peptide bond is formed by the reaction of an 
activated carboxylic acid to a free deblocked amine. Many activation reagents have 
been developed and shown to be applicable for this reaction. In the beginning of the 
SPPS era, carbodiimide couplings were generally applied. Later on, highly efficient 
coupling reagents have been developed. In figure 2 (next page), a very limited 
selection of these coupling reagents are illustrated. In this thesis the HATU coupling 
reagent have been utilized, together with the non-nucleophilic base DIPEA. The 
addition of HOBt or HOAt, have been shown to ensure, the optical integrity of the 
stereogenic center at the C-terminal of the activated carboxylic acid in the coupling 
reaction36. 
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Figure 2. A selection of commonly used coupling reagents. 
 
 
The mechanism for the HATU/DIPEA peptide coupling reaction are proposed to 
proceed as shown on scheme 3.  
 
 
 
 
 
Scheme 3. Coupling mechanism for the formation of a peptide/amide bond with HATU or TBTU and 
DIPEA.  
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Current Methods for Tritium Labelling of Peptides and Proteins 
 
In this section the current methods for tritium labelling of peptides are given as a 
short overview. Several approaches have been attempted for this radiolabelling of 
poly-peptides, some methodologies more applicable than others. 
 
Tritiodeiodination 
 
An extensively used tritiation method for general labelling of new molecular entities 
(NMEs) in particular is the tritiodehalogenation reaction (please refer to Part I of this 
thesis for an overview of general tritium chemistry). This tritiation method has also 
been used for peptides in several publications 37-46. The method has advantages in the 
labelling of peptides and proteins with a tyrosine residue included into the peptide 
backbone, because these residues are readily iodinated using organic or enzymatic 
iodinations47-49. Alternatively, an iodinated tyrosine can be incorporated in the 
synthesis of the peptide.     
 
 
 
 
 
Scheme 4. A general tritiodeiodination reaction on peptide or proteins in two chemical steps.  
 
In scheme 4, a general overview of tritiodeiodination on peptides is outlined. First 
step is iodination of a tyrosine residue with the use of an electrophilic iodide source, 
secondly the actual tritiodeiodination is performed using gaseous tritium and a 
heterogenous palladium catalyst. 
 
Tritioacylation 
 
The commercial availability of tritioacylation reagents, such as [3H]acetic anhydride 
have made this method for labelling of peptides and, in particular, proteins one of 
the preferred choices50. 
 
The introduction of N-tritioacetoxyphtalimide and N-succimidyl 2,3-[3H]propionate 
with a high specific activity have made these reagents favourable. They eliminate 
some of the disadvances from the smaller [3H]acetic anhydride, such as its volatility 
and unavoidable loss of radioactivity (50%) when this reagent is applied. 
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Tritioacylation reagents are readily available by synthesis which is shown on scheme 
5. The N-tritioacetoxy-phthalimide reagent has been prepared by radical 
tritiodehalogenation of the iodinated precursor51 and N-succinimidyl tritiopropionate 
can be prepared, either by gaseous reduction of an unsaturated propenyl/propynyl 
acid followed by coupling to N-hydroxy succinimide or by the direct reduction of the 
already coupled succinimidyl52, shown in scheme 5.  
 
 
 
 
 
 
Scheme 5. A general tritio- acetylation/-propionylation labelling of peptides and proteins. The labelling 
reagent N-tritioacetoxy-phtalimide can be prepared using radical tritiodeiodination with Bu3SnT and N-
succimidyl tritiopropionylate by tritiation of the corresponding alkene/alkyne. 
 
 
Tritiation by conjugation onto peptides and proteins with these reagents can be 
performed onto free amino (lysine residues or N-terminal) and thiol functionalities 
but not hydroxyl groups. Labelling can be performed in buffered solutions at pH 7-8 
and at conditions from 0oC to room temperature in a wide variety of solvents 
(MeCN, DMSO, MeOH, dioxane and water) 52-54.  
 
Although this method is preferred as a tritiation method of proteins, the conjugation 
interferes with the biological properties of the labelled molecule. Especially if a 
small peptide substrate is labelled, this conjugation could be a significant structural 
change and have a great impact on the peptide affinity towards its target. At 
physiological pH the lysine residues are protonated and conjugation will prevent 
this.  
 
Olefinic Hydrogenation using Homo- and Hetero-geneous Catalysts 
 
The incorporation of tritium into peptides has also been reported by olefin 
hydrogenation of unsaturated amino acids. A prerequisite for this method to work is 
introduction of an unsaturated amino acid residue into the backbone of the peptide. 
Several more or less successful methods have been described; an exotic enzymatic 
2’,3’-oxidase of tryptophan have been reported 55, otherwise the perhaps most 
accessible way is with the use of an unsaturated amino acid in SPPS 56-60. 
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On scheme 6, three different labelling reactions are illustrated (Please refer to Part I 
of this thesis for a more general overview of different hydrogenation methods). A 
standard olefinic hydrogenation uses either a heterogeneous palladium or a 
homogenous rhodium (Wilkinson’s) catalyst in an organic solvent and tritium gas.  
 
In the examples in scheme 6 two different methods have been highlighted for 
tritiation of dehydroproline. The first uses Spillover Tritium (ST) with a solid 
catalyst and the second a heterogeneous catalyst in solution. A large difference in 
specific activity is noted in these two reactions. It must be noted that there is no 
general trend in which method gives the highest specific activity60.   
 
 
 
Scheme 6. Literature examples of deuterium and tritium labelling of unsaturated amino-acid residues of 
tryptophan, proline and alanine55, 57, 60. Three hydrogenation methods are illustrated here, homogeneous 
with Rh(I), heterogeneous with PdO and solvent-free high temperature H/T exchange. 
 
It is also important to notice that the tritiation of dehydrotryptophan and 
dehydroalanine in the reactions above is performed at the stereogenic center of the 
amino acid residue. This is why these two methods, in my opinion, are in general not 
applicable in labelling of peptides and proteins. A subsequent necessary resolution 
of the two enantiomeric generated peptides could be imagined as a doubtful 
procedure.   
 
 
High-Temperature Solid-State Catalytic Isotope Exchange 
 
The last method, which will be mentioned in this section, for tritium labelling of 
amino acid residues in peptides, is the use of Spillover Tritium (ST) in solvent free 
reactions61. This labelling technique is performed in solid state at high temperature 
with the use of a low pressure of tritium gas.  
 
In general the peptide/protein is evaporated onto a solid support e.g. aluminium 
oxide, and a solid hydrogenation catalyst such as palladium, rhodium or platinum is 
 Part II. Development of New Tritium Labelling Methods for Peptides. 
added62. When this solid mixture is heated to 100oC - 200oC under an atmosphere of 
hydrogen gas - isotopic exchange (H/T exchange) will occur randomly and with high 
labelling efficiency (SA up to 2000 Ci/mmol  70 T/mmol).  
 
The High Temperature Solid-State Catalytic Isotope Exchange (HSCIE) labelling 
method has been employed for proteins isolated from extremophile 
microorganisms63 with only minor loss of enzymatic activity when labelled at 
temperatures below 120 oC 64. This method is limited to a few published examples 
because of the known loss of amino-acid chirality and denaturation at elevated 
temperatures62, 65. 
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Homogenous Catalysis and Peptides 
 
A brief introduction to the concept of homogenous catalysis, followed by an 
overview of applications with peptides and proteins is described in this section.  
 
The field of homogenous catalysis is enormous and is thus the subject of extensive 
research in chemistry groups, and excellent research articles, as well as, many 
reviews on this topic, have been published66, 67.   
 
 
Palladium and Phosphorus Ligands in Organocatalysis 
Some of the most popular catalytic C-C bond formation reactions involves the use of 
palladium(0) complexed by phosphorous ligands. Palladium (0) is a d10 element and 
most of the stable and isolable palladium(0) complexes follow the 18- of 16-electron 
rule68 (with equivalent 4 or 3 lone-pair donating ligands).  
 
Palladium(0) complexes (e.g. tetrakis(triphenylphosphine)palladium(0)) tend to exist 
as a coordinatively saturated 18 electron tetrahedral d10 complex, but depending on 
the ligand, they readily dissociate into the reactive and coordinatively unsaturated 
16- or less-electron species. Two properties of the coordinating ligands are primarily 
considered to determine the reactivity of the catalyst – the electronic and the steric 
properties of the ligand. Before the 1970’s electronic properties, of ligands, were 
general considered to dictate the reactivity of the catalyst, until, Chadwick Tolman 
in the 1970’s investigated phosphine ligand steric properties in depth. Quantitative 
ligand dissociation of nickel(0) carbonyl substituents were correlated with measured 
phosphine cone angles68-71. The experimental values from these experiments and the 
measured cone angles are illustrated on figure 3, and as it appears, the more bulky 
phosphines (with large cone angles) replace less carbonyl ligands from Ni(CO)4. For 
more precise determination of the phosphine cone angles calculations by 
mathematical/computational methods or estimation by x-ray structural data is today 
the method of choice69.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. (Left) Plot (reproduced from the litterature68) of the experimentally measured phosphorous 
Tolman cone angle () versus the ligands binding ability towards Ni(0). (Right) (a) Original device by 
Tolman, for experimentally measurement of the Tolman angle of phosphine ligands72. 
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The extent of ligand dissociation in phosphine palladium complexes increases in the 
order PMe3 < PMe2Ph < PMePh2 < PEt3 < PPh3 < P(iPr)3 < PCy3 < PPh(tBu)2 < 
P(tBu)3. In general phosphines with large cone angles tend to dissociate to a larger 
extent than the phosphines with smaller cone angles. This gives rise to low ligated 
and reactive 14 e- and 16 e- species. Hartwig et al. have performed investigations of 
the properties of low-ligated palladium species with bulky-phosphines. It was found 
that these are very efficient for some reaction types (e.g. for the cross-coupling of 
aryl-chlorides which are normally inactive in these reactions)73-77.  When the tri.-
tert.-butylphosphine ligand (a bulky phosphine with a cone angle of 182o) is 
employed with palladium, it forms a bis-ligated 14 electron palladium species. This 
ligand has been utilized and found useful for cross coupling reactions. Because of 
the low ligated palladium an increased reactivity is observed and often reactions can 
be performed at room temperature. Cross-coupling reactions with P(tBu)3 have been 
pioneered by Gregory Fu et al78-83. The increased reactivity / reaction rate is expected 
to be a consequence of a favoured oxidative addition step in the catalytic cycle (a 
general catalytic palladium cycle is shown in scheme 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. General accepted cross coupling reaction mechanism. X = Halogen, OTf. L = Phosphine 
ligand. Het = Boron, Silicon, Tin ect. 
 
The cross coupling catalytic cycle consists of three important individual steps. First 
the oxidative addition of palladium(0) across an aryl-X bond for the formation of a 
palladium(II) species. The X stated in the scheme is the leaving group, and the 
kinetics for this reaction depends on the element. Approximate orders of reactivity of 
varying leaving groups are as follows: I > OTf > Br > Cl >> F. Following step of the 
cycle is the transmetallation step. It has been proven that many C-heteroatom 
compounds are feasible for this.  
 
Important cross-coupling reactions include: The Suzuki coupling with use of C-
boronic acids84, the Stille coupling with the use of C-alkyltin compounds85 and the 
Hiyama coupling with use of C-silicon86-88.    
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Palladium(0) Catalysed Reactions for Conjugation of Peptides and Proteins 
In the past decade palladium catalysed reactions for site specific conjugation of 
peptides and proteins have gained more interest. Although the reported examples are 
sparse; Suzuki, Sonogashira and Heck type cross coupling of iodinated 
phenylalanine and tyrosine residues have been presented in the literature.  
 
Although proteins can be functionalised they are still difficult to functionalise by 
organic reactions. The large steric hindrances from neighboring amino acids residues 
limit access to the reaction site within the protein89. This could result in prolonged 
reaction times or no availability at the reaction site. 
 
The pioneering example of protein bioconjugation, by an aqueous Sonogashira 
coupling, were reported by Schmidtchen and Dibowski in 199890. In their paper they 
present the use of water soluble phosphines as the palladium ligand. 
 
Subsequent examples include; Arylation of diiodotyrosine91, one-pot borylation and 
homo-coupling of iodinated tyrosines92 and functionalization of p-iodo-
phenylalanine of proteins93 (figure 4).  
 
 
 
 
Figure 4. Suzuki-Miyaura cross coupling for bioconjugation of p-iodo-phenylalanine in the WW 
domain of the Pin1 protein (Time 20 h., Temp. 20 oC).93 The illustration have been generated from a 
PDB file (1I8H.pdb) using UCSF Chimera as the software94. 
 
 
Other important examples include the Heck and Sonogashira coupling of 
alkene/alkyne derivatives onto iodinated amino acids95, 96. These few publications are 
outstanding examples, demonstrating homogenous catalysis with palladium(0)-
phosphines on peptides and proteins as the diversity of amino acid functionalities 
such as hydroxyl, carboxylic acid, amine, thiol could be imagined to ‘poison’ and 
deactivate the catalyst. 
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Silicon in Cross-Coupling Reactions 
Silanes (R4Si) and hydrosilanes (R4-nSiHn) have many applications in synthetic 
organic chemistry. They are used as reagents in palladium cross coupling reactions, 
as radical and non-radical reducing agents. Their strong advantages are manifested 
in combination with transition state metals, where they function as both reducing and 
C-Si and C-C bond forming reagents. In combination with a radical initiator (e.g. 
AIBN) they can also function as radical based dehalogenation reagents97. 
 
The silicon based C-C cross coupling reaction is a well known reaction discovered 
by Tamejiro Hiyama88 in 198886, 87. This reaction uses fluoride as a silicon activation 
reagent for the formation of a penta-coordinate silicate ion which is much more 
active in the cross coupling reaction98. Silicon cross coupling reactions have since 
been well studied and found many useful applications for C-C bond formation. One 
of the pioneers is Scott Denmark, who, as an example, has described the use of 
silanols in various palladium coupling reactions99. Also trialkoxy-silicon compounds 
have been used in coupling reactions, with78 and without100 the use of phosphine 
ligands.    
 
Hydrosilanes which are demonstrated as relevant hydrogen labelling reagents later in 
this thesis, have also found many other useful applications. In combination with a 
suitable and homogeneous hydrogenation metal catalyst they can be employed as 
reducing agents for e.g. hydrosilylation of unsaturated C-C bonds101.  
 
Hydrosilanes have also been demonstrated as suitable carbon silicon bond formation 
(C-Si) reagents in palladium cross coupling reactions. Especially in recent years a 
number of publications have emerged on this topic. Triethylsilane has e.g. been used 
in a triethylsilyl-aryl couplings with the use of PtO2102 or palladium catalysts103, 104 
and aryl-iodide as the substrate.  
 
 
 
 
 
 
Scheme 8. Reported method for a) Carbon Silicon bond formation103 or b) reduction of aryl-iodides105. 
The same catalyst and reaction conditions form the diffent products. As reported the different reaction 
paths is determined by the substrate in these reactions. 
 
 
On the other hand, triethylsilane has also been reported as selective 
hydrodehalogenation reagents in the same reaction, but with slightly different 
substrates, with homogeneous palladium(0) catalysts. Depending upon the choice of 
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phosphine ligand, substrate and reaction conditions, the hydrosilanes therefore either 
functionalise or hydrodehalogenate the substrate as shown on scheme 8. The 
selectivity in the two reactions schemed above are argued to be an effect of steric 
hindrance. While the ortho-iodoanisole forms only the reduced product, the para-
iodoanisole substrate was reported gives up to 86% silylation and approximately 
10% reduction. At the end of the result section, two similar reactions with the same 
reaction conditions, but without the use of base are shown. 
 
Recent publications report the use of triethylsilane as reducing reagents (for the 
substrates Ar-OTf and Ar-I) with the use of palladium and bulky phosphine ligands 
105-107.  
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Silicon Hydrogen (Si-H) Activation Chemistry 
 
As described in the last section, the application of Si-H activation chemistry is a very 
useful tool for the formation of the synthetically useful C-Si bond. In addition, the 
hydridic character of the hydrosilane makes these useful reductive reagents. 
 
Silicon-Hydrogen bond activation chemistry has been a topic of interest for many 
years, especially due to the ability of Si-H -bond coordination to transition 
metals108-112.  
 
The formation of stable M(d)–Si-H()  complexes have been well studied and 
characterised and the process of complexation is believed to proceed as illustrated on 
figure 5. Theoretical investigations, IR and other spectroscopic methods have 
confirmed the theory about the Si-H  donation as well as the metal(d)- 
backbonding. Formation of a -complex followed by an oxidative addition step of 
the Si-H bond is one of the key steps in the mechanism in hydro and/or silylation 
reactions.  
 
 
 
 
 
 
 
Figure 5. a) The reaction scheme for the oxidative addition of a silicon-hydrogen bond to a transition 
metal (M). The transition state involves the initial formation of a M(d)Si-H() complex followed by 
the oxidative addition. b) Illutration of the M(d)Si-H() bonding molecular orbitals. c) Illustration 
of the M(d)Si(*) bonding orbitals. (* = anti bonding orbital). d) The molecular orbital diagram of 
the bonding orbitals and energy levels.  
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Olefinic Hydrogenation with Homogeneous Rhodium(I) Complexes 
The application of homogenous rhodium catalyst has been reported for 
hydrogenation and tritiation of olefinic substrates113, 114. Rhodium is one of the most 
important transition metals for this reaction and it works at relatively low hydrogen 
pressures. The Wilkinson’s catalyst ((Ph3P)3RhCl) was developed in 1966115 and was 
shown to hydrogenate a variety of olefinic substrates when dihydrogen was 
employed.  
 
The mechanism for this hydrogenation is well understood116 and proceeds through 
the catalytic cycle illustrated in scheme 9. This hydrogenation method has also been 
utilized in this thesis for hydrogenation of a lipid conjugated peptide. Please refer to 
the result section for details. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9. Mechanism for homogenous olefinic hydrogenation with Wilkinson’s catalyst (L = Ph3P). 
 
 
The mechanism in short; The 16 electron square planar ‘ground state’ complex 
undergoes oxidative addition of dihydrogen to the dihydridorhodium(III) (18 e-) 
species. The subsequent dissociation of L and -complexation of the alkene is then 
the next step in the hydrogenation process.  
 
One of the key advantages of this catalyst is that it does not affect functional groups 
such as CHO, OH, CN, Cl, COOH and O, which makes this applicable for use with 
peptides and proteins. Isotopic scrambling is also observed with this hydrogenation 
catalyst as illustrated in the result section from the labelling of a conjugate peptide. 
Also refer to the results presented in part I of this thesis for another examples of 
isotopic scrambling.  
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Results 
 
Description and Synthesis of the Peptide Substrates for Hydrogen Labelling 
 
Two substrates/model peptides were synthesised for homogeneous hydrogen 
labelling experiments. For this standard SPPS was employed, using the Rink amide 
resin for synthesis of an enkephalinoid peptide and the Wang resin for synthesis of 
Angiotensin-I. The two substrates are shown on figure 6.  
 
 
 
Figure 6. The two synthesised peptide substrates (model compounds) for homogenous hydrogen 
labelling , N-octenyl-enkephaline and Iodo-[Tyr4]-angiotensin-I. The red arrows indicating the target of 
labelling. 
 
N-octenyl-enkephalin 
The idea behind the unsaturated lipid conjugated substrate (N-octenyl-enkephalin) 
was investigation of homogeneous hydrogen labelling of peptides on a conjugate 
part.  
 
The acetylated hexamer peptide of the sequence Ac-Arg-Phe-Met-Trp-Met-Lys-NH2 
(named acetylines117 – acetylated enkephalines) was found to have very high affinity 
towards opioid receptors. In a large screened chemical library of more than 52 
million hexapeptides, this peptide was found to have selective antagonistic 
properties for the , 	3, 
 opioid receptors with the impressive IC50 values 1.9 nM, 
0.7 nM and 24.7 nM respectively118. It bears no resemblance to any known native 
opioid peptides, but it could be a promising therapeutic peptide. The biology is, 
though, outside the scope for this work. Here it is used as a model peptide for 
demonstration of double bond hydrogenation. Also in contrast to the increasing 
demand in the medicinal industry for tracing conjugate parts of “new” polymer 
drugs, this peptide could be imagined as a suitable model substrate for tritiation. For 
convenience this synthetic peptide will be named N-octenyl-enkephalin throughout 
this thesis, although it has no structural similarity to the opioidic peptide 
enkephalins119.  
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Iodo-[Tyr4]-Angiotensin-I 
The other substrate selected and synthesised was iodo-[Tyr4]-angiotensin-I. A 3-
iodo-tyrosine residue was incorporated into the backbone of the peptide in the 
synthesis. This peptide is a ten-mer biological relevant peptide, though without 
known therapeutic value. It was chosen as a substrate for development of new 
homogenous hydrodehalogenation reactions. The peptide was also chosen as a 
model peptide, as it contains a variety of functional groups that could interfere in 
homogenous catalysis.     
 
General Materials and Methods for SPPS. The peptides were synthesised by manual 
SPPS using Fmoc protection strategy with HATU/DIPEA as the coupling reagents 
and the DIC asymmetrical anhydride method for loading of the Wang resin. Manual 
reaction vessels with glass-filters were used with rotation (shown in figure 7). 
Protected amino acids, resins and reagents were used as received from GL Biochem 
(Shanghai). The actual loading of the resin was not determined; instead the 
specifications from the vendor were used for the stoichiometric reagent and theoretic 
yield calculations. For the Wang resin the loading was specified to 1 mmol/gram 
resin and for the Rink amide resin 0.5 mmol/gram resin.    
 
 
 
 
 
Figure 7. Manual SPPS reaction vessel (5 ml) from Peptides International Inc. 
 
 
General Procedure. Loading of the Wang resin was performed using the 
symmetrical anhydride loading method employing diisopropylcarbodiimide (DIC) as 
the reagent. The Rink amide resin was initially Fmoc deblocked and loaded using 
standard HATU/DIPEA coupling. In each amino acid coupling 4 eq. Fmoc protected 
amino acid, 3.9 eq. HATU and 8 eq. DIPEA were used. After each coupling and 
Fmoc deblocking steps a Kaiser test was performed for a qualitative evaluation of 
the coupling/deblocking quality. In case of blue/purple-ish beads after an amino acid 
coupling, the coupling was incomplete and consequently a second coupling was 
performed. The Kaiser tests were positive (blue) after all Fmoc deblockings. For 
further details about the peptide synthesis (procedure and results from Angiotensin-I 
synthesis) please refer to the supplemental information of the manuscript in 
appendix.  
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The peptide synthesis flow-diagram used in these syntheses is illustrated in scheme 
10.  
 
 
 
 
 
Scheme 10. General flow diagram for SPPS of the two substrates. 
      
 
N-(oct-2-enyl)-enkephaline. In a manual SPPS reaction vessel Fmoc-Rink amide 
resin (678 mg) with a specified loading of 0.5 mmol/gram were deblocked with 20% 
piperidine in DMF (4-5 ml). In a small beaker Fmoc amino acids (4 eq.) and HATU 
(3.9 eq.) were balanced out and dissolved in a minimum amount of dry DMF 
(typical 4-5 ml) then DIPEA added. This acylation reagent mixture was used in the 
sequential amino acid couplings (30-40 min.) and piperidine (2 x 4-5 ml 20% 
piperidine in DMF) in the Fmoc deblockings. The acylations were performed in 
following order; FmocNH-Lys(Boc)-OH, FmocNH-Met-OH, FmocNH-Trp(Boc)-
OH, FmocNH-Met-OH, Fmoc-Phe-OH, Fmoc-Arg(Pbf)-OH and at the end 2-
octenoic acid. After completion, the peptide was cleaved with reagent B, (88 % 
TFA, 5% H2O, 5% phenol and 2% triisopropylsilane). After removal of the reagents 
under reduced pressure, resolvation in a minimum amount of 40% MeCN with 0.1% 
TFA and filtration of insoluble compounds through a Wattman GFC filter; the crude 
material was subjected to preparative HPLC for purification. 
 
Preparative RP-HPLC was performed on a Knauer Smartline. (Components: 
Manager 5000, Pump 1000, UV Detector 2500) with a Eurosphere C-18 column (20 
x 250 mm) at ambient temperature (20oC). Mobile phase: A (5% MeCN, 0.1% TFA) 
and B (99.9% MeCN, 0.1% TFA). Gradient: 0-4 min (0%B), 4-17 min. (0%B to 
35%B), 17-25 min. (35%B to 100%B), 25-28 min. (100%B), 28-29 min. (100%B to 
0%B), 29-33 min. (0%B). Flow: 10 ml/min.  
 
The peptide was collected at 27.6-28.3 min. and the combined fractions lyophilized, 
yielding 18 mg (theoretical 5% of specified loading of the resin). The peptide was 
analysed to have a purity >95% (figure 8).  
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Figure 8. Analytical HPLC of N-(oct-2-enyl)-enkephaline after purification. 
 
 
Analytical HPLC was performed on a Waters Breeze system. Pump: Waters 1525, 
Binary Pump. UV Detector: Waters 2787, Dual  Absorbance Detector with the 
Phenomenex Luna C-18 column at ambient temperature (20oC). Mobile phase: A 
(5% MeCN, 0.1% TFA) and B (99.9% MeCN, 0.1% TFA). Gradient: 0-3 min 
(0%B), 3-15 min. (0%B to 60%B), 15-20 min. (60%B to 100%B), 20-23 min. 
(100%B), 23-24 min. (100%B to 0%B), 24-27 min. (0%B). Flow: 1 ml/min. 
 
Iodo-[Tyr4]-Angiotensin-I and Angiotensin-I. Experimental details about 
synthesis, materials and methods are described in details in the Supplemental 
Information, in Appendix I.  
 Part II. Development of New Tritium Labelling Methods for Peptides. 
Olefinic Hydrogenation of N-Octenyl-Enkephalin 
 
Homogenous hydrogenation of unsaturated compounds is an important tool in 
organic synthesis and it is also well understood120. In this section, the results from 
the homogenous hydrogen labelling of the conjugated N-octenyl-enkephalin are 
described in detail. 
 
As mentioned in the beginning of Part II of this thesis, hydrogenation of peptides 
and proteins in aqueous solvents would be desirable. For the investigation of 
hydrogenation in water a commercial water soluble rhodium(I) hydrogenation 
catalyst were employed in these experiments and compared to the original Wilkinson 
catalyst (see figure 9).  
 
The experiments were designed as qualitative investigations of hydrogen 
incorporation into the peptide conjugate part.  
 
 
 
 
 
Figure 9. Catalyst used for homogenous deuterium labelling of 2-octenylated enkephaline. Catalyst A: 
RhCl(mTPPTS)3, where mTPPTS = tris(meta-sulfonatophenyl)phosphine. Catalyst B: RhCl(PPh3)3 – 
tris(triphenylphosphine)rhodiumchloride. 
 
The overall results from the hydrogenation reactions are listed in scheme 11 and the 
incorporation of proton- and deuterium- atoms into the substrate were measured by 
ESI-MS as shown on figure 10 (next page). 
 
 
 
 
 
Scheme 11. Results from the hydrogenation reactions. The positions of incorporated hydrogen are 
proposed to be in the conjugated octenoic acid functionality of the octenylated enkephaline. 
 
In the reactions using aqueous solvents the hydrogenated product corresponds to 
addition of two protons when H2O was used, and two deuterons when D2O were 
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used, as the solvent. In the non-aqueous reaction where the Wilkinson’s catalyst was 
employed in DMF as the solvent, multiple deuterium incorporations (1-6 D) was 
observed.    
 
In these reactions the hydrogen donor in the aqueous hydrogenation were shown to 
originate from the protic solvents when the water soluble rhodium(I) catalyst 
((mTPPTS)3RhCl) were employed.  
 
  
Figure 10. Mass spectra of the products from the hydrogenation reactions after 3 hours at room 
temperature. 
 
The use of the water soluble hydrogenation catalysts of both rhodium and iridium 
and the isotope source from protic solvents has also recently been reported in the 
literature121. The general accepted mechanism for the H/D exchange of the rhodium 
catalyst is illustrated on scheme 11. An oxidative addition of deuterium (D2) 
followed by an X+/D exchange is the reported explanation for these observations 
(where X = H+ or D+). 
 
Interestingly this means that the hydrogen donor could be aprotic solvent and the 
electrons for the oxidation be dihydrogen / dideuterium. The mechanism for the H/D 
exchange on the rhodium(III) catalyst is proposed to proceed as shown on scheme 
11 as it was presented in the literature122.  
 
 
 
 
 
Scheme 11. Illustration of proposed catalytic H/D exchange cycle of the dideuterio-rhodium(III) 
complex122. 
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It must be concluded that the water soluble rhodium catalysts are not feasible as 
aqueous tritiation catalysts. The application of homogenous (rhodium/iridium) 
catalysts for hydrogen labelling of olefinic substrates is a useful method for 
deuteration and tritiation reactions in non-protic solvents. It has been illustrated that 
the employment of Wilkinson’s catalyst in DMF is a promising hydrogenation 
catalyst for tritium labelling of conjugated peptide fragments containing unsaturated 
carbon-carbon bonds. Indications from the results here suggest isotopic scrambling 
and multiple deuterium incorporations. The isotopic scrambling mechanism is 
proposed in the result section of part I and similar mechanism can be imagined with 
the Wilkinson’s catalyst in this hydrogenation.          
 
General Hydrogenation Procedure. In a round bottomed flask (1 ml) the substrate 
N-octenyl-enkephalin (1-2 mg) and catalyst (3-4 mg) were dissolved in the solvent 
(0.5 ml). The flask was mounted onto the manifold system and the reaction mixture 
cooled to -192oC with liquid nitrogen. The reaction was evacuated to below 5*10-6 
bar and flushed with argon twice. The mixture was warmed to room temperature and 
stirred for 5 min. (for deoxygenation) before it was recooled with liquid nitrogen.  
 
The flask was evacuated to below 5*10-6 bar and deuterium gas (D2) was introduced 
onto the manifold system and over the reaction mixture. The reaction was allowed to 
warm upon room temperature and the deuterium pressure in the reaction was 
adjusted to approximately 1 atm. (~ 1050 mbar).  
 
The reaction mixture was stirred for 3 hours at room temperature (20oC) and the 
reaction stopped. Semi-purification was performed before MS analysis. Labile 
deuterium were removed by 2 sequential lyophilisations with H2O:MeOH (1:1, 5 
mL). The lyophilised products were solubilised in H2O (5 mL) and a few drops of 
MeCN added then applied onto a preactivated C-18 plus SEP-PAK®. The SEP-PAK 
was washed with H2O (5 ml) and the products eluted with MeCN:H2O:TFA 
(95:5:0.1, 5 ml). After lyophillation and dissolution of the peptide product in H2O 
the hydrogen incorporation was determined by ESI-MS.        
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Gaseous Deuteriodeiodination of Iodo-Angiotensin-I  
 
One of the preferred tritium labelling methods for small molecules and peptides is 
the hydrodehalogenations reaction using a heterogeneous catalyst on a solid support 
and tritium gas (T2).  
 
When this method is employed for labelling of peptides it could be imagined that the 
choice of catalyst and/or support is important for the yield. The yields will 
dramatically decrease when this method is used on larger substrates (proteins). As 
described earlier, it is speculated to be caused by clotting/sticking of the substrate to 
the catalyst or support2 or by inaccessibility to the active site (Ar-I). Initially, a series 
of different catalyst and supports were investigated with deuterium gas (for 
deuteriodeiodination of iodo-angiotensin) to get a perspective of these effects. In the 
same series, a few homogenous catalysts were also applied for comparison. The 
overall reaction is depicted in scheme 12 and the results summarised in table 1. 
 
 
 
Scheme 12. Heterogeneous deuteriodeiodination of iodo-[Tyr4]-angiotensin-I. 
 
Catalyst Solvent 
D2 
[mbar] 
Reaction Time Yield Recovery 
Specific 
Labelling 
Heterogenous Catalysts 
5% Pd/BaSO4 DMF 750 2 hours 51% 31% 100% 
5% Pd/BaSO4 DMF 1050 2 hours 70% 25% 100% 
5% Pd/BaSO4 DMF 1230 2 hours 58% 0% 100% 
10% Pd/C DMF 1000 2 hours 63% 0% 100% 
5% Pd(OH)2/C DMF 1230 2 hours 48% 0% 100% 
10% Pt/C DMF 800 3 hours Trace - - 
5% Ru/C DMF 800 3 hours 0% - - 
Homogenous Catalysts 
PdCl2* DMF 1050 2 hours 82% 19% 100% 
Pd(OAc)2* DMF 1230 2 hours 79% 0% 100% 
Pd(PPh3)4 DMF 750 2 hours 0% 0% - 
RhCl(PPh3)3 DMF 800 72 hours 0% 0% - 
 
Table 1. Selected entries from parallel heterogeneous deuteriodeiodination of iodinated angiotensin-I. * 
Palladium(II)chloride and palladium(II)acetate are both initially homogenous but in the reactions with 
hydrogen gas (D2) the reaction turns almost immediately black and becomes heterogeneous. 
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The table of results show the yield and the recovery yield. These corresponds to the 
isolated deuterio- and iodo- peptides amounts respectively. Yields are calculated 
from the intensities in ESI-MS, assuming identical ionization efficiency of each 
peptide in the electrospray interface.  
 
The results from these deuteriodeiodination reactions give a somewhat clear image 
of the performance of the different catalyst and supports. In summary, as expected, 
the heterogeneous palladium catalyst is most effective in this hydrogenation 
reaction. When the palladium(II) catalysts (palladium chloride and palladium 
acetate) were employed, the reaction remained clear orange and homogeneous until 
the reactions were subjected to hydrogen gas. The palladium(II) was reduced and 
almost instantly turned black and inhomogeneous. For comparison the phosphine 
ligated Pd(0) catalyst, tetrakis(triphenylphosphine)palladium(0), was tested in same 
D2 reaction. No deuteration was observed with the use of this catalyst and the similar 
result with Wilkinson’s catalyst. These latter reactions though stayed homogeneous. 
 
General procedure for gaseous deuteriodeiodination of iodo-angiotensin-I. 
 
In a round bottomed flask (1 ml) the substrate (2-4 mg, iodo-angiotensin-I) was 
dissolved in DMF (0.5 ml) and a small amount of catalyst (2-4 mg) added. The flask 
was mounted onto the manifold system and frozen with liquid nitrogen. It was then 
evacuated to below 5*10-6 bar, flushed twice with argon and allowed to warm to 
room temperature while stirring for 5 minutes (for degassing of solvent). 
Subsequently the reaction mixture was frozen with liquid nitrogen, evacuated to 
below 5*10-6 bar, before deuterium gas was introduced over the reaction. After 
heating to room temperature (20oC) the hydrogen pressure was noted and the 
reaction left for stirring for an appropriate time. The products were then analysed 
after a SEP-PAK semi-purification for the removal of both DMF and catalysts. The 
distribution of product and starting material was measured by ESI-MS, the yield and 
recovery calculated by weight and specific labelling determined by ESI-MS. 
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Silane and Palladium(0) Hydrodeiodinations of Iodo-Angiotensin-I.  
 
Moving towards the use of homogeneous catalysts for hydrodeiodination of the 
iodinated peptide substrate (iodo-angiotensin-I) - a suitable hydrogen donor was 
needed. As it was shown by the gaseous D2 experiments (in the previous section), 
none of the homogeneous catalysts were able to hydrogenate to give the deuterated 
products.  
 
A hydridic hydrogen donor, on the other hand, could be believed to perform the H/I 
exchange in presence of a suitable cross coupling catalyst. One requirement for the 
choice of hydride was that it could be synthesised from hydrogen gas and eventually 
be transferred to tritium (T2) chemistry. The metalloids boron, silicon and tin allow 
for mild coupling with diverse electrofiles in presence of sensitive functionalities of 
various kinds (which is needed for peptides). Also, because boron, silicon and tin 
tritides can be synthesised from lithium tritide (see Part I) these were attractive to 
investigate with homogeneous catalysts. Interestingly, the preparation of silicon 
tritides and their applications as reducing agents in a palladium(0)-aryl triflate 
coupling were reported. As briefly described previously, silanes are suitable tritium 
labelling reagents in a palladium-aryl triflate coupling reaction123. 
 
We therefore set out to investigate silicon hydrides as potential reductive 
hydrodeiodination and hydrogen labelling reagents. Two silanes, the electron rich 
triethylsilane (Et3SiH) and the electron deficient triethoxysilane (EtO3SiH), where 
acquired from commercial vendors and employed with the substrate with and 
without a palladium catalysts. 
 
The results from these initial/preliminary silane and palladium(0) hydrodeiodination 
reactions are listed in table 2.   
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Catalyst Solvent Silane Amount Reaction Time 
Specific 
Labelling 
Conversion 
Pd(0) mediated hydrodehalogenation with Silane 
None DMF Et3SiH 50 uL 24 hours - 0% 
None DMF EtO3SiH 50 uL 24 hours - 0% 
       
Pd(PPh3)4 DMF Et3SiH 50 uL 24 hours 100% 14% 
Pd(PPh3)4 DMF Et3SiH 50 uL 96 hours 62% 100%
A 
Pd(PPh3)4 NMP Et3SiH 50 uL  24 hours 100% 77% 
       
Pd(PPh3)4 DMF EtO3SiH 100 uL  2 hours 45% 100%
A 
Pd(PPh3)4 NMP EtO3SiH 100 uL  24 hours 70% 100%
A 
Pd(PPh3)4 NMM EtO3SiH 100 uL  24 hours - 0% 
Pd(PPh3)4 PEG400 EtO3SiH 50 uL  24 hours - 5%
B 
       
RhCl(PPh3)3 DMF EtO3SiH 100 uL 2 hours - 0% 
 
Table 2. Results from the protiodeiodination reaction using homogeneous palladium and commercial 
silanes - initial screening of reactants. Reactions were carried out in a total reaction volume of 1 ml and 
stirred at room temperature for the indicated time (20oC).   
A All starting material was consumed, but additional unidentified products observed in MS. 
B Aproximate conversion, peptide visual insoluble in PEG400 and PEG observed in MS.  
 
From the result table the hydrodeiodination reactions were successful when silanes 
were combined with a palladium(0) catalyst and no product was observed without 
palladium(0). It must be noted that reactions were observed to be homogeneous in 
all cases. 
 
For optimisation of reaction conditions a few parameters were changed, such as the 
solvent, reaction times and reagent. The solvents that gave the best conversion were 
N-methylpyrolidone (NMP), dimethylformamide (DMF), but for the other PEG400 
and N-methylmorpholine (NMM), no or little conversion was observed. Long 
reaction times with triethylsilane and the use of triethoxysilane also resulted in 
additional/unidentified products. As an example the mass spectrum from the reaction 
with (EtO)3Si1H in NMP is illustrated on figure 11. 
 
 
 
Figure 11. The mass spectrum from the hydrodeiodination of iodo-[tyr4]-angiotensin-I, with large 
excess of (EtO)3Si1H and mediated by tetrakis(triphenylphosphine) palladium(0). 
1H-[Tyr4]-Angiotensin-I 
Unidentified Product(s) 
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General Procedure for 1H-Silane Palladium(0) Hydrodeiodination.  
 
Handling and mixing of reagents were performed in a custom made argon filled 
glove box. The substrate iodo-[Tyr4]-angiotensin-I (2-4 mg, 1-3 mol) and the 
catalysts Pd(0) (or Rh(I)) (2-4 mg, 2-4 mol) was added to vials (10 ml size), then 
capped and weighed outside the glove box. The substrate was dissolved in DMF (0.5 
ml), and all solution transferred to the vial containing the catalyst. After gentle 
agitation of the reaction mixture for a couple of minutes, for total dissolution the 
catalyst, the silane (50 – 100 l, 300-600 mol) was added. Subsequently the 
reaction mixture was transferred to a round bottomed flask loaded with at stirbar and 
mounted onto the manifold system. It was then cooled to -192oC with liquid 
nitrogen, evacuated to below 5*10-6 bar and the flask filled with argon (to a pressure 
slightly below 1 atm.).  The products were then analysed after a SEP-PAK semi-
purification for the removal of DMF (total removal of the homogeneous catalysts 
were not possible by SEP-PAK). The products formed and starting material in the 
reaction was analysed by ESI-MS. Conversion was calculated by product ion-counts 
and dividing with the total added ion-counts on ESI-MS, expecting the same 
ionization efficiency of the products.   
 
 
Conclusion  
 
The use of hydridosilanes in combination with tetrakis(triphenylphosphine)-
palladium(0) turned out to be successful in these initial hydrodeiodination reactions. 
As presented here, a very large excess of silane is used with respect to the substrate 
and with these amounts this method cannot be transferred directly to tritium (T2) 
chemistry. The amount of synthesised tritiosilanes needed to be kept in the range of 
100-200 micromoles for safety reasons. This chemical amount would correspond to 
a theoretical 2.9-5.8 Ci of radioactivity (SA 28.9 Ci/matom T). Also tritiated butane 
would be formed as a by-product in the lithium tritide (LiT) synthesis (see Part I for 
details). For convenience, in the light of the radioactivity amounts, this chemistry 
was first attempted with small scale deuterium (D2) gas chemistry as a model for 
tritium. The general approach for the synthesis of deuteriosilane is illustrated in 
scheme 13 (for experimental details about the synthesis and analysis of 
deuteriosilanes, please refer to appendix I) and the synthesis of LiD on figure 12. 
 
 
 
 
 
Scheme 13. General synthesis of triethyldeuteriosilane. 
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The pictures on figure 12 are showing the reaction vessels (3 ml) in the three steps 
of lithium deuteride synthesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When the silane chemistry was transferred to deuterium chemistry the conversion of 
the iodinated peptide dramatically decreased with the use of the tetrakis-
(triphenylphosphine)palladium(0) catalyst. This was why, we initiated a screening of 
a series of phosphine ligands in combination with a palladium(II) source.  
 
The tuning of the phosphine ligands and the reaction conditions eventually gave full 
conversion of iodo-angiotensin to the corresponding deuterated peptide. These 
optimization studies as well as the results have been described in the manuscript in 
appendix I.  
 
In short, we found that with the use of the bulky electron rich tri(tert.-
butyl)phosphine as the ligand and subsequent addition of fluoride (for cleavage of 
hydroxyl-silylation products) successful hydrogen labelling occurred. 
Figure 12. Pictures of the reaction vessels (3
ml) in the synthesis of lithium deuteride (160
mol, 1.44 mg)  
 
(top left) Reaction of nBuLi with D2 after 2
hours.  
 
(top right) Frozen reaction vessels for lyo-
phillation of TMEDA, hexane and deuterio-
butane.  
 
(bottom right) Lithium deuteride after drying
under vacuum. 
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Silane and Palladium(0) Deuteriodeiodination of Glucagon-Like-Peptide-1  
 
The native unconjugated GLP-1 peptide was chosen as a suitable and larger 
substrate for the palladium(0) deuterio-silane labelling reaction. This was done in 
collaboration with our partners at Novo Nordisk A/S (NN). 
 
Glucagon-Like-Peptide-1 is a natural (pancreatic secreted and hormonal) peptide 
involved in regulation of glucagon plasma levels. This 30-mer peptide (residue 7 - 
37) has thus gained increasingly interest as a potent therapeutic target for the 
treatment of diabetes mellitus, and the number of publications about this peptide has 
grow exponentially over the last decade124. The conjugated GLP-1 peptide drug, 
Liraglutide®, marketed by Novo Nordisk A/S, was recently (January 25th 2010) 
approved by FDA as a therapeutic drug for regulation of blood sugar levels125. This 
conjugated peptide drug is the second GLP-1 analog to be adopted onto the 
American market.  
 
A crystal structure of GLP-1 complexed with the GLP-1 receptor was also recently 
published126. The structure is here illustrated as the red alpha helix in figure 13. The 
blue structure represents the GLP-1 G-coupled trans-membrane receptor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. An illustration of the crystal structure of GLP-1 in complex with the extracellular domain of 
the GLP-1 receptor126. The red helical structure is GLP-1 where the tyrosine residue, highlighted in the 
figure, was the target for deuterium and tritium labelling. The illustration was reproduced from the PDB 
file (3IOL.pdb) and image created with the UCSF Chimera software94. 
 
 
Tritium labelling of GLP-1 and the conjugate drug – Liraglutide® was an essential 
tool for ADME studies and for acquiring of the marketing license. The methods for 
labelling Liraglutide® on both the conjugate and peptide part by gaseous 
heterogeneous olefinic tritiation and tritiodeiodinations respectively, have been 
published37.  
 
Tyr19 
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As mentioned earlier both parts of these “new” type polypeptide drugs have to be 
accounted for in distribution, metabolic and excretion studies in the preclinical trials. 
The structure of Liraglutide and the structural targets for tritiation, at the isotope 
laboratories of Novo Nordisk (NN), are both illustrated in figure 14 (next page). 
 
 
 
Figure 14. The amino acid sequence and the conjugate part of the peptide drug, Liraglutide®, are here 
presented. The targets for tritiation are illustrated with the arrows and the method of tritiation in 
caption. 
 
The tritium labelled GLP-1 is routinely prepared at the isotope laboratories at NN, so 
the iodinated GLP-1 precursor was readily available. At the isotope laboratories at 
NN we prepared this precursor by an enzymatic iodination with the use of sodium 
iodide, hydrogen peroxide and lactoperoxidase. This is a proven method for 
iodination of proteins and other macromolecules in aqueous solutions127. The 
experimental details are, for confidentiality reasons, here not described in details. It 
can be mentioned, though, that a standard tritiation was performed for, educational 
and demonstration purposes. 
 
Results. The general approach for deuterium labelling of GLP-1 is shown below in 
figure 15. For elucidation of the formed products, the exact masses of the substrate 
and product peptides are listed, for the MALDI-TOF analyses. The experimental 
procedure for this labelling was identical to the general procedure for deuterium 
labelling of iodinated angiotensin. This procedure is described in the appendix. 
 
 
 
 
Scheme 15. The procedure for deuteriodeiodination of GLP-1 and the calculated exact masses for the 
relevant peptide products for the MALDI-TOF analyses. 
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After reaction the peptides were analysed on a mass-spectrometer. MALDI-TOF-MS 
was recorded on a Bruker Reflex IV MALDI-TOF Spectrometer using 2,5-
dihydroxybenzoic acid (DHB) in MeOH as matrix. The results are illustrated on the 
following spectra in figure 16 MS of the native GLP-1 and in figure 17 MS from 
the reaction.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Mass spectrum of Native GLP-1 acquired on MALDI-TOF 
 
The mass spectrum shown in figure 16 illustrates the m/z of the monoprotonated (M 
+ H+) and the sodium adduct (M + Na+) native GLP-1 peptide. This spectrum was 
used as the standard for the deuterium labelling.  
 
After the enzymatic iodination of GLP-1 a distribution of native, mono- and di- 
iodinated GLP-1 analogs were present in a mixture. A purification using preparative 
1H-[Tyr19]GLP-1 + H+ (M+1) 
1H-[Tyr19]GLP-1 + Na+ 
(M+22) 
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HPLC was performed for a pure mono-iodinated peptide substrate in order to label 
with tritium. (experimental details for purification is not presented here). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
D-GLP-1 + H+  
(M+H) 
D-GLP-1 + H+ 
+ 2 x D 
 
Figure 17. (top) Results of the analysis 
using mass spectrometry from the 
deuteriodeiodination reaction of iodo-
GLP-1, showing mono deuterated GLP-
1 and a compound consistent with 
further incorporation of 2 x D into the 
peptide. 
 
 
 
(right) The overall mass spectrum from 
the reaction showing approximate 
conversion.  
 
The peaks at m/z = 3485.7 corresponds 
to the incorporation of 2 x D in iodo-
GLP-1.  
Iodo-GLP-1 + H+ 
+ 2 x D 
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Conclusion from the GLP-1 deuteration 
 
The objective for labelling of iodinated-GLP-1 was selective deuteriodeiodination 
with the palladium(0) deuterio-silane method which is presented in appendix. 
 
The results from these reactions were not absolutely conclusive. This was due to 
observations based on the analysis of reaction products from the deuteration of GLP-
1. Some of the compounds, detected by MALDI-TOF, correspond to multiple 
deuterium incorporations into the molecule.  
 
Possible incorporation of 2 deuterium atoms into the iodinated substrate was also 
observed. A plausible theory for this observation could be hydrogenation of an 
unsaturated moiety in the peptide backbone; this would essentially give a mass of the 
product of +4 m/z units (it would be speculative to suggest which amino acid). For 
further investigation of this observation experiments must be conducted on selected 
aminoacid residues not present in the angiotensin-I substrate e.g. tryptophan.  
 
It has not been possible to elucidate the possible products from these labelling 
reactions and the HPLC analysis of GLP-1 product was all unsuccessful, probably 
because of palladium adducts or peptide fibril formation.  
 
From the results it has to be concluded that results, from the homogeneous deuterio-
silane labelling method of GLP-1, was unsuccessful, since the mono-deuterated 
GLP-1 was not selectively formed in the reaction. 
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Silane and Palladium(0) Tritiodeiodination of Iodo-Angiotensin-I 
 
The ultimate goal in development of the homogeneous deuteriodeiodination 
reactions was transfer of the developed deuteration methods to tritium chemistry. 
After the setup of a tritium manifold and dismantling of the deuterium gas, several 
attempts utilizing the silane chemistry with tritium have been attempted. 
 
The optimised reaction conditions for deuterium labelling of iodo-Angiotensin-I 
were used in the attempt to tritium label of this substrate. For radiochemical safety 
reasons, synthesis of triethyltritiosilane could not be followed by analytical methods. 
 
Short note about the safety issues 
 
Transferring the deuterium silane to tritium chemistry makes the practical 
procedures in the laboratory much more laborious. Safety issues - regarding the large 
amounts of radioactivity used in this chemisty - have a great impact on the chemical 
approach. One requirement for safe-handling of Ci amounts of tritium and synthesis 
of tritides is surveillance of tritium contamination levels on surfaces of the 
laboratory. For safety reasons, tritium contamination of surfaces and content in urine 
samples must be checked. In short, the work with tritium chemistry must comply 
with general guidelines and law requirements from the authorities128.    
 
General Procedure for the Tritium Experiments 
 
Lithium tritide (LiT). A round bottomed reaction vessel (1 mL) with a sidearm, 
septum and stirbar was mounted on the tritium manifold, evacuated and flame dried. 
The vessel was flushed with argon gas and evacuated 3 times to ensure an anhydrous 
and oxygen free vessel. After evacuation to a pressure below 5*10-3 mbar the flask 
was filled with carrier free tritium gas (600-700 mbar). TMEDA (50 L) then nBuLi 
(100 L, 160 mol, 1.6M in hexanes) were added to the flask with Hamilton 
syringes through the septum and almost immediately (within 5 - 10 minutes) a white 
preticipate of LiT was formed inside the reaction vessel. The reaction was allowed 
react for additional 2 hours at room temperature until full consumption of tritium 
gas. 
 
The reaction vessel was cooled with liquid nitrogen and the residual tritium gas 
absorbed on the uranium waste bed. The tritiated butane (by-product), solvent 
(hexane) and TMEDA were then lyophillized to a vessel mounted onto the 
distillation branch.  
 
The formed LiT was further dried under vacuum for complete removal of residual 
TMEDA yielding offwhite solid LiT (theoretical amount of 160 mole, 1.44 mg, 
4.61 Ci).  
 
The reaction vessel was flushed 3 times with argon to ensure an inert atmosphere 
and left under an argon atmosphere (800 mbar) before the next reaction. 
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Triethyltritiosilane (Et3SiT). A solution of triethylchlorosilane (320 L, 0.5M in 
THF, 160 mole) was added to the prepared lithium tritide. The reaction was left 
with stirring for 1 hour at room temperature to ensure full consumption of lithium 
tritide before addition of the peptide and catalyst.   
 
Preparation of the triethylchlorosilane solution (0.5M in THF). Triethylchloro-
silane (170 L, 
 = 0.898, 152 mg, 1 mmol) was added to an oven dried vial and 
diluted with dry THF (1830 L). This reagent solution was subjected to GC to 
ensure that there had been no decomposition of the chlorosilane before adding to the 
prepared lithium tritide.  
 
Tritiodeiododination performed by following procedure. In a homemade argon 
filled glovebox, iodo-Angiotensin-I (2-3 mg, 1-2 mol) was solubilised in DMF (0.7 
mL) in a vial. To this vial was then added the catalyst* (20 mol, 100 L) prepared 
in toluene. The peptide and catalyst were gently agitated for 5 minutes before adding 
to the prepared triethyltritiosilane mounted on the tritium manifold. Reaction was 
left stirring for 3 hours before the reaction was treated with TBAF (160 mol in dry 
THF). The reaction was left for another hour then workup of the reaction was 
performed. 
 
Prior to workup a Sep-Pak® Plus (320 mg) C18 cartridge equipped with a 1.2 μm 
Whatman GF-C filter was preconditioned with ethanol (5 ml) followed by a flush of 
distilled water (5 ml).  
 
The reaction mixture was then syringed out of the reaction vessel and added to a 
capped vial containing distilled water (5 ml). This diluted mixture was then filtered 
through the Whatman filter and applied onto the Sep-Pak®. The filter and Sep-Pak® 
was then washed with ultra-purified water (5 ml) for the removal of salts and DMF 
solvent. Afterwards the filter was disposed and the products were eluted using a 
mixture of 80% MeCN, 20% Water and 0.1% TFA (3 ml). For removal of labile 
tritium, the products were lyophilized 3 times with 50% MeOH in H2O (3 ml). The 
products were then subjected to HPLC for purification and analysis.  
 
*Preparation of paladium catalyst (Pd(0) + P(tBu)3). The catalyst was prepared in 
a vial externally prior to use in a small vial. Palladium(II) acetate was added 5 eq. of 
tri-tert.-butylphosphine (1M in toluene). Of this catalyst solution 20 μmoles was 
added to the substrate vial and it was left for 10 minutes before transferring to the 
reaction vessel containing the deuterosilane solution, leaving a pale yellow 
homogenous reaction mixture. After 3 hours of reaction time 1 eq. of 
tetrabutylammonium fluoride TBAF (160 μmole, fluoride) was added to the 
reaction. 30 minutes after this addition the workup of product was performed. 
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Discussion of Results 
 
From the 5 experimental tritiations performed the results from the last reaction 
provided the most promising results. As a result of problems with the Triatler HPLC 
radiodetector and other issues, which will not be discussed here, the first reactions 
were generally inconclusive. The results presented here are representative of the 
other performed reactions. 
 
The preparative and analytical HPLC traces from the reaction performed are 
illustrated in figure 18. From the radiotrace of the preparative HPLC appearance of 
many radioactive substances are observed. Due to the large excess of tritium (160 
μmole) in contrast to the amount of substrate (1-2 μmole) other radioactive 
compounds are also expected seen in the purification. The Sep-Pak semipurification 
does though remove a large quantity of the radioactive by products, silicates, 
tritiated solvents and so on. From preliminary HPLC method developments the 
angiotensin peptides eluted at 15-17 minutes with the preparative methods. 
Therefore this area of the chromatogram is of particular interest, though fractions of 
all parts of the chromatogram were collected and measured by liquid scintillation 
counting for radioactivity quantification. 
 
  
Page 40 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. (top) Results from preparative HPLC purification, radiotrace the. (middle) Analytical HPLC 
trace. (bottom) Analytical HPLC UV trace of Angiotensin-I and iodo-Angiotensin-I. 
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With LSC the amount of radioactivity in the 15-17 minute fraction was determined 
to be 64 MBq of which the main peak (17.7 min) in the analytical HPLC trace, could 
represent the tritium labelled Angiotensin. The delay between the UV detector and 
radiodetector and the use of a large solid scintillation loop, have resulted in the 
broadening of the peaks and difference in the retention time of .53 minutes. 
 
Considering the results from this reaction, the overall conclusion for, the use of 
tritium with the silane-Pd(0) as a method  for labelling of peptides is not completely 
promising. Here a significant difference between the tritium reactions and the 
reactions performed with deuterium is shown. It is, at this point, not totally clear 
why this difference is observed when the silane chemistry is transferred to tritium.  
 
If the tritiosilane and palladium(0) methodology is going to be an applicable method 
for labelling of peptides/proteins further investigations of this reaction have to be 
conducted.  
 
First of all, it has to be clear, whether or not the triethyltritiosilane is formed in the 
reaction from lithium tritide. It is only proposed that this reagent is synthesised, no 
proof is though present for this formation. A good understanding of the reaction -
mechanism and -kinetics would be preferred in the transfer of this deuterium 
chemistry to tritium. An investigation of the isotopic effect in the synthesis of the 
hydrido-silane could be beneficial for at least the first synthesis in this labelling 
reaction – in these tritium experiments analysis of intermediate products have not 
been possible.     
Page 42 
Discussion; Scopes and Limitations for Tritium Labelling with Silanes and 
Palladium(0) 
 
An investigation of the developed deuterio-triethylsilane method, used in the 
deuterium labelling of angiotensin-I, was continued on small molecules (defined 
here as molecules with Mw < 500 Da). These experiments were initiated due to the 
inconclusive results in the tritium labelling reactions of this peptide substrate.  
 
Experiments performed with small iodinated aromatic molecules as the labelling 
substrates could possibly yield a better understanding of the reaction mechanism and 
potentially lead to a labelling method for sensitive substrates. The use of NMR as a 
analytical tool for reaction kinetics and identification of the reaction intermediates 
and products will give a clearer indication of the reaction. At this point a few simple 
reactions have been performed with HPLC as the analytical tool.  
 
Recently, the deuterated triethylsilane (Et3SiD) has become commercial available 
which will make screening of reaction conditions much easier. The preliminary 
results, presented in the following section, give a brief summary of the labelling 
reactions performed with the commercial reagents.  
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Preliminary results from deuteriodeioniation of small molecules with commercial 
triethyldeuteriosilane and bis(tri-tert.butylphosphine)palladium(0). 
 
As hydridosilanes in combination with palladium catalysts have been reported to 
deiodinate simple aromatic compound, which was briefly described in the 
background. This important published103, 105 reaction has a direct relevance to this 
ph.d. project, due to the idea of utilizing tritiated silanes as labelling reagents. 
Preliminary results in the investigation of this method, reactions with (recently 
available) commercial triethyldeuteriosilane, simple small molecules and three 
catalysts were tested. In the parallel reactions 5 equivalents of silane were used 
together with 10 mol% of catalyst (scheme 14 and 15).    
 
 
 
 
 
Scheme 14. The deuteriodeiodination reactions of p-iodo-anisole (1) and 3-hydroxy-4-iodobenzoic acid 
(2) using commercial Et3SiD and palladium catalyst are shown. 
 
 
In the reaction using bis(tri-tert.butylphosphine)palladium(0) as catalyst, an 
immediately reactivity was observed. From the time adding the catalyst and until 
applying onto the HPLC for analysis (figure 19 and 20) all starting material was 
converted into the corresponding deiodinated products. This is in conflict with the 
literature presented results, because no silylated product was observed in these 
reactions. Instead these preliminary reactions, illustrates that very promising 
hydrodeiodination reactions can be performed fast at room temperature and with 
catalytic amounts of palladium catalysts. A rhodium(I) and a iridium(I) based 
catalyst were also tested in the same reaction, though only very little to no 
conversion were observed over a long period of time.  
 
 
 
 
Scheme 14. The attempted deuterodeiodination reactions with Wilkinson’s catalyst and a Ir(I) based 
catalyst are shown. No, or only a little, conversion were observed after 96 hours.  
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Figure 19. HPLC results from the reaction with
4-iodo-3-hydroxybenzoic acid, UV (290 nm)
traces of:  
 
(top left) 3-hydroxy-benzoic acid (Sigma-
Aldrich). Rt. = 4.37 min. 
 
(top right) 3-hydroxy-4-iodobenzoic acid
(Sigma-Aldrich). Rt. = 7.67 min. 
 
(left) products after 15 minutes reaction time.
Deiodinated product, Rt. = 4.51 min.   
Figure 20. HPLC results from the reaction with
p-iodo-anisole, UV (256 nm) traces of:  
 
(right) anisole (Sigma-Aldrich). Rt. = 9.12 min.
 
(bottom right) p-iodo-anisole (Sigma Aldrich).
Rt. = 11.12 min. 
 
(bottom left) product after 15 minutes reaction
time. Deiodinated product, Rt. = 9.15 min.   
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Procedure. In general, the solvents (THF and NMP) were degassed with bubbling 
of argon in dry round bottomed flasks.  
 
A reagent solution of triethyldeuteriosilane (Et3SiD) was prepared prior to the 
reactions. The reagent (~500 mg) was transferred to a sealed vial (20 ml), weighted 
and diluted to a concentration of 50 mg/ml (427 mol/ml) with THF. This solution 
was added in the reagent amounts stated below in the parallel deuteration reactions.   
 
The same procedure was used to prepare the catalyst solution. Under an atmosphere 
of argon bis(tri-tert.-butylphosphine)palladium(0) was added to a vial and dissolved 
in NMP to a concentration of 4.4 mg/ml (8.5 mol/ml). The same regarding the 
rhodium and iridium catalyst (8.5 mol/ml) 
 
The reactions were performed (in parallel) in oven dried round bottomed flasks (50 
ml) under argon with total substrate concentrations of 1 mg/ml for direct 
applications of aliquots to HPLC injections. 4-iodo-anisole (20 mg, 85 mol) was 
added to the reaction flask in NMP (18 ml), then added the reagent solution (1 ml, 
427 mol, 5 eq.) and subsequently the catalyst solution (1 ml, 8.5 mol, 0.1 eq.).   
 
From the reaction mixture aliquots were collected at diffent times, transferred to a 
HPLC vial and subjected directly to analysis. 
  
Conclusion. Preliminary experiments show promising results using hydridosilanes 
as labelling reagents for small molecules. The possibility of the chemical syntheses 
of tritiated silanes makes these reagents attractive for labelling of especially small 
molecules with sensitive functional groups. Immediate hydrodeiodination of the two 
substates were observed when 5 eq. of deuteriosilane were employed with 
homogeneous palladium. With use of rhodium and iridium catalysts a very slow 
reaction rate was observed but still product could be observed, in both reactions.  
 
At this point, the identification of the hydrodeiodinated product is based on HPLC 
analysis alone. Further analyses, mass spectrometry and NMR will confirm that it is 
deuterium incorporation and also the degree of specific labelling. It is however 
slightly possible that it is a proton instead of deuterium labelling.   
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Proposed Future Experiments with Silanes and Palladium(0) 
 
The method with use of hydrogen labelled silanes as reagents for labelling molecules 
with sensible functional groups is presented. This method is though not in-depth 
understood and still many experiments could be imagined for the optimisation of the 
reaction conditions.  
 
For a better understanding of the reaction mechanism further investigations must be 
conducted. These experiments could be investigation of the reaction rate, the isotope 
effect or the tolerance towards a series of functional groups. Eventually this method 
could turn out to be an alternative labelling method for molecules with unsaturated 
bonds, benzaldehydes, carbonyls in general or aliphatic and aromatic halogen. 
 
The silane utilised in these reactions are non-UV active and volatile. This gives rise 
to problems of detection by HPLC-UV and with volatile radioactivity. 
 
Investigations of synthesis and reactivity of UV active and non-volatile tritiosilanes 
is proposed. One example could be dimethylphenylhydridosilane.      
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Abstract 
In our efforts in the development of new reactions for the efficient labelling of peptides and 
proteins with tritium, we here wish to report the use of silanehydrides and homogenous Pd(0) 
mediation for the protio- and deuteriodeiodination of o-iodo-tyrosine of peptides at room-
temperature. 
 
Introduction 
Tritium labelled compounds is an essential tool for ADME studies of new drug candidates and of 
new chemical entities in particular. Current methodologies for the efficient tritium-labelling of 
peptides  include tritioacylation1, spillover isotope exchange2-3, olefin reduction4-7 and 
hydrodehalogenations, e.g. using Pd/C and gaseous tritium8-13. The latter has been one of the 
preferred labelling methods for peptides whilst tritioacylation with N-succinimidyl [2,3-3H] 
propionate presently is the reagent of choice for conjugation and labelling of free amino-groups 
on both peptides and proteins1,14-16. In contrast, low or no isolated yields are often observed in 
reactions using heterogeneous palladium on supports and tritium gas in combination with larger 
peptides and proteins.17 Plausible theories are that the substrate sticks or clots to the metal or 
support, or that the halogenated amino acid is not available at the surface of the metal-hydride 
and thus not accessible for the reaction with tritium at the metal surface. We therefore set out to 
investigate the potential of using homogeneous palladium as a labelling technique for hydrogen-
halogen exchange of iodinated peptides. A homogeneous transition-state metal mediated reaction 
could possibly reduce both clotting and steric hindrance at the halogenated reaction site and 
would potentially lead to increased reaction rates and/or yields.  
 
Homogenous catalysis has been extensively studied and has found a broad range of useful 
applications in synthetic chemistry. Numerous homogenous palladium(0) species have been 
reported to catalyse the cross-coupling reactions between organoboron18 (Suzuki-Miyaura), 
organostannane19 (Stille) and organosilane20-22 (Hiyama) compounds and arylic or alkylic 
halogen substrates. Despite these achievements, only a few groups have applied the cross-
coupling techniques for the functionalisation of peptides and proteins. With the use of water 
soluble phosphine ligands applicable for polar substrates Schmidtchen23 and Ghadiri24 were able 
to perform novel functionalisation onto peptides and proteins. These pioneering examples 
include the use of Pd(0) (Sonogashira) cross-coupling on peptides in aqueous solution. More 
recently, groups have begun to use homogenous palladium catalysis as a tool for peptide and 
protein modifications25-28 including rhodium for olefine hydrogenation29. 
Literature examples of the use of silanes in cross-coupling reactions are limited in contrast to 
the much more frequent boron and stannate coupling reactions. Examples for the preparation and 
use of tritiosilanes as reducing agents have been reported30-31, and silanes have also been shown 
to reduce organic halides, mediated by palladium32. Yamanoi and Nishihara demonstrated the 
use of hydrosilanes and a palladium or rhodium catalysts for the silylation (Si-C) of aromatic 
halides33-34. Although the objective for their work was functionalisation of the arylic halogenide 
to give organnosilanes, they describe that the use of the bulky tert.-butylphosphine as ligand for 
the palladium cross-coupling reaction, almost exclusively defunctionalised and substituted the 
aromatic iodide to an aromatic hydrogen35. Interestingly this reduction was also observed when 
the Wilkinson catalyst (RhCl(PPh3)3) was employed in the same reaction. But changing one of 
the phosphine ligands with a carbonyl ligand (RhCl(CO)(PPh3)2) reversed the selectivity, now to 
give predominantly silylation35.   
 
The hydrides (protides, deuterides and tritrides) of boron, tin and silicon can be synthesized by 
nucleophilic substitution with the use of lithiumhydride and the corresponding halogenide 
(Scheme 2 and 3)31,36. The use of tritides (T
-) as reducing agents has found its way to the 
radiochemistry laboratory and is today regularly used for radiolabelling of small molecules for 
drug development studies37. The weak hydride character derived from the small difference in 
electronegativity of silicon and hydrogen in silanes (Si-H) makes these reducing reagents 
promising in view of the multitude of functional groups often present in peptides. 
 
The objective of this work was development of efficient tritiation methods of an iodinated 
precursor by dehalogenation. To optimise the reductive hydrodehalogenation reaction the 
development work was performed using deuterium gas (D2), resulting in deuterated silanes and 
subsequently deuterated peptides. The use of deuterium allows for optimisation without the use 
of large amounts of tritium gas. When using deuterium, the analysis of deuterium incorporation 
may be achieved by mass spectrometry. In order to ensure that the developed chemistry will 
transfer smoothly to the intended tritium labelling methodology, deuterium labelling reactions 
were performed under typical radiolabelling (T) conditions starting with the synthesis of 160 
micromoles lithium deuteride (theoretically 160 micromoles T equals 4.6 Ci of radioactivity) on 
a custom build tritium/deuterium manifold system (RC Tritec). The reactions were performed in 
a sequential manner as one-pot reactions without isolation of the intermediate products.  
In the following, we present the preparation of deuteriosilanes which can be used as relatively 
weak hydride donors for exchange of iodide with a hydrogen isotope when using excess of 
silane. The reaction is proposed to be analogous to the reaction discovered by Hatanaka and 
Hiyama38 with the use of silanes in coupling with homogenous palladium.  
 
Results 
The method has been optimized using the iodinated natural peptide Angiotension-I as a model-
peptide. The iodinated substrate peptide [Iodo-Tyr4]Angiotensin-I was synthesized on solid 
phase using standard Fmoc, HATU/DiPEA chemistry (SPPS) in manual synthesisers outlined on 
scheme 1. The reference [Tyr4]Angiotensin-I material was obtained by splitting the resin before 
the tyrosine coupling. Please refer to the supporting information for experimental details. 
Angiotensin-I is a suitable model for the development of optimal reaction conditions. The ten-
mer peptide contains a tyrosine residue at the 4th position and carries a variety of functional 
groups which could interfere with the use of a homogenous transition metal complexes and 
peptides. 
 Scheme 1. Solid phase peptide synthesis of [Iodo-Tyr4]Angiotensin-I for labelling and the 
reference  compound (Angiotensin-I).  
 
We first investigated the palladium mediated dehalogenation of the iodinated peptide using 
commercially available triethylsilane (Et3SiH) and triethoxysilane ((EtO)3SiH) in combination 
with the standard tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) catalyst.  
The commercial triethoxysilane ((EtO)3SiH) proved to be an aggressive reducing agent 
corresponding with the high hydride character of the silane caused by the inductive effect of the 
ethoxy substituents. After attempts to prepare deuterium labelled triethylsilane and 
triethoxysilane, the triethylsilane was selected as the hydride doner due to instability of EtO3SiD 
in protic solvents. 
The lithiumhydrides of hydrogen-isotopes are ready available when synthesized in micromolar 
scale with n-butyllithium (160 μmoles) and TMEDA (N,N,N’,N’-tetramethylethylene-diamine) 
following litterature procedures39. Under an atmosphere of deuterium gas (600 – 800 mbar), we 
employed nBuLi (100 μL, 160 μmol) together with a slight excess of TMEDA (50 μL) as co-
solvent for breaking the nBuLi hexamer into more reactive species. The formation of 
lithiumdeuteride (LiD) was complete after 1 - 2 hours as no further consumption of deuterium 
gas was observed (scheme 2). 
 
 
Scheme 2. Formation of lithiumdeuteride. 
After formation of the hydride, the volatiles (butane, solvents and TMEDA) was removed under 
vacuum and the dry lithiumdeuteride was used directly in the subsequent reactions. 
 
 
Scheme 3. Synthesis of trialkylsilane. 
The formation of deuteriotriethylsilane from LiD and triethylchlorosilane (Scheme 3) was 
investigated using GC with FID detection, and we found almost complete conversion within 30 
minutes. The reactions were performed at room temperature in anhydrous THF and the formed 
deuteriosilane was used without further purification in the subsequent labelling reaction. 
Isolation and purification of the triethylsilane was attempted but  with no success, as the silane is 
highly volatile, and is synthesized in less than 160 μmoles. The GC-FID chromatograms from 
the synthesis of deuteriotriethylsilane, starting material and reference triethylsilane are stacked 
and illustrated on figure 1. 
 
Figure 1. Stacked GC-FID chromatograms from silane synthesis. 
The 1H-NMR analysis of the Ei3SiD product demonstrate the expected loss of a J2 coupling 
between the -ethylene and Si-H bond. Please refer to the supporting information for further 
details. 
After having optimised the reaction conditions for the efficient formation of the 
triethylhydridosilane, attention was focused on the palladium mediated hydrodehalogenation 
reaction.  
A number of phosphine ligands were investigated. The reactions were performed at room 
temperature and the conversion of starting material and formation of deuterated peptide was 
measured by mass spectroscopy (MS). A silylated byproduct was also formed and its formation 
monitored in MS. By tuning the steric properties of the ligand and the lewis base character of the 
phosphor the conversion and yield could be optimized. Please refer to table 1, for a selected list 
of tested phosphine ligands.  
Table1:Optimisationofphosphineligand
Reaction nr. Phosphine Reagent amount Conv. * Products* 
- No Phosphine 135 μmole Et3SiD 100% 100% DC 
- DPPP 256 μmole Et3SiD N/AA TracesA 
- PCy3 135 μmole Et3SiD 0% 0% D 
- DPPF  160 μmole Et3SiD 10% 30% H/ 70% DB 
1 PPh3 1100 μmole Et3SiD 15% 100% D 
2 PPh3 320 μmole Et3SiD 14% 100% D 
4 P(o-furyl)3 270 μmole Et3SiD 69% 28% D + 38% D/TES 
9 P(tBu)3 160 μmole Et3SiD 100% 36% D + 64% D/TES 
*Conversion of [Iodo-Tyr4]Angiotensin-I and analysis of products formed in the optimisation 
reactions were determined by mass-spectrometry where D means [D-Tyr4]Angiotensin-I and 
D/TES corresponds as [D-Tyr4]Angiotensin-I functionalised with a triethylsilyl group. Reaction 
number refers to the supplemental information.  
A Several unidentified products seen in MS.   
B Estimated ratio of H and D by MS.  
C Reaction with Pd(OAc)2, instantly formation of palladium black, inhomogenous reaction. A full 
conversion and labelling observed by MS with Pd adducts.    
 
Besides the phosphines listed in table 1, we also tested the non-phosphorus DABCO, but the 
reaction turned black instantly, possibly due to silane mediated reduction of Pd(II) to palladium 
black. This was also found in the reaction with Pd(OAc)2 and absence of a phosphine ligand. 
Due to the apparent non-homogeneity of these reactions, they were not investigated further. 
It was found that the bulky and electron donating tri-tert.-butyl phosphine ligand (reaction 9) 
gave the best conversion of the iodinated peptide to deuterated product. It should be emphasised 
that this ligand is very sensible to oxidation, and that the reactions must be performed under inert 
atmosphere (argon).  
After having identified the optimal ligand, attention was turned to the necessary quantity of 
Et3SiD. It was found that with an increase of the amount of prepared silane from 50 to 135 
μmole, the conversion of substrate went from only traces of deiodinated product to complete 
deiodination. Results are summarized in table 2, where the quantity of the deuterated silane is 
calculated on the basis of the quantity of nBuLi used in the preparation lithium tritide, as no 
method was available for its direct quantitation.  
Table2:Optimisationofdeuteriosilaneandpalladiumquantity
Reaction nr. Et3SiD / Pd Conv.§ 
5 50 / 10 μmole 1%* 
6 95 / 10 μmole 22%* 
7 135 / 10 μmole 74%* 
8 135 / 20 μmole 100%  
§ Conversion of was determined by MS.  
* Clear palladium adducts was observed in MS. 
 
The observed dependence on the quantity of the silane may be explained by the simple fact that 
the reaction involves handling of very small quantities of highly air sensitive materials (BuLi and 
LiT).  
 
The results in Table 2 also show that the use of larger amounts of the palladium catalyst results 
in increasing yields. It should be noted, that an excess of catalyst to iodinated peptide is 
employed. The handling of catalytic amounts (in the nanomolar range) of the palladium catalyst 
is difficult and not an important parameter in these experiments. The successful formation of 
deuterated (or tritiated) peptide is the ultimate goal of this work. On the other hand a suitable 
balance must be found, as the use of a very large excess of palladium may pose a problem in its 
the later removal after labelling reaction.  
 
As shown in table one, the reaction also resulted in the formation of an undesired byproduct from 
triethylsilyl (TES) conjugation with the deuterated peptide. Further experiments demonstrated its 
effective elimination through treatment with trifluoroacetic acid (TFA) or tetrabutylammonium 
fluoride (TBAF). The formation of TES conjugated angiotensin can be explained by a reaction 
between hydroxyl groups on the deuterated or iodinated peptide and unreacted chloro-silane or 
the potentially formed iodo-silane.   
Table 3 summarizes the effect of TBAF added at the end of reaction. 
Table3:Optimisationofreactiontimeanduseoffluoride
Reaction nr.§ TBAF / L Time Conversion D/TES-product* D-product* 
2 0 eq. / PPh3 3 h 14% 0% 14% 
3 1 eq. / PPh3 3 h + 0.5 h 30% 0% 30% 
9 0 eq. / PtBu3 3 h 100% 64% 36% 
10A 1 eq. / PtBu3 1 h + 0.5 h 11% 0% 11% 
11B 1 eq. / PtBu3 3 h + 0.5 h 100% 0% 100% 
§ Reaction nr. refers to the supplementary information.  
* The ratio between products ([D-Tyr4]-Angiotensin-I and triethylsilyl-[D-Tyr4]-Angiotensin-I) and substrate 
([iodo-Tyr4]-Angiotensin-I) was determined by mass-spectrometry. Amount of used Et3SiD was 160 μmole in 
reaction nr. 3, 9, 10 and 11, and 320 μmole in reaction nr. 2.  
 
It was found that the addition of TBAF to the reaction mixture seems both to eliminate the 
formed TES-product and to accelerate the deuteration reaction (see reaction 2 & 3). The 
mechanism for this was although not investigated further.  
With these optimisations, we were able to perform the efficient deuteration of iodinated 
angiotension starting from deuterium gas in just one day.  
 
Conclusion. This study concerns the use of silanes the in selective dehalogenation of an 
iodinated model peptide using homogenous palladium catalysis. The reaction uses mild reducing 
conditions and has been shown to tolerate several peptide functional groups such as e.g. amides, 
carboxylicacids and phenol. We have demonstrated that it was possible to label an iodinated 
model peptide (Angiotensin-I) with deuterium using this chemistry. Although the exact 
mechanism for this deuteriodeiodination reaction is not clear, we propose that the reaction could 
occur through the generally accepted palladacycle illustrated in scheme 3. The tri-tert.-
butylphosphine ligand is well known to generate low-ligated and very reactive palladium 
species40-43 which after oxidative addition into the aromatic iodine bond could undergo 
transmetallation with the synthesised deuteriosilane.  
We suggest a reaction mechanism as described below (Scheme 4). This is in line with a recent 
publication showing that the addition of base to the system results in formation of C-Si silylated 
products.44.  
 
 Scheme 4. Proposed mechanism for the deuteriodeiodination of an iodinated aromatic 
compound. 
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 General Information 
All reactions were performed on a custom build deuterium or tritium manifold system 
(Illustration 1A and 1B) manufactured by RC Tritec AG, Switzerland. Deuterium gas was 
supplied onto the manifold and all chemical manipulations were performed in glassware and in 
amounts analogous to working with tritium. Reagents and solvents were used as received from 
Sigma-Aldrich without further purification. Catalysts, phosphines and compounds unstable to 
oxygen where handled under an argon atmosphere in a custom made glovebox. Solvents where 
deoxygenised by ultra sonic irradiation followed by thorough bubbling with argon.  
 
Illustration 1A. Picture of the deuterium/tritium manifold system. 
 Illustration 1B. Schematic drawing of the deuterium/tritium manifold system and reaction 
vessel used for lithium deuteride (LiD) synthesis.  
Instruments 
Gas Chromatography was performed on a Varian 3900, with manual injection and equipped with 
a FactorFour™ (Fused Silica) capillary column (VF-200ms, 30m x 0.32mm ID, DF=1.0, Varian) 
and a FID detector. Mass spectrometry was performed on a Bruker Esquire 4000 iontrap (IT) 
equipped with a electrospray ionization (ESI) interface.  Preparative rp-HPLC was performed on 
a Knauer Smartline. (Components: Manager 5000, Pump  1000, UV Detector 2500) with the C-
18 column at ambient temperature (20oC). Analytical rp-HPLC was performed on a Waters 
Breeze system, Pump – Waters 1525, Binary Pump. UV Detector – Waters 2787, Dual  
Absorbance Detector with the C-18 column at ambient temperature (20oC).  Ultra purified water 
was supplied from a Sartorius arium® 611 water system. Lyophilisation of products were 
performed on a Hetosicc freezedrier, Heto.   
Materials 
Sep-Pak Cartridges; Sep-Pak® Plus C-18 Cartridges. Syringe Filter; Whatman Glass Microfiber 
GF/C, 25 mm diameter, 1.2μm pore size. Syringes and Needles; Single use Syringes (1, 2, 5 mL) 
and disposable Needles (Ø 0.08 x 120 mm, 21 G x 4¾", Sterican®), Braun. 
Solvents and Reagents 
Chemicals where used as received from the supplier. Moisture sensitive compounds was stored 
in at 5oC in desiccators if necessary. Deuterium gas (D2) (97.9%) was supplied from AGA. 
N,N,N’,N’-Tetramethylethylene-diamine (TMEDA, 99%), n-Butyllithium (1.6 M in hexanes), 
N,N-Dimethylformamide (DMF, anhydrous 99.8%), Tetrahydrofuran (anhydrous, 99.9%, 
inhibitor-free), chlorotriethylsilane (TESCl, 99%), tetrabutylammonium fluoride (TBAF, 
trihydrate, 97%), palladium(II) acetate (99.9%+ metal basis), tri-tert.-butylphosphine (1M in 
toluene) where all supplied by Sigma-Aldrich.  
The Fmoc protected amino acids where used as received from supplier GL Biochem (Shanghai) 
Ltd.( Fmoc-His(Trt)-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ile-OH, Fmoc-Tyr(Trt)-OH, 
Fmoc-Val-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(tBu)-OH). Fmoc and TBDMS protected 3-iodo-
tyrosine was synthesised prior to acylation. 
 
  
Experimental details 
 
[Iodo-Tyr4]Angiotensin-I and [H-Tyr4]Angiotensin-I   
The peptide substrate and reference compound were synthesised on solid support with standard 
Fmoc chemistry using HATU/DiPEA as the activation protocol. The synthesis of the two 
peptides was performed by splitting resin (20:1) after the isoleucine coupling. 
 
 
 
Loading Protocol: 500 mg Wang resin (loading approx. 1 mmol / g.) was placed into a manual 
peptide synthesis glass-reactor (10 ml, Peptides International Inc.) and loaded with the first 
amino acid with the symmetrical anhydride procedure.  
 
Symmetrical anhydride procedure: Fmoc-Leu-OH (1767 mg, 5 mmol) was agitated with DIC 
(391 μL, 2.5 mmol) in dry DCM for 20 minutes. The solvent was removed in vacuum and the 
anhydride was redissolved / suspended in 4 mL DMF. This was added to the resin with a 
catalytic amount of DMAP and the reactor was left rotating for 5 hours. After filtration the resin 
was rinsed 4 times with DMF and 4 times with DCM before it was dried down.   
 
Fmoc Deprotection: The resin loaded with the Fmoc protected amino acid was swelled with 
DMF and subsequently treated with 20% piperidine in DMF for Fmoc deprotection. The resin 
was washed twice with DMF then twice with DCM before performing the Kaizer test and the 
peptidyl resin was swelled in DMF before the acylation step.   
 
Acylation: In each coupling-step 4 eq. of Fmoc protected amino acid and 3.9 eq. HATU was 
mixed with a minimum amount of DMF for total dissolution. 8 eq. of DIPEA was added and the 
solution was subsequently transferred to the N-deprotected peptidyl resin. The resin was agitated 
gently by rotation for 30 – 40 minutes before the remaining acylation agents was washed off with 
4 times DMF and 2 times DCM. Kaizer test was performed after each acylation step, to ensure 
complete coupling.  
 
Cleavage: A mixture of 90% trifluoroaceticacid (TFA), 5% triisopropylsilane (TIS), and 5% H2O 
(4 ml) was applied to the resins for 3 hours for cleavage of peptide and protecting groups. After 
completion, the resin was extracted with 10 times of pure water. The residual TFA was gently 
removed under reduced pressure and finally the crude product was lyophilized.    
 
[Iodo-Tyr4]Angiotensin-I 
The crude product was dissolved in water (5 mL) and gently washed with ethyl acetate (2 x 5 
mL). The organic phase was discarded and the aqueous solution containing the peptide was 
purified on a preparative HPLC system with UV detection set at 280 nm. Column: C18-Knauer. 
(250mm x 20 mm, 5 μm Eurosphere-100) Flow: 10 mL/min. Eluents: A) 5% acetonitrile, 0.1% 
TFA, purified H2O. B) 99.9% acetonitrile, 0.1% TFA.  
Gradient: (0 min. - 4 min., 0% B); (-17 min., 35% B); (17 - 25 min., 100% B); (25 - 28 min., 
100% B);(- 29 min., 0% B); (29 - 33 min, 0% B). The product ([Iodo-Tyr4]Angiotensin-I) was 
collected after 17.4 min and lyophilised to yield a white flocculent powder: 319 mg. 
 
The purified peptide was analysed on an analytical rp-HPLC system equipped with UV detection 
at 280 nm. Column: Phenomenex® Luna PFP(2) (250 mm x 4.6 mm, 5 μm). Flow: 1 ml/min. 
Eluents: A) 5% acetonitrile, 0.1% TFA, purified water. B) 99.9% acetonitrile, 0.1% TFA.  
Gradient: (0-2 min, 0% B); (-40 min, 100% B); (40-42 min, 100% B); (-44 min, 0% B);(44-50 
min, 0% B). The substrate ([Iodo-Tyr4]Angiotensin-I) eluted at 17.4 min. Purity was determined 
by HPLC-UV to be: 97% (figure 1, top). The identity was confirmed by mass spectrometry 
illustrated on figure 1, bottom. 
 
  
Figure 1. (top) HPLC chromatogram. (bottom) MS of [Iodo-Tyr4]Angiotensin-I (C62H88IN17O14, 
Mw = 1421.6) after purification.  m/z = 1422.7 (M + H+), m/z = 1444.5 (M + Na+). 
  
Angiotensin-I 
The crude product was dissolved in water (5 ml) and washed with 2 x EtOAC (5 ml). The 
organic phase was discharged and the water including peptide was applied onto preparative 
HPLC for purification detection at 280 nm. Column: C18-Knauer. (250mm x 20 mm, 5 um 
Eurosphere-100) Flow: 10 ml/min. Eluents: A) 5% acetonitrile, 0.1% TFA, H2O. B) 99.9% 
Acetonitrile, 0.1% TFA. Gradient: (0-4 min, 0% B); (-17 min, 35% B); (-25 min, 100% B); (25-
28 min, 100% B); (-29 min, 0% B); (29-33 min, 0% B). The desired product (Angiotensin-I) was 
collected after 17.4 min and lyophilised to yield a white flocculent power: 16 mg.  
 
The product was analysed on analytical rp-HPLC equipped with column: Luna PFP(2). (250mm 
x 4.6 mm, 5 μm) Flow: 1 ml/min. Eluents: A) 5% acetonitrile, 0.1% TFA, H2O. B) 99.9% 
acetonitrile, 0.1% TFA.  
Gradient: (0-2 min, 0% B); (-40 min, 100% B); (40-42 min, 100% B); (-44 min, 0% B); (44-50 
min, 0% B). The desired product (Angiotensin-I) eluted at 16.8 min. Purity determined by UV 
detection: 97% (figure 2, top) and the identity of the product was confirmed by MS (figure 2, 
bottom). 
 
 
Figure 2. (top) Analytical HPLC of Angiotensin-I after purification. (bottom) MS of 
Angiotensin-I (C62H89N17O14, Mw = 1295.7) after purification.  m/z = 1296.8 (M + H+), m/z = 
1318.6 (M + Na+), m/z = 1340.6 (M + 2 x Na+), m/z = 1362.6 (M + 3 x Na+). 
  
 
Figure 3. (1H-NMR, D2O, 500 MHz) [Iodo-Tyr4]Angiotensin-I. 
 
Figure 4. (1H-NMR, D2O, 500 MHz) Angiotensin-I 
N-Fmoc-3-iodo-O-TBDMS-Tyrosine 
 
Scheme 1. Fmoc protection of 3-iodo-tyrosine 
In a 100 ml round-bottomed flask 3-Iodo-tyrosine (2164 mg, 7.05 mmol) and Fmoc-OSu (2607 
mg, 7.73 mmol) was mixed with DCM (30 ml) to give a white suspension. 
Diisopropylethylamine (2.58 ml, 14.80 mmol) was added and the suspension allowed to react 
overnight at room temperature. A solution of KHSO4 (2M, 2 mL) was added to the reaction 
mixture and the resulting suspension was stirred vigorously for 1 hour (a white precipitate was 
formed almost instantly). The product was isolated by filtering through a medium frit, washed 
with purified water (2 x 20 mL) and dried in vacuum before analysed. Yield: 2.96 g. (79%). 
Product showed one compound on TLC and ESI-MS confirmed a mass of m/z = 551.9 (M + 
Na+) and m/z = 1079 (2xM + Na+). The product was used in the following reaction without 
further purification. 
 
Scheme 2. TBDMS protection of N-Fmoc-3-iodo-tyrosine 
 
Fmoc-(3-iodo)-tyrosine (616 mg, 1.16 mmol) was dissolved in DMF (10 mL) and imidazole 
(316 mg, 4.66 mmol) was added. TBDMS-Cl (2.5 eq., 438 mg, 2.91 mmol) was added to the 
solution and the reaction was stirred for 3 hours for completion. The reaction mixture was added 
to a solution of KHSO4 (25 mL, 0.4 M) and subsequently extracted with EtOAc (3 x 30 mL). 
The combined organic phases were evaporated and dried over night under vacuum giving the 
crude product as a slightly yellow sticky solid (823 mg). 
The crude product was purified using flash-chromatograpy with heptane, ethylacetate and 
methanol as eluents. The product eluted over many fractions and those were collected and 
evaporated to give the final product  623 mg (84%) which was used as the monomer in the 
synthesis of the iodinated angiotensin-I peptide. ESI-MS showed m/z = 666.2 (M + Na+), m/z = 
682.2 (M + K+) and m/z = 1309.2 (2 x M + Na+). 
  
General procedure for the deuterium labelling using tri-tert.-butylphoshine, palladium 
acetate and deuteriotriethylsilane. 
 
Lithiumdeuteride (LiD). 
A 3 mL round bottomed flask with a side arm (for the addition of reagents) and magnetic-bar 
was mounted on the manifold system, evacuated to below 5x10-3 mbar and flame dried. The 
flask was flushed with deuterium gas and evacuated repeatedly to ensure an anhydrous and 
oxygen free reaction vessel. Finally the flask was loaded with deuterium gas to a pressure of 800 
mbar. TMEDA (50 μL) and nBuLi (100 μL, 1.6M in hexane) were added with a syringe through 
the septum and within 5 - 10 minutes a white precipitate of LiD was formed. The reaction was 
stirred and allowed to react for 2 hours. Subsequently the flask was cooled with liquid nitrogen 
and the deuterated butane (byproduct), solvent (hexane) and TMEDA was removed under 
reduced pressure. The formed LiD was thoroughly dried under vacuum until dryness (white and 
flaky LiD, theoretical amount of 160 μmole, 1.44 mg). Finally the reaction vessel was flushed 
with argon at 800 mbar to ensure an inert atmosphere before the following reaction. 
 
Deuterio-triethylsilane (Et3SiD).  
Under an atmosphere of argon a solution of chlorotriethylsilane (0.5M, 2 mL) in dry THF was 
prepared in a just prior to use. This solution (300 μl, 150 μmol of TESCl) was added to the 
lithiumdeuteride in the flask mounted on the manifold. The suspension was allowed to react for 1 
hour at room temperature under stirring. The reaction was confirmed by GC-FID to be near 
completion after 30 minutes. (GC: RtSi-(D/H) =  4.50 min.; RtSi-Cl = 10.99 min.). GC-
chromatograms are illustrated on figure 5 – 7, 1H-NMR on figure 8 and 9. 
 
CG-FID specifications: Column Oven Temperature Program (0 - 3 min., 40 oC); (4 oC/min. until 
100 oC); (40 oC/min until 260 oC); (3 min. at 260 oC); injector temperature: 220 oC. 
 
The resulting suspension of deuteriotriethylsilane and LiCl in THF was used directly in the 
labelling step.   
 
Figure 5. GC-FID chromatogram of deuteriotriethylsilane (Et3SiD) after 30 minutes reaction 
time. 
 
Figure 6. GC-FID chromatogram of triethylsilane (Et3SiH) as received from Sigma-Aldrich. 
  
Figure 7. GC-FID chromatogram of chlorotriethylsilane (Et3SiCl, Rt. = 10.98) as received from 
Sigma-Aldrich. 
 
Figure 8. (1H-NMR, CDCl3, 500 MHz) Deuteriotriethylsilane  (Et3SiD) 
 Figure 9. (1H-NMR, CDCl3, 500 MHz) Triethylsilane (Et3SiH) as received from Sigma-Aldrich. 
 
  
Deutero-deiodination of [Iodo-Tyr4]Angiotensin-I. (Reaction 11)  
A solution of the palladium catalyst was prepared prior to use under argon; Palladium acetate 
was added tri-tert.-butylphosphine (5 eq., 1M in toluene) and allowed to react at room 
temperature for 30 minutes (a change from deep orange to bright yellow coloured solution is 
observed). 
 
In a vial [Iodo-Tyr4]Angiotensin-I (2.9 mg, 1.56 μmoles) was dissolved in thoroughly 
deoxygenised DMF (600 μL). To the substrate vial the palladium catalyst (20 μmole, 100 μL) 
was added. It was allowed to react in 10 minutes before all was transferred to the reaction vessel 
containing the synthesised deuteriotriethylsilane, leaving a pale yellow homogenous reaction 
mixture. After 3 hours of reaction time 1 eq. of TBAF (160 μmole, fluoride) was added to the 
reaction and after 30 minutes the workup of product was performed. 
  
A Sep-Pak® Plus C18 Cartridge (360 mg) with a 0.45 μm Wattmann CF-C filter was 
preconditionized with Ethanol (5 ml) for 1 min. then washed with distilled water (5 ml). Semi-
purification of product was performed by mixing the reaction with 5 times the volume of purified 
water (5 ml) and filtering the preticipate through the filter and Sep-Pak. The filter and Sep-Pak 
was washed with ultra-purified water (5 ml) for the removal of salts and polar compounds. The 
filter was disposed and the peptide eluted from the Sep-Pak using a mixture of 80% MeCN, 20% 
Water and 0.1% TFA (5 ml). 
  
Products and conversion of substrate was analysed using MS (ESI-IT) and HPLC. The final 
purification was performed by preparative HPLC with the following configuration. 
 
Preparative HPLC: Column: C18-Knauer. (250mm x 20 mm, 5 um Eurosphere-100) Flow: 10 
ml/min. Eluents: A) 5% acetonitrile, 0.1% TFA, H2O. B) 99.9% acetonitrile, 0.1% TFA.  
Gradient: (0-1 min, 0% B); (-25 min, 50% B); (-30 min, 100% B); (30-32 min, 100% B);(-33 
min, 0% B); (33-34 min, 0% B). The desired product ([Tyr4-2H]Angiotensin-I) was collected in 
the interval 21-21.6 min, then lyophilized to give an isolated yield: 1.19 mg, app. 0.68 μmoles, 
44%. The product was identified by rp-HPLC (figure 10) and MS (figure 11). 
 
Analytical-HPLC: Column: Luna PFP(2). (250mm x 4.6 mm, 5 μm) Flow: 1 ml/min. Eluents: A) 
5% Acetonitrile, 0.1% TFA, Purified Water. B) 99.9% Acetonitrile, 0.1% TFA.  
Gradient: (0-2 min, 0% B); (-40 min, 100% B); (40-42 min, 100% B); (-44 min, 0% B);(44-50 
min, 0% B). The desired product ([Tyr4-2H]Angiotensin-I) was eluting at 16.7 min. Purity: 
96.5%. 
 
Figure 10. HPLC chromatogram of [D-Tyr4]Angiotensin-I. 
 
Figure 11. MS of [D-Tyr4]Angiotensin-I (C62H88DN17O14, Mw = 1296.7) after purification.  
m/z = 1297.7 (M + H+), m/z = 1319.6 (M + Na+), m/z = 1341.6 (M + 2 x Na+), m/z = 1362.6 (M 
+ 3 x Na+). 
Supplemental MS Spectra for reaction 1-10. 
Conversion of [Iodo-Tyr4]Angiotensin-I to the labelled [D-Tyr4]Angiotensin-I was calculated 
from MS-spectra intensities (I), product / (product + starting material). The ionization of the 
substrate and product peptide are estimated to be approximately equal in the ESI interface. All 
spectra where recorded using the same acquisition parameters as follows. 
 
 
  
  
Figure 12. MS of reaction 1. [D-Tyr4]Angiotensin-I, m/z = 1297.8 (M + H+); [Iodo-
Tyr4]Angiotensin-I, m/z = 1422.7 (M + H+). Conversion: 14.7% 
 
 
 
 
Figure 13. MS of reaction 2. [D-Tyr4]Angiotensin-I, m/z = 1297.8 (M + H+); [Iodo-
Tyr4]Angiotensin-I, m/z = 1422.7 (M + H+), m/z = 1526.5 (M + Pd(0) + H+). Conversion: 14.2%. 
 
 
Figure 14. MS of reaction 3. [D-Tyr4]Angiotensin-I, m/z = 1297.7 (M + H+), m/z = 1401.6 (M + 
Pd(0) + H+); [Iodo-Tyr4]Angiotensin-I, m/z = 1422.6 (M + H+), m/z = 1526.3 (M + Pd(0) + H+). 
Conversion: 29.6%. 
 
 
Figure 15. MS of reaction 4. [D-Tyr4]Angiotensin-I, m/z = 1297.8 (M + H+), m/z = 1401.6 (M + 
Pd(0) + H+); [D-Tyr4]Angiotensin-I + triethylsilanyl, m/z = 1412.8 (M + H+), m/z = 1516.6 (M + 
Pd(0) + H+); [Iodo-Tyr4]Angiotensin-I, m/z = 1422.6 (M + H+).  Conversion: 68.7%. 
 
 
Figure 16. MS of reaction 5. [D-Tyr4]Angiotensin-I, m/z = 1297.9 (M + H+), m/z = 1400.7 (M + 
Pd(0) + H+); [Iodo-Tyr4]Angiotensin-I, m/z = 1422.7 (M + H+), m/z = 1526.6 (M + Pd(0) + H+). 
Conversion: 0.9%. 
 
 
Figure 17. MS of reaction 6. [D-Tyr4]Angiotensin-I, m/z = 1297.8 (M + H+), m/z = 1400.6 (M + 
Pd(0) + H+); [Iodo-Tyr4]Angiotensin-I, m/z = 1422.7 (M + H+), m/z = 1526.4 (M + Pd(0) + H+). 
Conversion: 21.9%. 
 
 
Figure 18. MS of reaction 7. [D-Tyr4]Angiotensin-I, m/z = 1297.8 (M + H+), m/z = 1400.6 (M + 
Pd(0) + H+); [Iodo-Tyr4]Angiotensin-I, m/z = 1422.6 (M + H+). Conversion: 73.6%. 
 
 
Figure 19. MS of reaction 8. [D-Tyr4]Angiotensin-I, m/z = 1297.7 (M + H+), m/z = 1402.6 (M + 
Pd(0) + H+); [Iodo-Tyr4]Angiotensin-I, m/z = 1422.6 (M + H+). Conversion: Nearly 100%. 
 
 
Figure 20. MS of reaction 9. [D-Tyr4]Angiotensin-I, m/z = 1297.7 (M + H+); [D-Tyr4]-
Angiotensin-I + triethylsilanyl, m/z = 1411.8 (M + H+), m/z = 1516.5 (M + Pd(0) + H+).  
Conversion: Nearly 100%. 
 
 
Figure 21. MS of reaction 10. [D-Tyr4]Angiotensin-I, m/z = 1297.8 (M + H+); [Iodo-
Tyr4]Angiotensin-I, m/z = 1422.7 (M + H+). 
Unidentified compounds, m/z = 1435.6, m/z = 1477.6.  
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Preface and Background 
 
A series of radioiodination labelling reactions of small molecules have been 
performed as side projects in this graduate work. One of these, the labelling of a 
gamma-hydroxybuturic acid (GHB) receptor ligand, was presented on the 10th
 
 
International Isotope Society symposium in Chicago, 2009.  
This is why a short overview of radioiodine, this elements isotopes and presentation 
of the very useful radioiododestannyllation (for labelling of small molecules) are 
presented here. The conference proceeding with chemical results of this one 
labelling is a representative illustration of the usefulness of this reaction. Research 
and biological uses of these receptor ligands are submitted for publication elsewhere.     
 
Isotopes of iodine are very often used in pharmaceutical R&D and in clinical 
practices. Around 30 radioisotopes of iodine have been reported, where the only 
stable is iodine-127. The ease of chemistry with iodine/iodide makes radioisotopes 
of this element very attractive to use as tracers, not only for small molecules but also 
for peptides and proteins.1
 
  
Isotope Decay* T Uses ½ 
Iodine-123 EC  13.2 h Considered “Ideal” isotope for thyroid 
imaging.  
Iodine-124 +
Hard energy 
radiation (>600 keV) 
) 4.2 d Potential PET isotope, though not used 
heavily in humans due to dose 
considerations from the hard 
electron/gamma emissions. 
Iodine-125 EC  
Soft energy CE and x-ray 
emission (max 35 keV) 
59.4 d Used in in-vitro pharmacology studies. 
Evaluation of receptor ligand affinity. 
Iodine-127 - Stable - 
Iodine-131 - 8.0 d 
Medium/hard energy CE and 
#\^`{| 
Classical isotope for thyroid uptake and 
imaging purposes. Have been used for 
several decades for this purpose. 
 
Table 3. Short list of the most frequently used radioiodine isotopes in R&D and clinical practises. *The 
iodine isotopes possess complex decay patterns for more }}}\}2
 
. 
One of the proven very useful methods for labelling with iodine is the 
radioiododestannyllation reaction. With the use of an organic oxidant, such as 
chloramine-T, in combination with iodide (I-), the in-situ generation of an 
electrophilic iodide (I

 
) gives the possibility for reaction on a “nucleophilic” carbon.  
1. Welch, M. J.; Redvanly, C. S., Handbook of Radiopharmaceuticals - 
Radiochemistry and Applications. John Wiley & Sons Ltd.: 2003. 
2. } \ }  } }  ` }
Laboratory. http://www.nndc.bnl.gov/nudat2/  
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Abstract 
A series of 4-substituted gamma-hydrobutyric acid analogues have been synthesized and subjected 
to a specific GHB binding assay[1, 2]. Within this series some halogenated analogues showed very 
good displacement of a specific GHB receptor binder. Here we present how we have used the 
synthesis of two I-125 labelled GHB neuroligands by radioiododestannylation. The I-125 labelled 
compounds 1 and 2* were readily prepared (Scheme 1) and are currently undergoing 
pharmacological evaluation in the hope for elucidation of the GHB binding sites and GABA 
neuroreceptors. The tributyl-stannate precursor in its lactone form was reacted with electrophilic 
125-iodine (generated from carrier-free Na125I in presence of chloramine-T). Efficient labelling was 
achieved within 30 minutes and subsequent deprotection achieved by lactone hydrolysis. RP HPLC 
purification and reformulation using SEP PAK C18 cartridges, rinsing with purified water, elution 
with ethanol and finale dilution with purified water gave the labelled compounds 1 and 2* in 
excellent radiochemical yields (83% and 88% respectively).  
 Scheme 1. Electrophilic radioiodo-destannyllation followed by lactone hydrolysis. 
 
Short Introduction 
Gamma-hydroxy-buturic acid (GHB) is a small neuroreceptor ligand with an affinity for the 
gamma-aminobutoric acid (GABA) receptors. It is a metabolite of GABA and has been found in 
micromolar concentrations in the mammarial brain[3]. The compound is listed as an illicit drug, 
because of its drug-abuse potential (street name: Fantasy) and examples of uses as a date rape 
drug[4]. The pharmacological effects of the compound make it useful for the treatment of cataplexy, 
a symptom associated with the excessive daytime sleeping (Narcolepsy) condition[5, 6]. GHB is also, 
therefore, a registered pharmaceutical drug called Xyrem® formulated as the sodium oxybate[7]. 
Because of the public concern about the misuse of GHB along with the pharmaceutical use, 
investigation of the pharmacodynamics of GHB is required. 
Radioiododestannyllation has been proven to be a widely applicable method for labelling organic 
molecules with radioiodine[8]. Electrophilic iodine can be created (as ICl-) insitu by the reaction 
of NaI with the oxidant Chloramine-T[9]. This has proven to be an efficient method for 
radiolabelling with radioiodine. In this example we have used a palladium coupling reaction for the 
synthesis of the organostannate using hexa-n-butyl-ditin and tetrakistriphenylphosphine-palladium.  
 
Proceeding 
(1) 4-hydroxy-4-[4-(2-iodobenzyloxy)phenyl]butanoic acid. Chloramine-T trihydrate (40.8 mg, 145 
μmole) was suspended in a mixture of EtOAc (4.75 mL), DMF (0.25 mL), acetic acid (50 μL) and a 
small amount of water were added (50 μL) to dissolve the compound. This reagent solution (1000 μL) 
was added to the tin precursor (1.19 mg, 2.1 μmole) in a small HPLC vial, the vial was capped and 
shaken to dissolve the compounds. The I-125 NaI (30 μl, 3 mCi) was added to the vial and which was 
reclosed quickly after. The vial was shaken and left to react for 30 min. 
Sodium metabisulfite (9.70 mg) in water (350 μL) was added to quench excess Chloramine-T and the 
reaction mixture was washed with purified water  (3 x 300 μL). The organic layer was evaporated to 
dryness under an argon flow.  
Subsequently, the reaction mixture was dissolved in acetonitrile (500 μL) and NaOH (20 μL, 4M) the 
latter to hydrolyse the lactone. The sample was shaken and left night over at 5oC, then it was 
neutralized with HCl (80 μL, 1M) and immediately subjected to HPLC for purification.  
The desired product 1 was collected at 24.7 minutes, then analysed to have a radiochemical purity of 
97% and a total activity of 2.48 mCi (83%). HPLC Conditions: Buffer A (4.9% MeCN, 95% Water, 
0.1% TFA), Buffer B (99.9% MeCN, 0.1% TFA). Gradient: 0 min. to 15 min. (30% B); 15 min. to 35 
min. (gradient to 100% B); 35 min. to 45 min. (100% B); 45 min. to 46 min. (gradient to 30% B). 
The product was diluted with five times of ultra purified water and loaded onto a pre-activated C-18 
Sep-PAK (160 mg). It was then washed with ultra purified water (5 mL), eluted with EtOH (5 mL) 
and subsequently diluted to a concentration of approximately 5 MBq/ml with a dilute NaOH 
solution (0.001M). 
The radiochemical analysis (Figure 1) was performed on the same HPLC system as the preparation, 
with a Rarroll Ramsey S105 radio detector equipped with a silicon diode.  
(2)* Fotoligand. The fotoligand with similar structure as 1 was labeled with the same procedure 
described above. Since it was a light sensitive compound all experiments were performed under 
minimal light conditions. The desired iodinated product 2 was collected at 26.7 minutes, then 
analysed to have a radiochemical purity of 100% and a total activity of 1.75 mCi (88%). 
* The structure of 2 is yet to be revealed as investigation of the compound is ongoing in the 
laboratory. 
The radiochemical purity and analysis (Figure 2) was determined by the same method as with 
compound 1. 
 
 
 
   
 Figure 1. HPLC Radiogram for RCP of 1. Figure 2. HPLC Radiogram for RCP of 2.
Material and Methods 
Chemicals were used as arrived from the supplier. Carrierfree Sodium[125-I]Iodine was purchased 
from Perkin Elmer with a radioactive conventration of 10 mCi/100 μL.  
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Preface to Part III. 
 
This part concludes the investigation of small molecule transformations and catalysis 
with the supramolecular self-assembled cluster [Ga4L6]-12 from this point on 
represented by (1). The focus of the research was on cationic reactions and has taken 
advantages of earlier investigations of the cluster. In this part two types of reactions 
are described; cationic 6 electrocyclizations of iminium/ammonium substrates and 
proton-mediated cationic sigmatropic rearrangements (aza-Cope Mannich) in basic 
solutions. 
 
The research presented in this part was performed in the laboratories of Prof. Robert 
G. Bergman, Department of Chemistry, University of California, Berkeley. An eight 
month period of the total three year phd program was spent in his laboratories. 
During this research visit, studies were conducted on organic reactions mediated by 
a rationally-designed spontaneously-assembling supramolecular cluster that was 
developed in the laboratory of Prof. Kenneth Raymond, Dept. of Chem., UC 
Berkeley.  
 
IN SUMMARY THIS PART CONSISTS OF;  
 
1) A short introductory/background section to the field of “supramolecular 
chemistry” and “the cluster”,  
 
2) A section which is divided into three sections describing the two main reaction 
types in focus, “6 electrocyclization” and “sigmatropic rearrangement”. Before 
each of these sections, a “short background” and “introduction to the research 
ideas” is presented and thus left out of the main introduction chapter. 
 
3) And last “the experimental section”. 
 
The research I have conducted in the Bergman group do not have any direct 
association with my radiochemistry phd project performed at the Risø National 
Laboratory, DTU, but shall be seen as an independent part of my graduate studies. 
The Bergman group focuses on a broad range of research subjects within the area of 
inorganic, organometallic and physical organic chemistry. Specifically, in 
collaboration with Prof. Kenneth Raymond, the exploration of organic chemical 
transformations and catalysis using supramolecular assemblies is an area of 
significant interest in the Bergman group.  
 
The initial idea for the project was to utilize host-guest methodology for the 
mediation of 6-electrocyclization reactions with the [Ga4L6]-12 supramolecular 
cluster (1). After spending time on this project, the focus of research eventually 
turned to literature known sigmatropic rearrangements. In my hands, the latter 
project proved to be more successful. 
 
The stay at UC Berkeley has become an experience of my lifetime. It has given me a 
more thorough understanding of general synthetic and organometallic chemistry and 
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the approach to scientific questions. Furthermore, the opportunity for an 
international adventure and to work with different scientific disciplines has in every 
sense broadened my basic view of how research is to-be conducted. In my research 
visit, I have worked with supramolecular chemistry, a branch of chemical sciences 
that was an all new experience for me. It is a broad chemical branch that I think will 
become very prominent in the future. It is already used in a small degree in 
radiochemistry (e.g. cryptants for K18F labeling reactions and as chelators for 
radioisotopes) - maybe it will eventually find a broader application in this, my 
possible future, field.  
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Background: “Chemistry Beyond the Molecule” 
Definition of Supramolecular and Host-Guest Chemistry. 
 
Supramolecular chemistry is the definition of a sub-group of the chemical sciences 
that was defined by one its leading proponents, Dr. Jean-Marie Lehn. He received 
the Nobel Prize for his work in the area in 1987,1, 2 "for….development and use of 
molecules with structure-specific interactions of high selectivity". In the late 
sixties/early seventies, Lehn and co-workers achieved the synthesis of cage-like 
molecules, biaza-polyoxo-macrobicycles (cryptants), and showed that these 
molecules have the ability to molecular recognize Group I cations3. Originally the 
term supramolecular chemistry was used to define the chemistry of non-covalent 
interaction between a host molecule and a guest as depicted in figure 1. 
 
Figure 1. The basic concept of molecular host – and non-covalent recognition of guests with 
high selectivity. 
 
Whilst defining an area of chemical research, the term “supramolecular chemistry” 
incorporates long-standing ideas that encompass a number of chemical fields. Non-
covalent complexes and non-covalent interactions upon the molecular level are 
found widely in most of the chemical sciences and, perhaps more importantly, in the 
systems that drive life, such as enzymes (a supramolecular catalysis process) and 
neuroreceptors (a supramolecular complex respons). The field of supramolecular 
chemistry has progressed towards an informational science; underpinned by the 
understanding of chemical self-organization processes and the use of this knowledge 
to gain control of small molecule transformations through host-guest recognition 
processes.4 The field has gained enormous attention in the last couple of decades and 
numerous examples of chemical systems, either designed or accidently created, that 
would belong under this definition have been reported. 
 
Supramolecular chemistry, in its simplest form, involves the non-covalent but 
specific binding of a guest molecule or element to a molecular host. Binding of the 
host to the guest forms a host-guest complex. Important questions arise as to why 
selective and strong binding occur. The host molecule is defined as a molecular 
structure with binding sites with the capacity to bind small molecules through 
hydrogen-bond donating or accepting groups, ion-pair (electrostatic), van-der-waals, 
-acid or -base interactions or metal to ligand binding. In general there must be an 
entropic favor for the guest to bind strongly to the host structure. Donald Cram, the 
fellow supramolecular chemistry Nobel Laureate of Lehn, explained the host-guest 
concept in a series of papers5.         
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Supramolecular Catalysis 
 
Within the world of biology/biochemistry there are numerous examples of 
extraordinary molecular transformations performed by enzymes – reactions that 
proceed with remarkable efficiency and selectivity. One could argue that beginning 
from the origin of life (spontaneous generation and self-replication) molecular 
complexity has increased. Enzymes found in nature have a very high specificity and 
in most cases suffer from only limited product inhibition. The enzymes or enzyme 
mimic (in the case of this part; the supramolecular assembly) are able to increase the 
rate of reactions by orders of magnitude, if compared to the uncatalyzed reaction. An 
increase in reactivity initiated through chemical recognition of a substrate, the guest 
molecule6. In figure 2, the very basic transformation of substrate to product is 
represented schematically. The fundamental ideas behind this model were proposed 
by Pauling more than 60 years ago; the initial molecular recognition and 
stabilization of the transition state of the reaction.7 Enzymes are dynamic 
macromolecules with molecular weights that in general exceed 10 kDa. They are 
made of polypeptides that fold into unique secondary (alpha helix and beta sheet), 
tertiary and quaternary structures depending on the amino acid sequence, chemical 
environment and the intra- and inter- molecular interactions of the sub-units. 
 
 
 
Figure 2. Basic schematic of enzyme (supramolecular catalysis) process. 
 
The biological systems have provided many of the ideas and are the inspiration 
behind the development of supramolecular chemistry. Supramolecular systems have 
been designed to mimic the structure and function of much more complex biological 
processes,8, 9 and it has been a dream for chemists to create artificial enzymes for a 
long time. Indeed, some supramolecular hosts that have been synthesized within the 
laboratory to possess catalytic activity.  
 
From this point onwards this part will focus on the supramolecular assembly and the 
experiments that have performed with this Host. 
Introduction to and Synthesis of The Assembly. 
 
The supramolecular spontaneously self-assembled cluster (K12Ga4L6 where L = 
N,N’-bis(2,3-dihydroxy-benzoyl)-1,5-diaminonaphtalene) or compound (1), 
investigated in this work will be, in this part, be referred to as: (the) cluster, 
assembly, host, catalyst or nano-vessel. Structure and formation of (1) are shown on 
next page. The ligand span are illustrated by blue lines and the metal centers by the 
red spheres. 
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The assembly (1), was first synthesized in 1998 in the group of Prof. Kenneth 
Raymond, UC Berkeley.10 This supramolecular structure is a tetrahedral assembly, 
based on six bis-bidentate ligands which span the tetrahedron edges and four 
octahedral gallium metal centers (M4L6 stoichiometry) which sit at the vertices. The 
structure of this assembly was designed based on the symmetry of the ligand to 
metal centers, and was correctly predicted using molecular modeling prior to its 
synthesis.11 The assembly contains a large internal cavity that is capable of 
accommodating guests of various sizes. 
 
The synthesis of the supramolecular cluster is uncomplicated.10, 12 Synthesis of the 
ligand (H4L, 0.3) is outlined in scheme 1 and 2. The first step is a diacylation of 1,5-
diaminonaphtalene for the formation of (0.2).   
 
 
Scheme 1. Diacylation of 1,5-diaminonaphtalene. 
 
The second step is a global demethylation of the four aryl methyl ether groups for 
formation of (0.3). This demethylation is performed over a period of 5 days at 
ambient temperature in boron tribromide (scheme 2). 
 
 
Scheme 2. Tetrademethylation to form H4L. 
 
The assembly is then formed by the reaction of 6 : 4 : 12 mixture of (0.3), Ga(acac)3 
and potassium hydroxide in MeOH - A reaction that proceeds via a stepwise 
deprotonation of the ligand, followed by a complexation to gallium to form the self-
assemblied cluster. The cluster (1) can be precipitated out of the reaction by 
reducing the solvent volume and subsequent slow addition of Et2O or acetone. The 
reaction and formation of (1) is outlined in scheme 3. 
 
Scheme 3. Formation of [K12Ga4L6] or compound (1). 
 
Even though there is no stereogenic carbon present in the ligand the self-assembly is 
chiral as synthesized. In the synthesis of the molecular structure (1) four stereogenic 
centers are formed around the tris-bidentate metal centers. This produces the two 
homochiral  and  configured products.10, 13 As isolated the cluster is 
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racemic, although further experiments have shown that it may be resolved using the 
chiral cation S-nicotinium as the guest.14  
Short Introduction to Reactivity of The Assembly. 
 
The highly anionic, water soluble assembly (1) encapsulates a variety of both neutral 
and cationic molecules, and can also catalyze molecular transformations within the 
cavity. The hydrophobic cavity of the assembly strongly binds appropriately sized 
cationic guests, including alkylammonium salts and organometallic complexes.15, 16 
Interestingly the cluster was found to recognize and stabilize iminium ions (formed 
by the addition of secondary amines to ketones) in water, as well as making amines 
stronger bases by protonation and encapsulation.17 The internal solvent accessible 
volume of the assembly have been estimated to be 250 – 430 Å3, depending upon the 
size of the guest molecule. The nature of the amide bonds in the ligands, gives it a 
degree of flexibility, allowing overall conformity change of the structure and 
provides a dynamic encapsulation environment that may respond to the size of the 
guest.18 In aqueous solution, the major driving force for guest encapsulation has been 
proposed to be solvent reorganization.19, 20 
 
The assembly can also serve as a nano-sized reaction vessel, and can catalyze 
reactions in aqueous media. One of the early examples reported was the aza-Cope 
rearrangement of enammonium substrates,21-23 followed by hydrolysis of the 
iminium product to form aldehydes. This reaction is accelerated by binding the 
substrate molecule in a reactive conformation within the confinement of the interior 
cavity of (1), lowering the entropic barrier for the reaction. Another remarkable 
property of this cluster is that it enables proton-mediated reactions under basic 
conditions by increasing the basicity of bound guests.24 It was shown to catalyze 
acetal deprotection to form carbonyls25, 26 and catalyze the hydrolysis of 
orthoformates27. Very interestingly, the hydrolysis was shown to follow the 
Michaelis-Menten model of enzyme kinetics28 – inhibition with a competitive 
inhibitor (Pr4N+) in the orthoformate hydrolysis experiments confirmed enzyme-like 
reactivity (figure 3). A short selection of the known reactivities of the assembly is 
out-lined in scheme 4.    
 
 
 
 
 
Scheme 4. Overview of selected Encapsulations and Catalytic Reactivities of [Ga4L6]-12. 
 
 
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
 
 
Figure 3. Eadie-Hofstee plot showing the 
inhibition of the catalytic hydrolysis of 
HC(OEt3)3 with NPr4+ as the competitive 
inhibitor in H2O, pH=11, 50oC and 4.0 mM of 
(1). 
 
 
 
Plot shows the decrease in initial velocity of 
the hydrolysis rate with increased equivalents 
of the inhibitor. 
 
 
The limitations and scope of cluster encapsulation and reactivity are based on the 
size and selectivity towards substrates. The size of substrate is important; too large 
substrates do not encapsulate and will thus not react. To overcome this problem, the 
Raymond group, have synthesized clusters with extended ligands based on a pyrene 
bridge.29 
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Investigated Reactivity with The Assembly 
 
In the work presented here, studies have been undertaken to investigate and expand 
the scope of, the use of (1) as a catalyst for transformation of appropriately-sized 
cationic substrates (or intermediates) via host-guest encapsulation. This section has 
been divided into further two sub-categories based upon the reactiontypes 
investigated – “6 electrocyclizations” and “sigmatropic rearrangements”. For the 
substrates within this series that did not encapsulate or react in the desired way, only 
brief discussion of results are mentioned, whereas the more promising substrates are 
discussed in more detail.  
6 electrocyclizations 

Short background, Research Ideas and Results. 
 
In 2008, Trauner, Bergman and coworkers published a paper about the Lewis acid 
catalyzed 6-electrocyclization reaction.30 Within this study, DFT (density 
functional theory) calculations suggested that electron-withdrawing groups in the 2-
position of a hexatriene system would decrease the energy barrier of the transition 
state for the electrocyclization reaction. These calculations were supported by 
experiments which led to the use of catalytic amount of the Lewis acid Me2AlCl that 
would coordinate to an ester substituent, increasing its electron withdrawing 
properties thus decreasing the transition state energy barrier and increasing the rate 
of reaction. Other DFT studies upon hexatrienes suggests that by altering the 
location and nature of the substituents, this electrocyclization reaction can proceed at 
much lower temperature than of an unsubstituted hexatriene.31 The idea to facilitate 
this reaction type with the cluster was to-be investigated as represented in scheme 5.
 
 
 
Scheme 5. Proposed 6-electrocyclization reaction mediated by the cluster. 
 
This idea could be approached in two different ways which would also take 
advantage of earlier work with the assembly. First approach was to synthesize a 
trieneamine (ii) and use the assembly’s ability to encapsulate protonated amines 
hoping that the protonated trieneamine would undergo electrocyclization within the 
cluster; the “encapsulation of enamine” pathway of scheme 5. For this pathway to 
succeed, the challenge of synthesizing a conjugated enamine had to be overcome. 
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
Few experiments with available model compounds rapidly concluded that it was not 
possible under the reaction conditions investigated (addition of amines to ,-
unsaturated ketones) and the only observed, and isolable reaction products were 
those formed by Michael-addition of the nucleophilic amine to the Michael acceptor, 
scheme 6. These experiments suggested that avoiding Michael addition chemistry 
would be a big challenge. As result we changed the focus to the other possible 
pathway and instead use the cluster’s ability of “molecular recognition of iminium” 
(iii) as a possible route towards catalyzing/facilitating 6-electrocyclizations. 
Followed by the encapsulation of an iminium ion, an in-situ iminium-enamine 
tautomerization and subsequent electrocyclization would yield the desired reaction 
products (v). For investigation this reactivity the central substrate to be synthesized 
was the dieneketone (2.3) or (i). 
 
 
 
 
 
Scheme 6. Attempt for enamine synthesis of sterically hindered , unsaturated ketone and amine 
showed Michael-Addition (beta attack) and no enamine. 
 
 
Attempts to synthesize the dieneketone (2.3) were made via Wittig chemistry 
depicted in Scheme 7. Although it was possible to synthesize and isolate the vinyl-
iodide, the essential purification of this compound proved to be difficult – limiting 
the utility of this approach. The first step in this proposed synthesis pathway was 
initial a standard Wittig reaction followed by halogen-metal exchange and reaction 
of the corresponding “organolithium” with an electrophile. The vinyl-iodide proved 
to be an extremely fragile, temperature- and light-sensitive compound. Even though 
a significant amount of time was used to investigate this pathway, the synthesis of 
the desired unsaturated substrate via this pathway turned out to be unsuccessful in 
my hands.   
 
 
Scheme 7. Unsuccessful reaction pathway for the synthesis of (2.3). 
 
Nevertheless, it was found possible to synthesize the diene-ester (2.1) with use of the 
Still-Gennari modification of the HWE (Horner-Wadsworth-Emmons) reaction. The 
reaction proceeded in very good yield and a high E:Z ratio when using the original 
procedure (scheme 8).32  
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Scheme 8. Synthesis of the diene-ester (2.1) with the Still-Gennari modification of HWE. 
 
The next step was the conversion of the ester (2.1) to the methyl-diene ketone (2.3). 
A literature procedure suggested this could be performed in an one-pot procedure 
with the use 1.25 eq. O,N-dimethylamino-alcohol and 4 equiv. of methyl Grignard 
(Scheme 9)33. Whilst this reaction would produce the Weinreb amide (2.2) in-situ, 
the extra equivalent of MeMgCl should undergo nucleophilic addition to the amide 
intermediate. A subsequent acidic quench would then produce (2.3). Despite this 
expectation, the reaction did not proceed to completion and stopped cleanly with the 
Weinreb amide (2.2). This product was isolated in an intermediate yield (in two 
attempts) and was used to create (2.3).       
 
Scheme 9. Attempted one-pot procedure from ester to methyl ketone. 
 
The Weinreb amide (2.2) was converted to the final ketone (2.3) by addition of one 
eq. methyl lithium followed by acid hydrolysis of the intermediate. The product was 
achieved in an intermediate yield, as is shown in scheme 10.  
 
Scheme 10. Addition of MeLi to Weinreb amide followed by acid hydrolysis of intermediate to give 
(2.3). 
 
With these substrates in hand, compounds (2.2) and (2.3) were investigated for 
reactivity with the assembly (1) to determine if they would form the desired iminium 
or enamine. The neutral substrates alone did not show any reactivity although 
possible encapsulation of (2.2) and (2.3) was observed by 1H NMR spectroscopy.  
 
Encapsulation of what was assumed to be the iminium from the diene ketone and 
amine, however, was observed and 1H NMR. The general approach is shown on 
scheme 11 and the 1H NMR followed over time shown on figure 4. 
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Scheme 11. Encapsulation of iminium with (2.3) and pyrrolidine and proposed reactivity within the 
cluster cavity. 
 
 
As it appears from the 1H NMR data a clear initial encapsulation of substrates was 
observed. After heating the reaction solution, the fine and defined 1H NMR 
resonances of the encapsulated material become very complex and the resonances 
apparent in the high-field region of the NMR convert into many new peaks. This was 
a promising result and suggests reactivity within the cavity of the cluster. The 
product of this reaction has a higher binding constant than the substrate (determined 
by integration of encapsulated peaks versus aromatic cluster peaks) which suggests a 
stoichiometric reactivity with no catalytic turnover.  
 
A standard experiment was performed with 20% cluster/catalyst loading for 
elucidation of catalytic activity. The product(s) of these experiments were ejected 
from the cluster with a strong-binding guest (Et4N+) and attempts were made to 
extract the organic product(s) into an organic solvent.  
 
The extraction and analysis of the product(s) was in all cases unsuccessful and 
therefore it was not possible to identify the product(s) formed. This was unfortunate 
but it also suggested that it was not the desired product formed as this is expected to 
be soluble in organic media, but this remains unclear. The undesired aza-
electrocyclization ammonium-product (scheme 11 above), which could be a 
proposed product, is possibly not soluble in organic solvents.    
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Figure 4. Illustration of the NMR spectra from experiment (2.4) showing the upfield/encapsulated area. 
The iminium ion formed showed a high binding efficiency inside the assembly, the suspected 
pyrrolidine sp3 carbon hydrogen atomes integrates approximately 1H per hydrogen. After heating the 
NMR tube (45oC for 3 hours) the encapsulated peaks gives a more complex pattern and shows clear 
reactivity.  
 
 
A control reaction was performed for determination of the importance of a 
conjugated diene  system in this electrocyclization reaction. A ketone (5-hexene-2-
one) with no conjugation was reacted with pyrrolidine (2.5), scheme 11, and 
followed by 1H NMR over time, depicted in figure 5. This experiment showed in 
contrast to (2.4), no reactivity over time but also good encapsulation of the iminium 
ion.  
 
 
 
Scheme 11. Encapsulation of the iminium of 5 eq. non-conjugated ketone and 5 eq. pyrrolidine (2.5) as 
a reference experiment. 
 
 
 
 
 
 
 
 
1H NMR (2.4)
Initial 
1H NMR (2.4)
1 hour, 45oC 
1H NMR (2.4)
2 hours, 45oC 
1H NMR (2.4)
16 hours, 45oC 
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Figure 5. 1H NMR of reference experiment (2.5) followed over 4 hours. Encapsulated area from 0.5 to 
-1.5 ppm, shows a clear encapsulation with ~ 11H integration which correlates to a binding efficiency 
of above 70% (15H on sp3 C). 
 
  
1H NMR (2.5)
Initial 
1H NMR (2.5)
1 hour, 60oC 
1H NMR (2.5)
4 hours, 60oC 
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Sigmatropic rearrangements of Trichloroacetimidates and Allylisoureas 
 
A series of cationic [3,3]-sigmatropic rearrangement reactions were attempted in the 
presence of the assembly (1). A special focus was the well-known thermal Overman-
rearrangement reaction types. The results of the research performed are summarized 
in this section.  

Short background, Research Ideas and Results. 

The well known “Overman” sigmatropic rearrangement reactions of 
trichloroacetimidates and allylisoureas were attempted with the supramolecular 
assembly (1). The cluster-reactions conducted to date turned out to be unsuccessful 
and are, therefore, only briefly summerized in this sub-chapter. 
   
In the late 1970s, Larry Overman conducted a thorough exploration of the 
sigmatropic rearrangements of trichloroacetimidates and allylisoureas (Scheme 12)34-
37.  Out of this research a number of versatile and applicable reactions were 
developed; these sigmatropic rearrangement reactions are still a subject of 
investigation. For instance, research groups are searching for Lewis acid catalysts 
that will make these rearrangements run at decreased temperatures38, 39. Since these 
reactions can proceed via a cationic transition state we set out to investigate the use 
of the assembly (1) to catalyze/mediate Overman rearrangements, as the idea, 
depicted in scheme 13.  
 
Scheme 12. Thermally sigmatropic rearrangement reaction of Trichloroacetimidates and Allylisoureas. 
 
 
 
 
 
Scheme 13. The idea of the Overman rearrangement with cluster. 
 
The substrates were readily obtained for these experiments. Both 
trichloroacetimidates and allylisoureas can be synthesized from the corresponding 
nitriles and allylalcohols in presence of catalytic base, in this instance sodium 
hydride. The synthesis of two trichloroacetimidates, (3.1) and (3.2), are shown in 
scheme 14, while the synthesis of the allylisourea (4.1) is depicted in scheme 15. 
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Scheme 14. Synthesis of Trichloroacetimidates (3.1) and (3.2). 
 
 
Scheme 15. Synthesis of Allylisourea (4.1). 
 
The substrates (3.1), (3.2) and (4.1) were evaluated for enhanced reactivity via 
binding in (1) using similar experiments to those conducted in the previous section 
and monitored by 1H-NMR. Reactions were performed using both, catalytic and 
stoichiometric amounts of substrate, and parameters such as pH, temperature, and 
cosolvents were varied. Unfortunately the trichloroacetamidate substrates are not 
encapsulated by the assembly and no sigmatropic rearrangement was observed in 
any of the reactions. Additionally the substrates were unstable in aqueous solutions 
and hydrolyzed over time in all cases (scheme 16). 
 
 
Scheme 16. Cluster experiment with trichloroacetimidates (3.1) and (3.2). 
 
The same experiment with the synthesized allylisourea (4.1) showed clear 
encapsulation in the NMR experiment (one example of a NMR experiment is 
depicted on figure 6). Consequently the otherwise well defined aromatic cluster 
peaks become disordered possibly as a result of a break of the assembly symmetry.  
 
Allthought this experiment gave promising encapsulation of substrate – the reference 
experiment (substrate without cluster) showed no difference – which concludes that 
the assembly in this case do not catalyze nor mediate the proposed sigmatropic 
Overman rearrangement. 
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Figure 6. 1H NMR experiment using 3 eq. of the allylisourea (4.1) in D2O at pD = 10, followed over 
time at 60oC.   
1H NMR 3 eq. (4.1) + (1)
Initial 
1H NMR 3 eq. (4.1) + (1)
1 hour, 60oC 
1H NMR 3 eq. (4.1) + (1)
16 hour, 60oC 
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Aza-Cope Mannich of Oxazolidines 
 
Short resumé 
 
During the exploration of stoichiometric and catalytic reactions that could be 
mediated by the supramolecular cluster [Ga4L6]-12 we have found that 5-vinyl-
oxazolidines undergo the aza-Cope-Mannich reaction in basic aqueous media to 
form 3-acetyl-pyrrolidines. This acid-catalyzed reaction was first discovered by 
Larry Overman in 1979, we hypothesized that this reaction could be performed 
catalytically in alkaline aqueous solutions (scheme 17). The catalytic reaction is 
limited to substrates that form products which do not bind more strongly to the 
cavity of the cluster than the substrates. Our best results were achieved with 
oxazolidines where R’ = H. 
 
 
Scheme 17. Proposed supramolecular catalysis of oxazolidines to pyrrolidines. 
 
Background 
 
A convenient synthesis of 3-acetyl-pyrrolidines through a sigmatropic rearrangement 
of homoallylamines containing a allylic hydroxyl group and aldehydes was reported 
back in 1979 by Overman and Kakimoto (scheme 18).40 These substrates, upon 
reacting with an aldehyde to form an iminium ion, undergo a reversible 2-azonia-
[3,3]-sigmatropic rearrangement (aza-Cope) followed by a irreversible 
intramolecular trapping of the iminium with the newly-formed enol (Mannich 
reaction). 
 
 
 
Scheme 18. Tandem aza-Cope Mannich reaction. 
 
An outstanding feature of 2-azonia-sigmatropic rearrangements is that they normally 
occur under much milder reaction conditions than Cope rearrangement of 1,5-dienes. 
Due to its usefulness, this reaction has gained attention from synthetic organic 
chemists and has been reported to be a versatile method for the synthesis of poly-
substituted 3-acetyl-pyrrolidines.41, 42 Furthermore, Overman employed the aza-Cope 
Mannich approach in his Strychnine total synthesis in 199343, 44. It has been proposed 
that this reaction is irreversible due to the formation of the carbon-carbon bond in 
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the Mannich cyclization step. Alternative sigmatropic rearrangement reactions 
typically require an enthalpic driving force, such as formation of aryl-alkene 
conjugation in e.g. benzoheterocyclic compounds40, 45, or as described earlier in this 
sigmatropic rearrangement section; rearrangements that form carbonylic compounds 
from imines (trichloro-acetimidates34, 36, 37 and allylic pseudoureas35).  
 
The aza-Cope Mannich reaction normally occurs at temperatures ranging from room 
temperature to 80oC. Overman et al found the reaction to proceed very well using 
the ammonium salt of the homoallyl aminoalcohol and an aldehyde in refluxing 
benzene for 5 hours. Overman et al. also found that if an aldehyde was refluxed with 
the free base of the homoallyl aminoalcohol in benzene the condensed 5-vinyl-
oxazolidine could be isolated in very good yields. These isolated oxazolidines also 
give the desired pyrrolidine product in the presence of an organic acid catalyst.   
 
From earlier reports, it is known that the cluster recognizes and stabilizes iminium 
ions in water,46 catalyzes sigmatropic aza-Cope rearrangements from enamines21, 23 
and is able to perform proton-mediated reactions in basic solutions24-28. Literature 
precedent suggests that this aza-Cope Mannich reaction could be performed with the 
cluster. 
 
Results and discussion 
 
The substrates for the aza-Cope Mannich reaction are readily available and 
procedures for their synthesis have been published47. The synthesis of homoallyl 
aminoalcohols (5.2) and (5.3) can be performed in a two step synthesis starting from 
isoprene. In a mixture e of Et2O, H2O, upon mixture of stoichiometric amounts of N-
bromosuccinamide and isoprene, the bromoalcohol (5.1) is formed selectively and 
can be purified by a fast distillation through a Vigreux column. Two aminoalcohols 
was synthesized from (5.1). Treatment of the latter compound with neat amine 
(propylamine) yielded the aminoalcohol (5.3). Alternatively, reaction with an 
aqueous methylamine solution yielded (5.2). The overall reactions are outlined in 
scheme 19. 
 
 
Scheme 19. Synthesis of homoallyl-aminoalcohols. 
 
 
During the course of these studies, it was found that oxazolidines were formed 
spontaneous upon mixing of the reagents in aqueous solutions. (This was a fact even 
though the initial idea for the aza-Cope Mannich reaction where recognition of the 
iminium formed by (5.3) and a ketone/aldehyde by the assembly, see scheme 22.)  
When a solution of (5.2) or (5.3) in Et2O are added to a slight excess of an aldehyde 
they form the corresponding oxazolidines within minutes at room temperature. After 
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an aqueous wash of the reaction mixture the oxazolidines were isolated cleanly as 
clear liquids and could be used directly as substrates without further purification. 
The overall reaction for the oxazolidine condensation is outlined in scheme 20. 
 
 
Scheme 20. Condensation of homoallyl-aminoalcohols to oxazolidines. 
 
As a point of comparison, the synthesis of 3-acetyl-pyrrolidines from the 
oxazolidines (5.4 – 5.8) was achieved by treating them with camphor-sulfonic acid 
(the Overman procedure).47 The products of these experiments were fully 
characterized and employed as standards for the assembly-catalyzed reactions. The 
individual oxazolidines and stoichiometric amounts of acid were heated in benzene 
for 24 hours at 60oC. The experiments were successful and provided the products 
(5.9 – 5.13) in a good yields (scheme 21). The product (5.13) was the only 
compound that could not be fully characterized by NMR as the conversion observed 
by GC-MS was only 90%. Products containing R’ = alkyl were obtained as a 
mixture of diastereomers (see experimental section for more detail regarding 
diastereomeric ratios). 
 
Scheme 21. Acid mediated aza-Cope Mannich of oxazolidine. 
 
Studies were undertaken to assess whether compounds (5.2 - 5.3) underwent 
encapsulation with the assembly (1). The hypothesis is represented schematically in 
scheme 22. From previous studies it is expected that there will be a limitation to the 
physical size of the substrates that can be encapsulated (approximately 10 – 12 
atoms), as a result the first substrate studied was (5.3).    
 
 
Scheme 22. The initial idea – Iminium recognition followed by aza-Cope-Mannich. 
 
The first encapsulation experiments for the aza-Cope Mannich reaction were 
performed in parallel by mixing the assembly (1), and a small range of different 
carbonyl compounds and the homoallyl-aminoalcohol (5.3) (3 uL). The overview of 
these experiments is listed in scheme 23.   
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Scheme 23. Parallel encapsulation screening of (5.3) + carbonyl compounds. 
 
Experiments where the aminoalcohol (5.3) were mixed ketones and the assembly (1) 
showed no encapsulation. These reactions were all followed over time and were also 
heated to 60oC, but neither reactivity nor encapsulation was observed by 1H NMR 
spectroscopy. In contrast, when aldehydes were mixed with (5.3) an almost instant 
reaction was physically observed as indicated by the formation of a cloudy 
solution/suspension. When analyzed by 1H NMR these samples showed a very clear 
encapsulation with at strong binding efficiency (integration versus cluster peaks). 
The NMR spectra of the encapsulated peaks are shown on figure 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. (top left/right) 1H NMR in the area 2.5 to  -3.0 ppm of reaction (5.14) (in H2O), shows clear 
encapsulation of compound, integration of ~ 18H, reveals a strong binding of substrate. After heating for 3 hours, 
the spectrum changes significally. (bottom left/right) 1H NMR of reaction (5.15), integration of ~ 16H shows a 
strong binding of substrate. This again shows significantly changes in the encapsulated material. 
1H NMR of (5.14)
3 hours, 60oC. 
1H NMR (5.15)
3 hours, 60oC. 
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Interestingly the two reactions shown in figure 7 both express reactivity of the initial 
encapsulated compounds, and also that they differ in the binding efficiency of the 
product formed. By unknown reasons the product(s) formed in (5.14) bind less 
efficient than the product(s) in reaction (5.15). Structurally the only difference 
between the two reactions is the methyl-group in the aldehyde but still the integrals 
of the encapsulated compound are significantly higher in (5.15). 
 
Two following experiments confirmed that the initially encapsulated compounds 
were in fact oxazolidine. These compounds are encapsulated as neutral guests 
formed spontaneously from the condensation of the aminoalcohol (5.3) and 
aldehydes.  
 
The 1H NMR spectra (encapsulated area) of the cluster reaction (5.16) and 
oxazolidine substrate (5.8) + cluster are depicted in figure 8. The initial 1H NMR 
was acquired after the standard equilibration time of 15 minutes; subsequently the 
NMR samples were heated for 60oC in 4 hours. As it appears from the spectra, the 
encapsulated compounds (starting material and product) are in both reactions 
identical.  
 
This suggests that the resting state of the encapsulated starting material is the 
oxazolidine heterocycle and not the iminium ion formed by the aminoalcohol and 
carbonyl.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. (left, top and bottom) The experiment showing 1H NMR spectra of initial encapsulation of 3 
eq. oxazolidine (5.8) with the assembly (1) and the product of reaction (5.13) encapsulated after 4 hours 
at 60oC. (right, top and bottom) The experiment showing 1H NMR spectra of encapsulated substrate 
and product from reaction (5.16) with 3 eq. aminoalcohol (5.3) and 3 eq. ethanal with the assembly (1). 
    
1H NMR of substrate (5.3) + ethanol, 
reaction (5.16)  (1)
Initial. 
1H NMR of reaction (5.16)
4 hours, 60oC. 
1H NMR substrate (5.8)  (1)
Initial. 
1H NMR product (5.13)  (1)
4 hours, 60oC. 
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The conclusions derived from these experiments are that;  
 
(i) oxazolidines spontaneous condense with aldehydes and aminoalcohols in water,  
 
(ii) oxazolidines encapsulate as a neutral guest, possible due to an entropically 
favorable encapsulation into the lipophilic cavity of the cluster (hydrophobic effect),  
 
(iii) upon heating of reaction mixtures new product(s) forms within the cavity of the 
cluster which were identified to be the corresponding pyrrolidine. 
 
The product formed in the two reactions from figure 8, was identified by GC-MS as 
2-acetyl-5-methyl-N-propylpyrrolidine. The product was compared to the 
synthesized pyrrolidine (5.13), both retention time and fraction pattern was identical. 
Too small amounts of product, impurities from the extraction of product and the 
complexity in the product NMR made identification of these by NMR impossible at 
this time. Consequently oxazolidines were, from this point and on, chosen as 
substrates.  
 
In the first NMR experiments catalytic turnover was not observed or just barely 
observable. Subsequent studies suggested that this observation was possibly due to a 
strong binding of the product to the cluster (product inhibition of catalysis).  
 
Substrates synthesized from homoallyl-aminoalcohols (5.2 and 5.3) with 
formaldehyde to give the oxazolidines (5.4 and 5.7) did, on the other hand, not suffer 
from product inhibition.  
 
Those two substrates were surprisingly converted into the corresponding 
pyrrolidines by a catalytic amount of assembly. The oxazolidines (5.4 and 5.7) also 
showed a decreased initial binding constant compared to substrates derived from 
other aldehydes. This lower binding efficiency of both substrate and product remains 
unexplained, but it indicates a fast exchange between the interior and exterior 
environment of the assembly. A possible explanation could be that these substrates 
are less lipophilic.  
 
In figure 9 (on the next page), one example of a catalytic reaction with the substrate 
(5.7) is illustrated showing the substrate decrease and product increase.     
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Figure 9. 1H NMR of catalytic reaction of oxazolidine (5.7) with 10% of assembly (1). Reaction were 
followed in unbuffered H2O every hour by NMR with use of the Watergate solvent suppression pulse 
program.  
 
 Signs mark the disappearence of substrate (the two signs on the left side is disappearance of vinyl 
peaks and on the right side the methyl).  
 
 Marks the increase of product (right the methyl  to carbonyl and left the CH  to carbonyl.). 
Initial 
1 hour, 45oC 
2 hours, 45oC 
3 hours, 45oC 
4 hours, 45oC 
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As it appears from the catalytic experiment(s) the reaction is more than 95% 
complete after 4 hours with the use of 10% catalyst loading in unbuffered H2O. This 
reaction was however left for 24 hours at 45oC, for total completion, extraction with 
CDCl3 and identified as the same pyrolidine as formed in the earlier mentioned 
original “Overman” acid mediated aza-Cope Mannich product. The 13C NMR of the 
products are shown on figure 10.  
 
 
 
Figure 10. (top) 13C NMR spectrum from CDCl3 extraction of the reaction between (5.7) and 10 mol% 
(1), reaction was extracted after 24 hours at 45oC. The first 4 hourly 1H NMR spectra are shown on 
figure 9. (bottom) 13C NMR spectrum of 3-acetyl-1-propyl-pyrrolidine (5.12) synthesized with acid 
((+)-camphor sulphonic acid) from corresponding oxazolidine. 
   
For assurance that the aza-Cope Mannich is performed by the cluster and not by 
other factors, e.g. ion strength or binding to the exterior of the assembly, a 
competitive inhibition experiment was conducted. In these experiments you use a 
known good guest to block the cavity, therefore we used 2 eq. tetraethylammonium 
(Et4N+) as the inhibitor and performed the same reaction and followed its course by 
1H NMR spectroscopy. A point kinetic log-plot of the integration of substrate is 
shown on figure 11. 
 
  
 
 
 
 
 
 
 
Figure 11. (right) Logarithmic point kinetics plot of 
concentrations of substrate. Calculated concentrations 
from integration of methylene (N-CH2-O) protons, 
normalized to the starting concentration of oxazolidine. 
Aromatic cluster peaks used as internal standard and 
pentafluorobenzene as external standard in the 
background reaction. 
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The plot of substrate concentration versus time clearly shows the assembly catalyzes 
the aza-Cope Mannich reaction. The initial rate, of the cluster catalyzed reaction, is 
fast and after 1 hour at 45oC the conversion of the substrate to product is > 70%. The 
inhibition of the cluster with 2 eq. of Et4N+ also slows down the reaction as we 
hoped, but as the plot also reveals, the conversion-rate is in this experiment is faster 
than the experiment in H2O alone. This suggest either competitive inhibition or that 
the ion strength / exterior of the assembly have some effect on the reactionrate. The 
background reaction was placed at 45oC for a total of 18 hours and submitted to GC-
MS for analysis of the compounds. This experiment showed two reaction pathways 
for the substrate in unbuffered solution; it either forms the pyrrolidine or hydrolyzes 
back to the aminoalcohol (5.3). The partition between the compounds in the sample 
was at 18 hours: Oxazolidine (30%), Pyrrolidine (39%) and Aminoalcohol (30%), 
which must be considered a significantly amount of hydrolyzed and also formed 
product, figure 12. 
 
 
 
Figure 12. CG-MS trace from the background reaction in H2O (18 h., 45oC). First peak at rt = 10.17 
min. corresponds the aminoalcohol, second peak at rt = 10.50 min. is the oxazolidine and last peak at 
13.17 corresponds to the pyrrolidine product. 
 
To overcome the background hydrolysis and formation of product, the oxazolidine 
(5.7) was subjected to 3 different buffered D2O solutions. On scheme 24 the results 
for the pD experiments are listed. 
 
Scheme 24. Conversion of (5.7) in buffered solutions at different pD values measured by GC-MS. 
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With regards to hydrolysis, this oxazolidine seams to be more stable at higher pD/pH 
values and therefore no ring-opening of oxazolidine, hydrolysis or sigmatropic 
rearrangements were observed under these conditions. At 4 hours at 45oC, no 
degradation of the starting material was observed at the high pD of 11.28. We set out 
to investigate the cluster experiments at this high pH.  
 
Four experiments were performed to investigate the pH effect on the catalytic and 
background hydrolysis reactions. These reactions were setup same way as the 
previous point kinetic reactions and the results are plotted on figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Logarithmic point kinetics plot of concentrations of substrate versus time.  
 
The effect of pH is compared in buffered (100 mM K2CO3 at pH=11.5) and unbuffered (H2O) solvent 
in the catalytic reaction  of compound (5.7).  
 
Calculated concentrations from integration of methylene (N-CH2-O) protons, normalized to the starting 
concentration of oxazolidine. Aromatic cluster peaks used as internal standard (integrated to 72H) in 
the cluster experiments and pentafluorobenzene as external standard (sealed tube) in the background 
reaction. 
 
 
The reaction was followed over 3 hours at 45oC and the plot of the integration 
clearly shows the effect of reaction at this buffered high pH solvent. The background 
reaction and the reaction with the use of 2 eq. of inhibitor show nearly no decrease in 
substrate in this time-frame which means a non-significant hydrolysis takes place. In 
the catalytic reactions, the comparison of the buffered and un-buffered looks almost 
identical. This suggests that the rate of this catalytic aza-Cope Mannich reaction is 
independent of the proton concentration (although we know it is, of course). These 
experiments are, however, only preliminary point kinetic studies and a more 
thorough study of the pH influence on the reaction rate must be completed before 
any conclusive statements can be made. The reaction is proposed to go through an 
initial protonation (cationic recognition of the substrate) followed by ring opening of 
the oxazolidine. One would therefore imagine that proton concentration may play a 
significant role in the reaction rate. 
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
 
For the two substrates that showed fast and clear catalytic reactivity with the cluster, 
two larger scale reactions were conducted in order to fully characterize the reaction 
product. Unfortunately the reaction was not all complete after 4 hours at 45oC when 
the reactions were extracted; remaining peak resonances from the starting material 
were present in the NMR spectrum. Data were compared with literature values, the 
pyrrolidines synthesized earlier and was this way identified. On scheme 25, the two 
reactions are depicted. 
 
 
 
 
 
 
Scheme 25. The two upscale reactions performed on the substrates with fastest and efficient turnover. 
 
 
All the synthesized oxazolidine substrates were tested for catalytic activity with the 
cluster. From these experiments it was found that alkyl substitution on the 2-position 
had a drastic impact on the reaction rate.  
 
In scheme 26, the reactions are tabulated and the retention time of the products 
listed. In the experimental section details of the reaction condition and 
conversion/turnover of the substrate listed. 
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Scheme 26. Overview of the compounds, catalytic cluster experiments and proton mediated together 
with the retention time from the CG-MS track for identification and conversion calculation. 
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
Conclusions to the aza-Cope Mannich reaction 
  
The results from aza-Cope Mannich reactions performed with the [Ga4L6]-12 
supramolecular cluster can be summarized with the following points.  
 
Allylaminoalcohol (5.3) spontaneously forms oxazolidines when mixed with 
aldehydes (5.14 - 5.16) in aqueous solutions, these neutral heterocycles encapsulate 
in the cluster. Upon heating a transformation of the substrate encapsulated within the 
cluster cavity occur. The same substrate (5.3) does not react with ketones.  
 
Oxazolidines can be easily synthesized (5.4 - 5.8) and be used as substrates in cluster 
experiments to form pyrrolidines (5.20 - 5.24). 
 
Oxazolidines are encapsulated in the assembly, where they protonate, ring-open and 
undergo the aza-Cope Mannich reaction; this reactivity can be turned off by the 
addition of inhibitor (Et4N+) to the reaction for prevention of substrate encapsulation. 
 
When the oxazolidines ((5.4) and (5.7)) are formed with formaldehyde, the 
transformation from oxazolidine to pyrrolidine occurs much faster and catalytically. 
In contrast to the oxazolidines substituted on the 2 position, where slow turnover 
was observed.  
 
At higher pH the background hydrolysis reaction decrease and the cluster 
experiments seems unaffected at this pH.   
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Experimental Section 
General 
 
Unless otherwise indicated, all operations were performed under anhydrous 
conditions and inert atmosphere employing standard Schlenk techniques under 
nitrogen. Glassware was dried in an oven at 160oC overnight or flame-dried prior to 
use. 
 
GC-MS analysis was performed on a Agilent Technologies 6890N gas 
chromatograph with a Agilent Technologies 5973 electron-impact mass-
spectrometry detector equipped with a Agilent DB-5ms, 0.25mm * 30 m * 0.5 um 
(catno. 122-5536) column. A standard method were in general used with a 
temperature gradient 50oC (3 min, 0oC/min), 200 oC (10 oC/min), 300 oC (15 
oC/min), 300 oC (0oC/min, 5 min) with a gas flow of 1.2 ml/min.  
 
NMR spectra were acquired using Bruker AV-300, AVQ-400, AVB-400 and AV-
500 spectrometers. Chemical shifts are reported as part per million (ppm, 
) and 1H 
and 13C chemical shifts are referenced to the corresponding residual protic solvent 
resonance. Signal multiplicity and shape are reported using the following 
abbreviations: s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; m, 
complex multiplet. Measurements of 1H NMR shifts performed in H2O as solvents 
were acquired using a Watergate solvent suppression pulse-program. Deuterated 
solvents were purchased from Cambridge Isotope Laboratories. 
 
All high-resolution mass spectra (HRMS) were recorded at the University of 
California, Berkeley Microanalytical Facility with electrospray ionization detection 
in positive mode. 
 
Solvents for cluster experiments were degassed prior to use by bubbling N2 gas 
through the solvent. Aprotic solvents used for synthesis of substrates were 
anhydrous and purified by passing through a column of activated alumina under 
nitrogen pressure.  
 
All reagents were obtained from commercial suppliers and used without further 
purifications unless stated otherwise. 
  
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
Synthesis of The Assembly 
 
(0.1) 2,3-dimethoxybenzoyl chloride: (NB: This is a reproduced procedure)48. In a 
flame dried Schleck-flask 2,3-dimethoxybenzoic acid (4.435 g, 24.43 mmol) was 
slowly added SOCl2 (10 mL, 16.3 gr., 137 mmol) at 0
oC and under N2. The solution 
was allowed to warm to room temperature and the resulting red-orange homogenous 
solution was stirred night-over (16 h.). The volatiles were then removed under 
reduced pressure and the resulting crystalline off-white powder was to added DCM 
(20 mL) stirred for 20 minutes and solvent were stripped off. This was performed 
twice before the compound was dried under reduced pressure to yield  
approximately 4.9 grams of white crystalline product. The compound was used as is 
in following reaction, assuming quantitative yield. 
 
(0.2) N,N'-Bis(2,3-dimethoxybenzoyl)-1,5-naphtylenediamine: (NB: This is a 
reproduced procedure10.) In the same dry Schleck-flask cooled to 0oC, the freshly 
prepared 2,3-dimethoxybenzoyl chloride (0.1) (4.9 gr., 24.4 mmol) and 1,5-diamino-
naphtalene (1.60 g, 10.1 mmol) was dissolved in DCM (40 mL). An excess of Et3N 
(5 mL) was slowly added, immediately forming white precipitate (Et3NHCl). The 
suspension was then stirred at 0oC for three hours. Additional DCM (40 mL) was 
added to the mixture, which was washed with water (100 mL), then dilute HCl (100 
mL, 1 M) followed by a dilute NaOH solution (100 mL, 1M). The organic layer was 
dried over MgSO4, filtered and concentrated on a rotary evaporator. Diethyl ether 
(20 mL) was added and the precipitate was collected by filtration and the product 
was air dried. This yielded tan powder (3.84 gr., 7.9 mmol, 78 %). The 1H-NMR was 
compared to the described in literature. 
 
1H NMR (300 MHz, CDCl3	 ppm 10.75 (s, 2H, NH), 8.56 (d, J = 7.6 Hz, 2H), 
7.89 (dd, J = 8.1, 1.5 Hz, 4H), 7.60 (t, J = 8.1 Hz, 2H), 7.27 (t, J = 8.1 Hz, 4H), 7.16 
(dd, J = 8.1, 1.5 Hz, 2H), 4.09 (s, 6H, OMe), 3.99 (s, 6H, OMe). 
 
(0.3) N,N'-Bis(2,3-dihydroxybenzoyl)-1,5-naphtylenediamine = L: (NB: This is a 
modified procedure described10.) In a flame dried Schlenk-flask (0.2) (2.108 gr., 
4.33 mmol) was dissoluted in DCM (30 mL) and cooled to -78 oC. This mixture was 
then slowly charged with BBr3 (8.5 mL, 90 mmol) via a syringe. The reaction 
mixture was allowed to warm to room temperature and stirred for 5 days for to 
achieve full demethyllation49.  The reaction mixture was then quenched with ice 
(250 gr.) in a round bottomed flask cooled in an ice bath. A notably intense reaction 
was observed while quenching.  The remaining suspension was placed on a rotorary 
evaporator and the volatiles (DCM) were removed gently under reduced pressure. It 
was then heated up to 90oC at atmospheric pressure and stirred heavily for 3 hours. 
The solids were collected by filtration, followed by washing with H2O (50 mL x5), 
MeOH (50 mL x 5) and last Et2O (50 mL x 2). The product was dried under vacuum 
night over to give a pale-tan off-white powder (1.303 gr., 3.03 mmol, 70%). 1H 
NMR of this was compared to the described literature. 
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1H NMR (300 MHz, d6-DMSO	 ppm 11.89 (bs, 2H), 10.92 (s, 2H), 9.62 (bs, 2H), 
7.92 (d, J = 8.4 Hz, 2H), 7.86 (d, J = 7.5 Hz, 2H), 7.65-7.59 (m, 4H), 7.03 (d, J = 7.5 
Hz, 2H), 6.84 (t, J = 7.8 Hz, 2H). 
 
(1)  K12[(Et2O)2  Ga4L6]: (NB: This is a procedure previously described12): In a 
flame dried shleck-flask the ligand (0.3) (1.3 gr., 3.02 mmol) was suspended in 
MeOH (150 mL) and degassed by 3 vacuum / N2 cycles. This was added KOH 
(0.504 M in MeOH, 17 mL, 8.57 mmol) and degassed again by 3 vacuum / N2 
cycles. To the resulting homogenous solution was added [Ga(acac)3] (739 mg, 2.01 
mmol) and KCl (61 mg, 0.82 mmol) and the resultant mixture was subsequently 
degassed 3 more times by vaccum/N2 cycles. The reaction was stirred for 4 hours 
before it was reduced to a third of the volume under vacuum. The assembly (1) was 
precipitated out by the dropwise addition of Et2O (approx. 30 mL) and isolated by 
filtration on a medium frit under a flow of nitrogen. The product was washed with 
Et2O (20 mL x 5), pentane (20 mL x 4) and again with Et2O (20 mL x 3) followed by 
drying overnight on the vacuum-line to yield a yellow powder (1.497 gr., 83%). The 
product was stored under nitrogen in a glovebox until used. A peak of methanol was 
observed, this could not be removed by vacuum over time and this is associated with 
the highly polarized ionic cluster. The molecular weight of the cluster is in further 
experiments standardized to 3600 DA, therefore giving a yield of 83%.   
 
1H NMR (300 MHz, D2O	 ppm 7.73 (d, J = 8.5 Hz, 12H, aryl), 7.56 (d, J = 7.4 Hz, 
12H, aryl), 7.11 (d, J = 8.1 Hz, 12H, aryl), 6.86 (d, J = 8.1 Hz, 12H, aryl), 6.64 (d, J 
= 7.1 Hz, 12H, aryl), 6.46 (t, J = 7.6 Hz, 12H, aryl), 3.24 (s, 2H, MeOH, exterior). 
Guest: 1.80 (bs, 8H), -0.30 (bs, 12H). 
 
 
 
  
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
(1.1) [Et4N+  Ga4L6]-11: In a small vial (1) (20 mg) was mixed in a standard de-
gassed solution of Et4NBr (approx. 10 eq.) in D2O (500 uL). The sample was shaken 
and NMR acquired after 30 min.  
 
 
 
 
 
 
1H NMR (300 MHz, D2O	 ppm 8.09-7.96 (m, 12H, aryl), 7.85-7.74 (m, 12H, 
aryl), 7.20 (d, J = 8.1 Hz, 12H, aryl), 7.06 (t, J = 8.1 Hz, 12H, aryl), 6.63 (d, J = 7.2 
Hz, 12H, aryl), 6.49 (t, J = 7.8 Hz, 12H, aryl), 3.46 (q, J = 6.9 Hz, 6H, Et2O 
exterior), 3.24 (s, 2H, MeOH exterior), 2.57 (q, J = 7.2 Hz, 76H, NEt4+ exterior), 
1.07 (t, J = 6.9 Hz, 9H, Et2O exterior), 0.75 (t, J = 7.2 Hz, 114H, NEt4+ exterior). 
Guest: -0.82 (m, 8H, NEt4+ interior), -1.70 (m, 12H, NEt4+ interior). 
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(1.2) [Et3NH+  Ga4L6]-11: In a small vial (1) (20 mg) was mixed in a standard 
degassed solution of Et3N in D2O. The sample was shaken and NMR acquired after 
30 min. 
 
1H NMR (300 MHz, D2O	 ppm 7.89 (d, J = 7.7 Hz, 12H, aryl), 7.72 (d, J = 8.5 
Hz, 12H, aryl), 7.20 (d, J = 8.1 Hz, 12H, aryl), 6.99 (t, J = 8.1 Hz, 12H, aryl), 6.66 
(d, J = 7.2 Hz, 12H, aryl), 6.50 (t, J = 7.8 Hz, 12H, aryl), 3.40 (q, J = 7.2 Hz, 6H, 
Et2O exterior), 3.24 (s, 2H, MeOH exterior), 2.31 (bs, 28H, NEt3 exterior), 1.04 (t, J 
= 7.2 Hz, 9H, Et2O exterior), 0.79 (bs, 42H, NEt3 exterior). Guest: -0.80 (bs, 6H, 
NEt3H+ interior), -1.85 (bs, 9H, NEt3H+ interior). 
 
 
 
  
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
Synthesis of Substrates for Electrocyclization and Sigmatropic 
Rearrangement 
 
(2.1) (2Z,4E)-methyl hexa-2,4-dieneoate. Procedure as described32. A solution of 
Phosphonoester (473 uL, 2 mmol), 18-crown-6 (529 mg, 2 mmol) in 20 ml 
anhydrous THF was cooled to -78oC under nitrogen and treated with KN(TMS)2 (2 
mmol, 0.3M in toluene, tritrated prior to use with fluorene, 2,6-ditertbutyl-4methyl-
phenol). Crotonaldehyde (145 uL, 2 mmol) was then added and the resulting mixture 
was stirred for 45 min at -78oC. A saturated NH4Cl sol. (30 mL) was added, and the 
reaction allowed to warm to r.t., and the product was extracted into diethylether (3 x 
40 mL). The ether extracts were washed with brine (50 ml), dried (MgSO4), filtered 
and solvents removed on a rotary evaporator. The product was isolated by flash 
chromatography. To yield a clear oil (2.1) 242 mg (86%). 
 
1H NMR (300 MHz, CDCl3)  ppm 7.37 (m, 1H), 6.53 (t, J = 11.33 Hz, 1H), 6.08 
(qd, J = 13.74, 6.85 Hz, 1H), 5.62-5.47 (d, 1H), 4.17 (q, J = 5.39 Hz, 1H), 1.86 (d, J 
= 7.97, Hz, 1H), 1.29 (t, 1H). GCMS showed the product: RT = 10.44 min (mz = 
140, M+). 
 
Z:E ratio = 24 based on the NMR dublet at ~ 5.5 (Z - low J) and ~ 5.75 (E - High J). 
 
 
(2.2) (2Z,4E)-N-methoxy-N-methylhexa-2,4-dienamide. Procedure as described33. 
To a slurry of Me(MeO)NH.HCl (112 mg, 1.25 mmol) and (2.1) (112 mg, 1 mmol) 
in 15 mL of THF at -5°C under nitrogen was added MeMgCl in THF (1.33 mL, 3.0 
M, 4 mmol) over 15 min. maintaining the temperature between -2 and -5 °C. After 
1h at -5°C the reaction mixture was warmed to 25°C over 1 h, aged overnight (12 
hours). The reaction mixture was then quenched into 1 M NH4Cl (15 mL) then 
heated to 30-35 °C for 15 min. The resulting mixture was extracted with Et2O (50 
mL x 2) and the combined organic phases dried over MgSO4 and filtered. After 
removal of solvents on a rotary evaporator the crude product was purified on a silica 
column to yield the weinreb amide as a pale yellow clear liquid: 101 mg (65%). 
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1H NMR (400 MHz, CDCl3)  ppm 7.43-7.36 (m, 1H), 6.48 (t, J = 11.35 Hz, 1H), 
6.08-5.98 (m, 2H), 3.66 (s, 3H), 3.22 (s, 3H), 1.85 (d, J = 6.81, 3H). CGMS showed 
on peak at 13.41 min, m/z = 155 (M+). 
 
 
 
(2.3) 3,5-diene-2-heptenone. A flamedried Slenck flask was charged with THF (20 
mL) and (2.2) (204 mg, 1.31 mmol). The flask was cooled to -78oC and MeLi was 
added (1.6 mL, 2.6 mmol, 1.6M).  Reaction turned from clear, to deep red / 
brownish indicating a immediate reaction. The reaction mixture was stirred at this 
temperature and followed by TLC for the fully consumption of weinreb amide, fully 
conversion was observed after 15 minutes. The reaction was quenched with a 
solution of NH4Cl (20 mL, 1M) and added Brine (10 mL). It was exctracted with 
Et2O (2 x 40 mL) and the combined organic layers where dried with MgSO4, filtered 
and evaporated. The product was chromatographed on a Biotage (column 12-M), 
and the fractions containing methyl-ketone was evaporated to yield (2.3) as yellow 
oil, 82 mg (56%). 
 
1H NMR (400 MHz, CDCl3)  ppm 7.48-7.31 (m, 1H), 6.37 (t, J = 11.32 Hz, 1H), 
6.13 (qd, J = 13.99, 6.91 Hz, 1H), 5.92 (d, J = 11.26 Hz, 1H), 2.22 (s, 3H), 1.88 (d, 
3H). 13C NMR (101 MHz, CDCl3)  ppm 198.9, 143.1, 141.9, 128.9, 122.6, 31.6, 
18.7. 
  
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
(3.1) Allyltrichloroacetimidate and (3.2) trans-crotyltrichloroacetimidate.  
Prepared by described procedure50. A flame dried Schlenk flask was charged with 
anhydrous diethyl ether (10 mL) followed by sodium hydride (24 mg, 1 mmol). To 
the resulting suspension allyl alcohol ((3.1), 680 uL, 10 mmol); (3.2), 855 uL, 10 
mmol) was added dropwise and after 5 minutes the solids had dissolved (H2 
evaporation). The reaction mixture was then cooled to 0oC with an ice-bath and 
trichloroacetonitrile (1 mL, 10 mmol) was added dropwise over a period of 5 min. 
The mixture was allowed to warm to room temperature over an period of 60 minutes 
and stirred for additional 60 minutes. The reaction was then neutralized with 
saturated NaHCO3 (10 ml). It was extracted with Et2O (3 x 10 mL) and the 
combined organic layers was dried over MgSO4 and concentrated in vacuum on a 
rotary evaporator. 
 
Yielding (3.1) as a clear orange oil: 1.78 gram (88%). 1H NMR (300 MHz, CDCl3)  
ppm 8.32 (s, 1H), 6.02 (ddd, J = 22.60, 10.68, 5.43 Hz, 1H), 5.43 (dd, J = 17.23, 
1.47 Hz, 1H), 5.30 (dd, J = 10.51, 1.20 Hz, 1H), 4.80 (d, J = 5.43 Hz, 2H). 13C 
NMR (75 MHz, CDCl3 )  ppm 162.44 (1C), 131.34 (1C), 118.46 (1C), 91.32 (1C), 
77.42 (2C). 
 
Yielding (3.2) as a slightly yellow oil: 1.76 gram (81%). 1H NMR (400 MHz, 
CDCl3) 
 ppm 8.25 (s, 1H), 5.87 (dq, J = 13.1, 6.5, 1H), 5.69 (dtd, J = 7.7, 6.4, 1.3, 
1H), 4.71 (d, J = 6.3, 2H), 1.73 (d, J = 6.4, 3H).  13C NMR (100 MHz, CDCl3) 
 
ppm 162.61 (C), 131.82 (CH), 124.30 (CH), 70.17 (CH2), 18.09 (CH3). 
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(4.1) 2-(1-methyl)-allyl-1,1-dimethylisourea. This is a modified proceeding 
described51. A solution of Dimethylcyanamide (0.5 mL, 6.13 mmol) and 2-buten-2-
ol ( 0.53 mL, 6.13 mmol) in dry diethylether (10 mL) was added 0.2 eq. 
sodiumhydride (15 mg, 0.61 mmol). The resulting mixture was stirred at r.t. for 3 h. 
after which additional DCM was added (20 mL) and the resulting solution was 
washed with water (3 x 20 mL). The organic phase was then washed with brine (30 
mL) and dried over MgSO4, then evaporated to give the product as a clear oil yield: 
471 mg (54%). 
 
1H NMR (300 MHz, CDCl3)  ppm 5.89 (m, 1H), 5.24 (d, 1H), 5.22 (bs, 1H), 5.12 
(d, 1H), 2.87 (s, 6H), 1.35 (d, 3H). 1H NMR (400 MHz, 8d-toluene)  ppm 5.82 (m, 
1H), 5.45 (bs, 1H), 5.15 (d, 1H), 4.95 (d, 1H), 2.44 (s, 6H), 1.26 (d, 3H). 
 
13C NMR (100 MHz, CDCl3) 	ppm 160.6, 139.0, 114.6, 72.48, 37.2, 20.6. 13C 
NMR (APT (CH/CH3 +) (C/CH2 -), 100 MHz, 8d-Toluene) 	ppm 159.3 (-), 139.4 
(+), 113.7 (-), 71.7 (+), 36.3 (+), 19.8 (+). 
  
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
Synthesis of Substrates for aza-Cope Mannich  
 
(5.1) 1-bromo-2-methyl-3-butene-2-ol: (NB: This procedure has previously been 
described47). A mixture of diethyl ether (35 mL), water (25 mL) and isoprene (15 
mL, 150 mmol) was rapidly stirred and cooled to 0oC in a flask fitted with at dry-ice 
condenser. N-Bromosuccimide (26.7 g., 150 mmol) was added in one portion, the 
cooling bath removed, and reaction was stirred at room temperature for 16 hours. 
Additional water (20 mL) and diethyl ether (20 mL) was added, the ether phase 
separated, and the aqueous layer extracted with diethyl ether (3 x 25 mL). The 
combined organic phases were dried with MgSO4, filtered and the ether removed on 
a rotary evaporator. The crude product was purified with a quick vacuum distillation 
through a short column, yielding a very pale-green clear liquid: 14.0 gram (57%). 
NMR chemical shifts matches the literature values. HR-ESI-MS nor EI-MS was 
achievable for this compound. 
 
1H NMR (400 MHz, CDCl3	 ppm 5.89 (dd, J = 17.2, 10.7 Hz, 1H), 5.36 (d, J = 
17.2 Hz, 1H), 5.18 (d, J = 10.7 Hz, 1H), 3.46 (s, 2H), 2.26 (s, 1H), 1.41 (s, 3H).  
 
13C NMR (100 MHz, CDCl3	 ppm 141.30, 114.66, 71.78, 44.68, 25.92. 
 
 
(5.2) 2-methyl-1-(methylamino)-3-butene-2-ol: (NB: This proceeding has 
previously been described47). To a small Schlenk flask aqueous methylamine (20 
mL, 40 % wt) was added, the flask was cooled to 0 oC, before (5.1) (3 gr., 18.18 
mmol) was added dropwise. The Schlenk-flask was sealed and allowed to warm to 
room temperature, then stirred overnight for 18 hours. To the reaction-mixture was 
added a saturated sodium hydroxide solution (20 mL, 50 % vol), the organic 
products were extracted with Et2O (3 x 40 mL). The combined organic phases were 
dried with MgSO4, and the solvent removed by rotary evaporation, yielding a clear 
colorless oil: 1.781 gr. (85%). 
 
1H NMR (400 MHz, CDCl3)  ppm 5.81 (dd, J = 17.2, 10.4 Hz, 1H), 5.29 (d, J = 
17.2 Hz, 1H), 5.08 (d, J = 10.4 Hz, 1H), 2.65 (ABX, Jab = 11.6, 1H), 2.44 (ABX, 
1H), 2.43 (s, 3H), 1.22 (s, 3H).  
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13C NMR (100 MHz, CDCl3)	 ppm 143.62, 113.00, 71.78, 60.99, 36.76, 25.86. GC-
MS (EI): Rt = 6.92 min, m/z = 84 (main fraction). HRMS (ESI+): calcd. for 
C6H14NO+ 116.1070, found 116.1066 (MH+). 
 
 
 
 (5.3) 2-methyl-1-(propylamino)-3-buten-2-ol: (NB: This proceeding has 
previously been described47). To a flame dried Schlenk flask n-propylamine (20 mL) 
was added and the flask cooled to 0oC. To this (5.1) (4.442 gram, 26.9 mmol) was 
added dropwise and the flask was heated to n-propylamine’s b.p. ~ 50oC before the 
flask was closed and heated to 60oC. The reaction was stirred at this temperature for 
6 hours before it was cooled to room temperature and the solvent reduced to half 
volume under vacuum. The resulting reaction mixture was partitioned between 
diethyl ether (40 mL) and aqueous NaOH (15%, 40 mL). The aqueous layer was 
extracted with diethyl ether (3 x 40 mL) and the combined organic phases were dried 
with MgSO4, then filtered and the solvent removed on a rotary evaporator. The 
product was purified by a vial-to-vial vacuum transfer, to yield a colorless liquid: 
3.48 gram (90 %). 
 
 Part III. Investigation of Guest-Host Mediated Electrocyclization and Sigma-tropic 
Rearrangement Reactions 
1H NMR (400 MHz, CDCl3) 	ppm 5.78 (dd, J = 17.2, 10.8 Hz, 1H), 5.27 (d, J = 
17.2 Hz, 1H), 5.06 (d, J = 10.8 Hz), 2.67 (ABX, Jab = 11.6 Hz, 1H), 2.56 (m, 2H), 
2.43 (ABX, Jab = 11.6 Hz, 1H), 1.44 (m, 2H), 1.20 (s, 3H), 0.87 (t, J = 7.2 Hz, 3H).  
 
13C NMR (100 MHz, CDCl3)	 ppm 143.71, 112.90, 71.49, 58.45, 51.83, 25.78, 
23.12, 11.53. GC-MS (EI): Rt = 10.16 min, m/z = 72 (main fraction). HRMS (ESI+): 
calcd. for C8H18NO+ 144.1383, found 144.1378 (MH+). 
 
 
 
General procedure for synthesis of oxazolidines  
 
(5.4 – 5.8): In a small scintillation vial (20 mL) the starting material (5.2) or (5.3), 
(4.5 – 5 mmol) dissolved in Et2O (5 mL) and cooled to 0oC. The aldehyde* (1.1 eq.) 
was added; the vial closed and allowed to warm to room temperature. After stirring 
of the reaction mixture for 30 min, the reaction was dried with MgSO4, filtered and 
solvents evaporated to yield the corresponding oxazolidine as clear to very pale 
yellow liquids (these where used without further purification in the cluster 
experiments). * for product (5.4) and (5.7) aqueous formaldehyde (37 % wt) was 
used.  
 
(5.4) 3,5-dimethyl-5-vinyloxazolidine: Yield: 493 mg (88%). 
1H NMR (400 MHz, CDCl3)  ppm 5.95 (dd, J = 17.2, 10.4 Hz, 1H), 5.25 (d, J = 
17.2 Hz, 1H), 5.03 (d, J = 10.4 Hz, 1H), 4.31 (ABX, Jab = 4.0 Hz, 1H), 4.27 (ABX, 
Jab = 4.0 Hz, 1H), 2.84 (ABX, Jab = 10.0 Hz, 1H), 2.67 (ABX, Jab = 10.0 Hz, 1H), 
2.41 (s, 3H), 1.36 (s, 3H).  
 
13C NMR (100 Mz, CDCl3)	 ppm 142.97, 112.02, 87.76, 81.02, 65.54, 40.69, 25.66. 
GC-MS (EI): Rt = 7.37 min, m/z = 127 (M+), 112 (main fraction), 96, 84, 72, 56, 42. 
HRMS (ESI+): calcd. for C7H14NO+ 128.1070, found 128.1065 (MH+). 
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(5.5) 2,3,5-trimethyl-5-vinyloxazolidine: Yield: 540 mg (87%) as a (1:3) mixture 
of diastereomers. 
 
1H NMR (400 MHz, CDCl3) Major diastereomer:  ppm 5.97 (dd, J = 17.2, 10.4 Hz, 
1H), 5.30 (dd, J = 17.2, 1.2 Hz, 1H), 5.05 (dd, J = 10.4, 1.2 Hz, 1H), 3.95 (q, J = 5.2 
Hz, 1H), 3.16 (ABX, Jab = 9.2 Hz, 1H), 2.36 (ABX, Jab = 9.2 Hz, 1H), 2.26 (s, 3H), 
1.33 (s, 3H), 1.31 (d, J = 5.2 Hz, 3H). Minor diastereomer:  ppm 5.92 (dd, J = 17.2, 
10.8 Hz, 1H), 5.23 (d, J = 17.2 Hz, 1H), 5.03 (d, J = 10.8 Hz, 1H), 3.92 (q, J = 5.2 
Hz, 1H), 3.06 (ABX, Jab = 9.2, 1H), 2.44 (ABX, Jab = 9.2 Hz, 1H), 2.28 (s, 3H), 1.39 
(s, 3H), 1.29 (d, J = 5.6 Hz, 3H). 
 
 13C NMR (100 MHz, CDCl3)  ppm 143.51, 112.23, 93.25, 79.45, 67.10, 37.90, 
25.31, 18.86. GC-MS (EI): Rtmajor = 7.74 min, Rtminor = 7.39 min, m/z = 140 (M+), 
98, 71 (main fraction), 56, 42, 27. HRMS (ESI+): calcd. for C8H16NO+ 142.1226, 
found 142.1221 (MH+). 
 
 
 
(5.6) 2-ethyl-3,5-dimethyl-5-vinyloxazolidine: Yield: 616 mg (90%) as a (1:3) 
mixture of diastereomers. 
 
1H NMR (400 MHz, CDCl3) Major diastereomer:  ppm 5.98 (dd, J = 17.2, 10.4 Hz, 
1H), 5.28 (dd, J = 17.2, 1.2 Hz, 1H), 5.04 (dd, J = 10.4, 1.2 Hz, 1H), 3.80 (m, 1H), 
3.16 (ABX, Jab = 9.2 Hz, 1H), 2.37 (ABX, Jab = 9.2 Hz, 1H), 2.27 (s, 3H), 1.76 – 
1.65 (m, 1H), 1.58 – 1.47 (m, 1H), 1.34 (s, 3H), 1.00 (t, J = 7.6 Hz, 3H). Minor 
diastereomer:	 ppm 5.93 (dd, J = 17.2, 10.8 Hz, 1H), 5.24 (d, J = 17.2, 1H), 5.04 (d, 
J = 10.8, 1H), 3.80 (m, 1H), 3.04 (ABX, Jab = 8.8 Hz, 1H), 2.44 (ABX, Jab = 8.8 Hz, 
1H), 2.28 (s, 3H), 1.76 – 1.65 (m, 1H), 1.58 – 1.47 (m, 1H), 1.38 (s, 3H), 0.97 (t, J = 
6.8 Hz, 3H).  
 
13C NMR (100 MHz, CDCl3)	 ppm 143.70, 112.10, 98.14, 79.25, 67.11, 38.37, 
25.82, 25.30, 8.92. GC-MS (EI): Rt (major) = 9.37 min, Rt (minor) = 9.05 min, m/z = 
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154 (M+), 140, 126 (major fraction), 98, 85, 70, 56, 42, 27. HRMS (ESI+): calcd. for 
C9H18NO+ 156.1383, found 156.1379 (MH+). 
 
 
 
(5.7) 3-propyl-5-methyl-5-vinyloxazolidine: Yield: 709 mg (91%). 
1H NMR (400 MHz, CDCl3)	 ppm 5.95 (dd, J = 17.2, 10.8 Hz, 1H), 5.24 (dd, J = 
17.2, 1.2 Hz, 1H), 5.03 (dd, J = 10.8, 1.2 Hz, 1H), 4.35 (s, 2H), 2.86 (ABX, Jab = 
10.4 Hz, 1H), 2.71 (ABX, Jab = 10.4 Hz, 1H), 2.50 (t, J = 8.0 Hz, 2H), 1.48 (m, 2H), 
1.36 (s, 3H), 0.91 (t, J = 7.6 Hz, 3H).  
 
13C NMR (100 MHz, CDCl3)	 ppm 142.99, 112.03, 86.22, 80.50, 63.81, 56.31, 
25.58, 18.42, 11.76. GC-MS (EI): Rt = 10.52 min, m/z = 154 (M+), 140, 126, 84 
(main fraction), 69, 57, 43, 27. HRMS (ESI+): calcd. for C9H18NO+ 156.1383, found 
156.1377 (MH+). 
 
 
(5.8) 3-propyl-2,5-dimethyl-5-vinyloxazolidine: Yield: 673 mg (87%) as a (1:1) 
mixture of diastereomers. 
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1H NMR (400 MHz, CDCl3)	 ppm both diastereomers: 5.99 (dd, J = 17.2, 10.8 Hz, 
1H), 5.92 (dd, J = 17.2, 10.8 Hz, 1H), 5.25 (m, 2H), 5.03 (m, 2H), 4.06 (m, 2H), 
3.22 (ABX1, Jab = 9.2 Hz, 1H), 3.10 (ABX2, Jab = 8.8 Hz, 1H), 2.55 (m, 2H), 2.36 
(ABX1, Jab = 9.2 Hz, 1H), 2.26 (ABX2, Jab = 8.8 Hz, 1H), 2.13 – 2.04 (m, 2H), 1.52 
– 1.44 (m, 4H), 1.39 (s, 3H), 1.34 (s, 3H), 1.31 – 1.29 (m, 6H), 0.94 – 0.89 (m, 6H).  
 
GC-MS (EI): Rt = 10.45 – 10.55 min, m/z = 166 (M+), 154, 140, 126, 99, 84 (main 
fraction), 69, 56, 41, 27. HRMS (ESI+): calcd. for C10H20NO+ 170.1539, found 
170.1536 (MH+). 
 
 
Acid mediated aza-Cope Mannich experiments 
 
General procedure for the synthesis of 3-acetyl-pyrrolidines. In small pop-cap 
vials (+)-camphor sulphonic acid (100 mg, 0.43 mmol) was dissolved in dry benzene 
(2 mL). To this solution the oxazolidine (5.4 – 5.8) (1 eq., 0.43 mmol) was added. 
The vials were closed, tightened and then heated to 60oC and left stirring for 24 
hours. The reaction mixtures were then added aqueous sodium hydroxide (6M, 2 
mL) and then extracted with Et2O (3 x 2 mL). The combined organic phases were 
dried with MgSO4, filtered and evaporated on a rotary evaporator to yield the 2-
acetylpyrrolidines as clear liquids. The conversion was determined by GC-MS. 
 
(5.9) N-methyl-3-acetylpyrrolidine: Conversion: 100%. Yield: 48 mg (88%). 
 
1H NMR (400 MHz, CDCl3)	 ppm 3.14 – 3.06 (m, 1H), 2.74 – 2.70 (m, 1H), 2.62 – 
2.53 (m, 2H), 2.48 – 2.42 (m, 1H), 2.31 (s, 3H), 2.14 (s, 3H), 2.03 – 1.98 (m, 2H).   
 
13C NMR (100 MHz, CDCl3)	 ppm 208.71, 57.62, 55.98, 50.77, 41.84, 28.53, 
27.03. GC-MS (EI): Rt = 10.26 min, m/z = 127 (M+), 112, 84, 67, 57, 42 (main 
fraction), 27. 
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(5.10) N-methyl-3-acetyl-5-methylpyrrolidine: Conversion: 100%. Yield: 47 mg 
(87%) as a (3:5) mixture of diastereomers measured by GC-MS. 
 
1H NMR (400 MHz, CDCl3) both diastereomers	 ppm 3.36 – 3.30 (m, 1H), 3.26 – 
3.22 (m, 1H), 3.16 – 3.08 (m, 1H), 2.91 – 2.84 (m, 1H), 2.30 – 2.22 (m, 3H), 2.25 
(smajordiastereomer, 3H), 2.22 (sminordiastereomer, 3H), 2.18 – 2.10 (m, 3H), 2.14 
(sminordiastereomer, 3H), 2.12 (smajordiastereomer, 3H), 1.66 – 1.54 (m, 2H), 1.08 – 1.05 (m, 
6H).  
 
13C NMR (100 MHz, CDCl3) both diastereomers	 ppm 208.83 (1C), 208.77 (1C), 
61.65 (1C), 60.89 (1C), 58.85 (1C), 57.79 (1C), 48.37 (1C), 48.16 (1C), 39.68 (2C), 
36.09 (1C), 35.28 (1C), 29.07 (1C), 27.64 (1C), 18.40 (1C), 18.01 (1C). GC-MS 
(EI): Rt (major) = 10.95 min, Rt (minor) = 11.10 min, m/z (both) = 141 (M+), 126, 
108, 98, 82 (main fraction), 71, 56, 44, 42, 28, 27. 
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(5.11) N-methyl-3-acetyl-5-ethylpyrrolidine: Conversion: 95%. Yield: 45 mg 
(90%) as a (1:2) mixture of diastereomers measured by GC-MS. 
 
1H NMR (400 MHz, CDCl3) both diastereomers	 ppm 3.37 (m, 1H), 3.26 – 3.22 
(m, 1H), 3.15 – 3.07 (m, 1H), 2.91 – 2.84 (m, 1H), 2.32 – 2.25 (m, 2H), 2.27 
(smajordiastereomer, 3H), 2.23 (sminordiastereomer, 3H), 2.20 – 2.15 (m, 2H), 2.15 
(sminordiastereomer, 3H), 2.13 (smajordiastereomer, 3H), 2.05 – 1.94 (m, 2H), 1.74 – 1.57 (m, 
4H), 1.22 – 1.12 (m, 2H), 0.89 – 0.85 (m, 6H).  
 
13C NMR (100 MHz, CDCl3) both diastereomers	 ppm 208.97 (1C), 208.83 (1C), 
67.96 (1C), 67.15 (1C), 59.08 (1C), 58.09 (1C), 48.57 (1C), 48.15 (1C), 39.97 (2C), 
33.29 (1C), 32.67 (1C), 29.64 (1C), 29.13 (1C), 26.10 (1C), 25.57 (1C), 10.43 (2C). 
GC-MS (EI): Rt (major) = 12.63 min, Rt (minor) = 12.75 min, m/z (both) = 155 (M+), 
108, 82 (main fraction), 67, 55, 42, 27. 
 
 
 
(5.12) N-propyl-3-acetylpyrrolidine: Conversion: 100%. Yield: 55 mg (91%). 
 
1H NMR (400 MHz, CDCl3)	 ppm 3.12 – 3.04 (m, 1H), 2.82 – 2.77 (m, 1H), 2.66 – 
2.61 (m, 1H), 2.57 – 2.53 (m, 1H), 2.44 – 2.29 (m, 3H), 1.14 (s, 3H), 2.02 – 1.96 (m, 
2H), 1.53 – 1.44 (hex, J = 7.6 Hz, 2H), 0.88 (t, J = 7.6 Hz, 3H).  
 
13C NMR (100 MHz, CDCl3)	 ppm 208.88, 58.04, 55.57, 53.91, 50.23, 28.51, 
26.41, 21.97, 11.96. GC-MS (EI): Rt = 13.12 min, m/z = 155 (M+), 126 (main 
fraction), 112, 84, 70, 55, 43, 27. 
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(5.13) N-propyl-3-acetyl-5-methylpyrrolidine: Conversion: 90%. Yield: 87%. 
 
The mixture of compounds made it impossible to assign NMR peaks. 
1H NMR (400 MHz, CDCl3): 
 
 
 
GC-MS (EI): Rt = 13.59 min, m/z = 169 (M+), 154, 140 (main fraction), 126, 110, 
96, 82, 68, 56, 43. 
  
Page  46 
Assembly mediated aza-Cope Mannich experiments. 
 
(5.14 – 5.16) 2-methyl-1-(propylamino)-3-buten-2-ol + aldehydes: General 
procedure for these cluster experiments: In the glovebox (1) (20 mg) was weighed 
out in small capped vial. In a second vial (5.3) (6 uL) and the aldehyde (12 uL) 
where syringed into a degassed (by N2 bubbling) solution of H2O (1000 uL) and D2O 
(100 uL). A noteworthy precipitate was formed, but after 5-10 min of gently 
agitation of the vial the reaction mixture became clear. Half of this substrate solution 
was then transferred to the vial with the cluster (1) - the mixture was shaken until 
dissolution of the cluster occurred. The samples (the cluster + substrates and 
substrate samples) were then transferred to a medium walled NMR tube and 
analyzed by NMR spectroscopy. The upfield areas of the spectra are shown on page 
14 and 15. 
 
1H NMR (400 mHz, D2O) Watergate Solvent Supression. 
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(5.18 – 5.19) N-alkyl-2-acetylpyrrolidine (Upscale x 5): In a small pop-cap vial 
(5.4) (37 mg, 289 umol) or (5.7) (44 mg, 283 umol) was dissolved in H2O (2.5 mL, 
100 mM K2CO3, pH = 11.5) with gentle agitation of the mixture. Total dissolution 
took between 5-10 minutes, after which the solution was degassed by N2 bubbling. 
To this mixture was then added 10 mol% (1) (104 mg or 102 mg), the vial closed 
and heated to 45 oC for 4 hours. After reaction was complete, Et4NBr was added to 
the reaction mixture (12.5 mg, 59 umol, 2 eq.) and the solution extracted with Et2O 
(3 x 3 mL). The combined organic layers were dried with MgSO4, filtered and the 
solvent evaporated on a rotary evaporator.  
 
1H NMR spectroscopy experiments showed a mixture of starting material and 
pyrrolidine product. The spectra are shown beneath. 
 
1H-NMR (400 MHz, CDCl3). 
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13C-NMR (400 MHz, CDCl3). 
 
   
 
1H-NMR (5.19). 
 
 
 
13C-NMR (5.19). 
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(5.20 – 5.24) General procedure for catalytic reactions with oxazolidines. In the 
glovebox (1) (20 mg, approx. 5.6 umol) was weighed-out in small capped vial. In 
other pop-cap vials the oxazolidines (5.4, 14.2 mg, 112 umol); (5.5, 15.8 mg, 112 
umol); (5.6, 17.2 mg, 112 umol); (5.7, 19.0 mg, 122 umol); (5.8, 17.8 mg,  106 
umol) were dissolved in buffered H2O (1000 uL, 100 mM K2CO3, pH = 11.5) and 
D2O (100 uL) with gentle agitation. The reagent solution was degassed by bubbling 
N2 gas through the solution for 10 minutes, subsequently half of the solution (550 
uL) was transferred to the vial with (1) and mixed until homogenous.  
 
The remaining reagent solution and the reaction mixture were transferred to separate 
medium-walled NMR tubes and analyzed. The samples were heated to 45oC in a 
water bath and the reactions followed by NMR spectroscopy. After the reaction was 
complete (for the exp. 5.20 and 5.23), Et4N+ (11.2 umol) was added to the cluster 
experiments, which were then treated with Et2O (3 x 3 mL). The combined organic 
phases were dried with MgSO4, filtered and evaporated. The background samples 
were treated the same way. Subsequently the products were analyzed by GC-MS to 
detect the conversion and result of the catalytic reactions.  
 
Identification of pyrrolidine product was based on GC-retention time and EI 
molecular fraction pattern; results are listed in table below. 
 
 
Exp. Reaction conditions Rt. and diastereomeric ratio Conversion. 
(5.20) 3 h., 45oC Rt. = 10.27 min. > 95 % 
(5.21) 9h, 45oC + 9h., 60oC Rt. = 10.95 and 11.11 min. (1:1) 65 % 
(5.22) 9h, 45oC + 9h., 60oC Rt. = 12.63 and 12.75 min. (1:1) 79 % 
(5.23) 3 h., 45oC Rt. = 13.15 min. > 95 % 
(5.24) 31 h., 45oC Rt. = 13.62 min. (1:1) 50 %  
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